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 ABSTRACT 
Heterotopic ossification (HO) is the pathological formation of ectopic bone and can 
be a devastating complication of military injuries. It causes multiple problems, 
including prosthetic limb fitting difficulties and ankylosis, ultimately causing loss of 
mobility, independence, and dignity. There is no effective prophylaxis and the only 
treatment is surgery, which causes rehabilitation delays and risks of bleeding and 
nerve injury. This work aimed to develop a new therapy for HO. A review of 
mineralised tissue analytical methods was performed and used to guide the study of 
human HO samples using X-ray micro computed-tomography, X-ray fluorescence, 
synchrotron X-ray diffraction / nano-tomography, Raman spectroscopy, and scanning 
electron microscopy. Screening of therapies demonstrated that hexametaphosphate 
(HMP) could dissolve hydroxyapatite (the mineral component of bone) under 
physiological conditions. Formulation engineering principles were applied to control 
this effect temporally and anatomically. A murine HO model was developed and used 
for feasibility testing of injected HMP as an HO therapy, showing that it had no 
adverse effect on normal bone. In summary, this project revealed the 
physicochemical structure of HO in unprecedented detail, discovered and developed 
a novel therapy, set up an animal model of HO, and showed that injected HMP is 
feasible in this model. 
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1 UNDERSTANDING HETEROTOPIC OSSIFICATION 
1.1 Clinical Considerations 
1.1.1 Historical and Contemporary Context 
Heterotopic ossification (HO) is the pathological formation of bone in soft tissues. 
Despite being first described in very early medical literature1,2 approximately 1000 
years ago, this condition still poses significant problems in modern times, most 
notably amongst military combat casualties (Figure 1-1).  
The relationship between military injuries and HO was first discussed in the medical 
literature of the American civil war.3 Writing about experience gained in the First 
World War, Colonel E G Brackett wrote a description of the macroscopic appearance 
and development of HO that would be familiar to those in the field today: 
“Excessive terminal bone production in… stumps was the rule. The most common 
form was an irregular mushrooming with a tendency to spurs on the inner aspect of 
the femur. Occasionally sharp exostoses were seen. These often were sharp enough 
and long enough to cause sufficient pain to warrant their removal.”4 
The recent conflicts in Iraq and Afghanistan have provided further examples of how 
HO can present a significant challenge as a consequence of combat injury. The 
burden of HO has been so great that Alfieri et al have described it as an “epidemic” 
and argue that it is the single biggest barrier to functional recovery for combat-injured 
patients.5 
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1.1.2 Aetiology 
HO is not the only form of pathological mineralisation. Many disease processes drive 
aberrant mineralisation and a wide variety of tissues can be affected: blood vessels, 
heart valves, eyes (band keratopathy), spinal ligaments (ankylosing spondylitis), 
peripheral nerves (neuritis ossificans), dermis (osteoma cutis), and subcutaneous 
tissue (panniculitis ossificans traumatica).6-14 In these conditions, the calcium 
phosphate mineral deposition does not usually demonstrate significant short or long-
 
Figure 1-1: 3D computed tomographic reconstruction 
of the pelvis and residual femora of a combat-injured 
patient. White arrows = heterotopic ossification. 
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range organisation, nor is it associated with collagen. In contrast, and despite 
demonstrating a disordered arrangement of these features, HO demonstrates many 
of the defining characteristics of bone such as lamellae, osteons, marrow cavities, 
bone forming and maintaining cells, and collagen. Thus, HO is uniquely similar to 
bone compared with other disorders of pathological mineralisation. Chapter 3 
contains a detailed analysis of the current understanding the structure of HO in 
addition to new results collected in the course of this project. 
HO may be caused by genetic or acquired factors. The genetic forms of HO are not 
the focus of this research project but have relevance due to historical attempts to 
treat them with polyphosphates and the insights that they provide into pathological 
bone formation. 
1.1.2.1 Genetic HO 
The pathological mechanism that causes the genetic form of HO known as 
fibrodysplasia ossificans progressiva (FOP) (Figure 1-2A) has been studied 
extensively and is well characterised: a heterozygous single nucleotide substitution of 
arginine to histidine (R206H) in the activin A type I receptor (ACVR1) gene.15,16 This 
gene encodes for the protein activin-like kinase 2 (ALK2), which is a receptor for 
bone morphogenic proteins (BMPs). ALK2R206H has greater sensitivity to the ligand, 
BMP-2, leading to increased phosphorylation and nuclear localisation of SMAD 
proteins, and increased Id1 promoter activity.17 Increased ALK2 activity subsequently 
leads to increased chondrogenic and osteogenic differentiation and the formation of 
bone in ectopic sites through endochondral ossification. 
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In contrast to FOP, progressive osseous heteroplasia (POH) (Figure 1-2B) occurs 
through intramembranous ossification and its genetic basis is less well characterised 
but is thought to involve heterozygous mutations in the GNAS1 (guanine nucleotide 
binding protein alpha stimulating) gene.19 The mutation inactivates the GNAS1 gene, 
which encodes for the alpha subunit of Gsα, and it is thought that this leads to 
dysregulation of cell lineage switching, resulting in excessive osteogenic 
differentiation of mesenchymal stem cells (MSCs).20 
1.1.2.2 Acquired HO 
HO may develop after almost any significant injury but is particularly common after 
blast injury, high-energy transfer gunshot wounds, central nervous system injury, 
A 
 
 
B 
 
Figure 1-2: A) 3D computed tomographic reconstruction of the thorax, spine, and 
upper limbs of a 12 year old child with familial ossificans progressiva. Reproduced 
from Shore et al.16 B) Plain radiograph of the trunk and pelvis of a 20 month old child 
with progressive osseous heteroplasia. Reproduced with permission from Urtizberea 
et al.18 
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burns, hip and knee replacement surgery, and elbow injuries. It is not clear whether a 
single common cellular and biochemical mechanism is responsible for the 
development of HO secondary to each of these causative events. The rest of this 
chapter will discuss acquired HO in more detail. 
1.1.3 Epidemiology 
Radiological evidence of HO was found in 64.6% of a cohort of combat injured 
patients.21 A similar figure of 62.9% is reported in a series of combat-injured patients 
who had undergone amputations.22 In the blast injury subset of these cases, where 
amputation was performed through the zone of injury, the rate of radiographically 
moderate or severe HO rose to 79.6%. It is worth noting that in the Afghanistan 
conflict, from 2003 to 2014, British service personnel suffered 416 combat 
amputations from 265 patients (giving the mean limbs lost per patient as 1.6).23 
A retrospective observational study of civilian amputations demonstrated that 22.8% 
of patients developed symptomatic HO.24 HO is also common amongst patients with 
traumatic brain injury (radiological evidence in 37% of patients),25 spinal cord injury (5 
to 60%),26 hip arthroplasty (5%),27 distal humerus fractures (8.6%),28 and burns 
(0.15%).29 
Leading researchers in the field have commented that the incidence of HO has been 
much higher in the cohort of injured combatants from the Iraq and Afghanistan 
conflicts compared to historical data. Potter et al propose that the reasons for this 
increase in HO include a high incidence of blast injury (due to increased use of 
explosive weaponry) and increased survival amongst seriously injured combatants  
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A 
 
B 
 
Figure 1-3: A) Plot of predicted probability of survival by New Injury Severity 
Score (NISS) value for each year of the conflict (Iraq and Afghanistan, 2003-
2012). Shaded regions indicate the 95% confidence intervals. B) NISS values 
associated with a predicted 50% or greater probability of survival. These 
data demonstrate a year-on-year improvement in survival during these 
armed conflicts. By the later stages, a significant proportion of the most 
seriously injured patients (NISS = 75) survived. Thus, the increased 
incidence of HO may be explained, at least in part, by these very seriously 
injured survivors. Reproduced (creative commons) from Penn-Barwell et al.30 
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 (due to improvements in body armour, medical care, forward surgical treatment, and 
rapid evacuation).31 
Thus the combination of exposure to blast,5 extremity amputation,32,33 and improved 
survival30 (Figure 1-3) is thought to have generated an extent and severity of HO not 
seen before. Historically, patients with these injuries would not have survived long 
enough to develop symptomatic HO after combat trauma. 
1.1.4 Clinical Problems Caused By HO 
Patients with HO experience a wide range of problems due to the mechanical effects 
of hard tissue in extra-skeletal sites. These include pain, loss of joint range of motion, 
joint ankylosis, skin ulceration, overlying skin graft failure, muscle entrapment, 
neurovascular entrapment, and prosthetic limb fitting difficulties (Figure 1-4).34 
Evriviades et al described the clinical impact of HO on patients eloquently as follows:  
“The development of HO can occur in the soft tissues very early and is 
sometimes found even before primary healing occurs. However, in the majority, it 
occurs after a number of months. The patient will typically have had an [improvised 
explosive device] injury and sustained bilateral traumatic above-knee amputations 
(often with other significant injuries), and will have initially done well with limb fitting 
and mobilization. They may develop increasing pain in their stumps and can often 
feel a hard lump or spike within the stump. In severe cases, the bone has actually 
eroded through the soft tissues. This may prevent them from mobilizing and poses a 
significant challenge to the prosthetics team.”35 
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Given the high prevalence of HO after civilian and combat-related limb amputations, 
it is worth noting the problems that these patients have with limb fitting. In the civilian 
setting, 50% of patients with HO require prosthetic modifications such as selective 
padding, hard socket reshaping, or new socket fabrication.24 Also, microbiological 
contamination is a key feature of the kind of high-energy military wounds that are 
predisposed to the formation of HO.35 One author reported that 100% of peri-
operative HO samples were positive for infection.22 
1.1.5 Financial Cost of HO 
There are no published data on the direct financial costs of HO. However, some 
indication may be gained from a paper by Masini et al who estimate that the direct 
cost of disability benefits for US service personnel with extremity injury sustained 
during the campaigns in Iraq and Afghanistan between October 2001 and 2005 to be 
A 
 
B 
 
Figure 1-4: A) Clinical photograph of HO ulcerating through the distal aspect of a long 
transfemoral amputation. Note the skin graft over the terminal portion of the residual 
limb. Reproduced (creative commons) from Alfieri et al.5 B) Preoperative clinical 
photograph of an above-knee amputee with severe heterotopic ossification beneath a 
split-thickness skin-grafted site. Reproduced with permission from Potter et al.31  
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$1.2 billion.36 Given that more than 10 years of conflict continued after the publication 
of that report, the true figure is likely to be vastly more than this estimation. If 64% of 
combat extremity injuries develop HO (see above), the proportion of this cost 
estimate that relates to HO prevention, treatment, and rehabilitation is likely to be 
significant. 
Another analysis, looking at the long term financial cost associated with UK military 
amputees has identified that approximately £288 million will be required over the next 
40 years.23 Again, this analysis does not specifically estimate the contribution that 
HO will make to this total figure but it illustrates that the magnitude of the financial 
cost in addition to the clinical and personal burden to the individuals. 
1.1.6 Current Prophylaxis 
There are currently no methods of primary prophylaxis that are entirely appropriate 
for the military population who are likely to be catabolic, at risk of gastric ulceration 
and renal injury, have open wounds and fractures, and are often in austere 
environments. 
1.1.6.1 Non-Steroidal Anti Inflammatory Drugs (NSAIDs) 
NSAIDs are used widely in civilian practice to cover a variety of situations where 
patients are at high risk of developing HO.37 An example is revision total hip 
replacement surgery where the patient has demonstrable HO secondary to the initial 
operation. However, there is evidence that, in addition to their normal side effect 
profile, NSAIDs increase the risk of non-union in the setting of HO prophylaxis after 
acetabular fixation.38 Impairment of fracture healing would be a particularly 
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problematic side-effect in major trauma patients as they are highly likely to have 
sustained at least one fracture as part of their pattern of injuries. Further, these 
patients are likely to have high risk of kidney injury, which is a major contraindication 
to NSAID use.39 
1.1.6.2 Radiotherapy 
Radiotherapy is also used in the elective civilian setting and has been shown to be 
effective but there is lack of consensus on timing and dose.40 Radiotherapy and 
NSAIDs may be given in combination for high-risk patients.41 There is a paucity of 
data to guide the use of radiotherapy in the traumatic injury cohort. Even if there was 
good evidence, the logistical challenges to delivering radiotherapy in austere 
environments are considerable. Further, there are multiple adverse effects of 
radiotherapy such as impaired wound and bone healing, which mean that it would be 
contraindicated in military patients who often have co-synchronous fractures and 
extremely challenging soft tissue wounds. 
1.1.6.3 Bisphosphonates 
Bisphosphonates are a class of drugs whose primary use is to prevent and treat 
osteoporosis. They have also been prescribed as prophylaxis against HO. However, 
their use remains controversial after a Cochrane review42 and other studies43 failed to 
find conclusive evidence of efficacy. There have been no studies looking at their role 
after major trauma. 
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1.1.6.4 Passive Movement Therapy 
Another Cochrane review44 investigating the use of passive movement physiotherapy 
in a heterogeneous group of patients (including traumatic brain injury and spinal cord 
injury patients at risk of HO) concluded that there is insufficient evidence show 
whether or not this therapy is effective. 
1.1.6.5 Experimental Prophylaxis 
One strategy that has shown immense promise is retinoic acid receptor gamma 
(RARγ) agonism to inhibit chondrogenesis.45 Without a cartilage scaffold, the 
endochondral processes that form HO are blocked and no mineral can be deposited. 
It is worth noting that, in the rodent model, there was a transient prolongation of 
fracture healing associated with RARγ agonism. Despite this concern, the treatment 
was so effective that the RARγ agonist palovarotene has been taken forward into 
clinical trials (NCT02279095) as a treatment for the genetic form of HO known as 
fibrodysplasia ossificans progressiva (FOP).46 
Another novel strategy has been demonstrated in a burn-tenotomy rodent HO 
model47 whereby hydrolysis of adenosine triphosphate (ATP) at the burn site led to 
reduced HO formation at a distant site. In addition to revealing a potential therapeutic 
strategy, this “remote ATP hydrolysis” method provides a further mechanistic insight 
into the role of phosphorylated SMAD proteins in the development of HO. 
In another rodent tenotomy model (without burn injury), treatment with the antibiotic 
echinomycin inhibited HO formation.48 The proposed mechanism is that echinomycin 
inhibits hypoxia-induced factor 1-α (HIF-1-α), a signalling molecule thought to be 
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crucial to the process of chondrogenic differentiation of mesenchymal stem cells in 
HO. 
It is important to note that all of the experimental and extant prophylaxes work by 
attempting to inhibit the cellular and/or biochemical pathways that are thought to 
cause HO. There are no published data on experimental or clinical treatments that 
have been designed to directly inhibit or disperse the mineral component of 
heterotopic ossification. 
1.1.7 Current Treatment 
1.1.7.1 Non-Operative Management 
Rest, analgesia, nerve blocks, and nerve ablations form the mainstay of non-surgical 
treatments.5 However, once HO has formed and matured, it has not been shown to 
regress or remodel significantly, so patients who remain symptomatic after 
optimisation of non-surgical management options will often require surgery. 
1.1.7.2 Operative Management 
In a civilian amputation study, 25% of patients were treated with NSAIDS, 8% with 
bisphosphonates, and 11% underwent surgery to resect the ectopic bone.24 In a 
series of military patients, 19% required surgical excision, with a mean interval 
between injury and excision of 8.2 months.22 Excision had a significant effect on the 
analgesic requirements of the patients: 63% were able to cease opioid analgesia 
completely. There is debate about the exact timing of surgery. If HO is excised too 
early then it may recur but waiting too long may delay the patient’s rehabilitation and 
return to function. A systematic review of studies of HO excision after brain injury did 
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not find evidence to support the view that early surgery predisposes to recurrence.49 
With appropriate timing of surgery and secondary prophylaxis with NSAIDS and/or 
radiotherapy, recurrence of HO rarely requires further surgery. In a large series of 
patients who had undergone primary HO excision secondary to acquired brain or 
spinal cord injury, only 5.8% required further surgery due to recurrence.26 
Despite the success of operative interventions in controlling HO, it must be stressed 
that these operations are technically extremely challenging  and come with significant 
risks of adverse events such as bleeding and damage to remaining soft tissues.35 
Standard practice at the UK Defence Medical Rehabilitation Centre, Headley Court, 
is that amputee patients are non-weight bearing for 6 weeks after surgery to their 
stumps (personal communication). Given that these patients can have multiple 
operations for soft tissue reconstruction, any additional requirement for surgery due 
to HO excision can add to their already significant period of non-weight bearing and 
this can have lasting effects on their rehabilitation potential. 
1.2 Pathophysiology 
1.2.1 Signalling and Cellular Factors 
There is significant controversy in the literature about the fundamental cellular and 
molecular mechanisms involved in acquired HO formation.50-52 Candidate cell 
populations of mesodermal, ectodermal, and endodermal origin have all been 
proposed.53,54 One of the key problems is that while there are many cell types that 
may be influenced to produce mineralisation in vitro or in vivo, this does not mean 
that they are responsible for HO in patients. Davies et al55 reviewed the evidence for 
and against all of these candidates and concluded that it is most likely that HO 
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results from complex signalling networks involving multiple cell types (Figure 1-5). 
However, consensus is building to favour the direct role of multipotent cells of 
mesenchymal origin.56 
One example of how intercellular signalling is important in the formation of HO comes 
from the work of Olmsted-Davis et al.57 They used a mouse bone morphogenic 
protein (BMP-2) model to demonstrate that hypoxic adipocytes were required for the 
differentiation of stem cells to chondrocytes, which is a key early step in the formation 
of ectopic bone. In addition to illustrating the role of multiple cell populations in the 
formation of HO, this work demonstrates that local physicochemical environment may 
play a role. Tissue hypoxia may not only stimulate intercellular signalling but will also 
lead to reduced pH through cellular anaerobic respiration. Low pH will, in turn, have 
an effect on the chemical phases that are stable in that environment and may even 
be exploited for the purposes of preventing and treating HO (see Chapter 4). 
Recent work has provided evidence that different cell types may even generate 
phenotypically distinct HO subtypes. In an Acvr1R206H knock in mouse model that 
phenotypically resembles the genetic from of HO (FOP), Mx1+ cells produced injury-
dependent intramuscular HO whereas Scx+ cells lead to injury-independent 
ossification of ligaments and tendons.58 
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The findings that HO may be caused by interacting networks of cells and that 
different cell populations can form distinct forms of HO raise several questions: Could 
the different distribution patterns of HO seen after different triggering events be due 
to different cell populations? Is HO seen after different causes even the same 
condition? Also, if more than one cell type can generate HO then is therapeutic 
blockade of one signalling pathway sufficient to prevent the condition clinically? 
Could the pathophysiological processes use alternative signalling pathways and cell 
populations to drive HO formation in spite of blockade at a single point? One way to 
overcome these concerns is to ignore the upstream signalling and cellular process 
and attempt to prevent or treat HO by inhibiting the formation of a key component of 
the final product of the process: hydroxyapatite. This is the fundamental principle that 
has been used to develop the novel treatment discussed later in this manuscript. 
1.2.2 Inflammation and HO 
There is significant support in the clinical59,60 and basic science61 literature for the 
central role of an exaggerated inflammatory response in the pathogenesis of HO. It is 
well recognised that patients who have suffered major trauma demonstrate 
multiphasic inflammatory dysregulation after injury with both acute and chronic 
components.62,63 This seems to fit with the observed clinical experience of HO in a 
number of interesting ways. It might explain why HO develops after weeks to months 
and then progresses for months to years, after which time it stabilises and becomes 
quiescent.50 It may also explain why the timing of excision surgery is important if 
recurrence is to be avoided.64 Finally, this may suggest an alternative mechanism of 
action for NSAID prophylaxis in HO. 
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1.2.3 Ossification Mechanism in HO 
It has been shown that there is upregulation in key osteogenic and chondrogenic 
gene transcripts (BMP2, BMP3, ALPL, COLL2A1, COLL10A1, COLL11A1, COMP, 
CSF2, CSF3, MMP8, MMP9, SMAD1, and VEGFA) in the soft tissues of high-energy 
combat wounds.65 The upregulation of these gene transcripts suggests an 
endochondral (as opposed to an intramembranous) model of development of 
acquired HO, something that has been confirmed separately in an animal model.66,67 
1.2.4 Early Detection 
Currently, HO is diagnosed using imaging techniques (see Chapter 2). However, 
significant benefits may be gained by earlier identification and better risk stratification 
of those patients who will go on to develop HO. Reliable risk stratification and 
prediction allows clinicians to target prophylactic therapies at the right patients thus 
reducing the risk of harmful side effects in those who would never have developed 
HO anyway. The increasing knowledge of cellular and biochemical pathophysiology 
of this condition has allowed the development of several techniques that set out to 
achieve this goal. For example, one group has shown that serum levels of interleukin 
(IL) 3 and 12p70 and wound effluent levels of IL-3 and 13 at the time of first 
debridement predicted those would go on to develop HO.59,60 However, it must be 
noted that these studies have not been validated in a civilian population and the 
authors stress that the complex interrelationship between the inflammatory markers 
remains incompletely understood. 
The same gene expression data that was used to demonstrate that HO forms 
through endochondral ossification could also be used as a predictor of HO in combat 
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wounds.65 There was a significant difference in the transcriptional activity of key 
osteogenesis-related genes between patients that developed HO and those who did 
not. This study may, however, be confounded by the finding that the HO group had a 
significantly higher injury burden, more bacterial colonisation, bigger wounds, and 
more amputations than the non-HO group. 
1.3 Discussion 
HO is a fascinating and debilitating condition (or perhaps group of conditions) that 
has been known about for a very long time. For many years it has been regarded as 
a rare complication of central nervous system injury or an inconvenient adverse 
effect of major surgery and so a handful of prophylactic approaches were discovered 
and developed to attempt to prevent it in those settings. However, since 2003, with 
the beginning of the conflicts in Iraq and Afghanistan and the subsequent on-going 
unrest in the region, our experience of this condition has changed completely. This is 
due to the alignment of a unique set of circumstances: increased incidence of blast 
injuries, increased incidence of combat-related amputations, and vast improvement 
in survival of even the most seriously injured patients. The result of this is that we 
have seen a significant increase in both the incidence and severity of this disease. 
The few prophylaxes that had been developed to prevent HO in the civilian setting 
have been shown to be either ineffective or inappropriate for the complex and often 
multiply injured military casualties, who are thus left at high risk of developing HO. 
Despite their severe injuries, these patients have been shown to have a high 
potential for good functional outcome with appropriate rehabilitation.68,69 However, it 
has been claimed that the single biggest barrier to achieving this potential is HO. This 
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is because not only does it prevent patients from using the highly advanced 
prosthetics that are made available to them but also because the surgery required to 
excise HO introduces multiple long delays into their rehabilitation, which have a 
cumulative deleterious effect on their final functional outcome. This challenging 
problem has generated a large amount of research activity recently. This activity is 
almost exclusively focussed on understanding and inhibiting the signalling and 
cellular processes involved. What has become clear is that these processes are not 
only extremely complicated but that different processes may be involved in different 
cases or at different times. The lack of clinical effectiveness of the experimental 
treatments developed as a result of this approach may be evidence of the ability of 
the HO-generating process to “work around” a prophylactic blockade. It is also clear 
that there has been little or no exploration of the concept of targeting the key 
component of the final product of these processes, the bone mineral hydroxyapatite. 
It is the hypothesis of the author that direct inhibition or dispersion of the bone 
mineral itself could be developed into a treatment or prophylaxis for HO. This 
manuscript details the steps taken to explore this hypothesis. These steps include 
exploring the methods available for analysing bone mineral (Chapter 2), using the 
most appropriate of these methods to analyse samples of human HO (Chapter 3), 
discovering a means of inhibiting and dispersing hydroxyapatite in vitro (Chapter 4), 
developing this into a deliverable treatment (Chapter 5), and testing this in an animal 
model of HO (Chapter 6). The primary goal of this work is to provide the proof of 
concept for this novel method of preventing and treating HO in order to lay the 
foundations for human trials in the future. Ultimately, the author and collaborators 
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hope that this treatment will go some way towards fulfilling the unmet clinical need of 
this cohort of severely injured survivors. 
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2 ANALYSING HETEROTOPIC OSSIFICATION 
2.1 Introduction 
In order to disperse the end product of the pathological bone formation process, we 
first need to understand its physical and chemical structure. Additionally, this 
knowledge may be used to help develop a directed treatment such that pathological 
tissue may be targeted rather than normal bone. Given the importance of 
understanding the structural and chemical features of pathological bone, this chapter 
outlines the methods used to evaluate bone structure and chemistry (summarised in 
Table 2-1). A version of this review has been published in Advanced Healthcare 
Materials.70  
Not all of the techniques discussed below have been used to analyse HO but all have 
been used to investigate biological mineralisation or mineralised tissue and were 
included because they have the potential to be used to study HO. Techniques have 
been divided into those that provide structural information and those that provide 
chemical information. This division is slightly artificial as many modalities can provide 
both types of information about mineralised tissue. 
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Table 2-1: Summary of analytical techniques discussed in this chapter 
 Resolution Information In Vitro,  
In Vivo,  
Ex Vivo 
Destructive? Advantages Disadvantages Preparation 
Required 
References 
Histology ~10µm Structure In Vitro 
Ex Vivo 
✓ Cost, widely used, 
minimal specialist 
equipment 
Expertise required to 
interpret images 
Sectioning, fixing, 
and staining 
34,48,56,61,71
-81
 
Fluorochrome 
Labelling 
~10µm Structure Ex Vivo ✓ Gives temporal 
information about 
new bone formation. 
Can be used for 
longitudinal analysis 
if multiple 
administrations 
Need to wait for 
fluorochrome label to be 
incorporated into newly 
formed bone 
Fluorochrome 
administration, 
sectioning, and fixing 
80,81
 
Transmission 
Electron 
Microscopy 
Angstroms Structure Ex Vivo 
In Vitro 
✓ Resolution Two-dimensional 
projection of three-
dimensional structure 
Embedding and 
sectioning 
82-85
 
Scanning 
Electron 
Microscopy 
~1nm Structure Ex Vivo 
In Vitro 
✓ Depth of field 
Resolution 
Technically demanding 
at very high 
magnification 
Coating of sample 76,78,86-88
 
Plain 
Radiography 
~1mm Structure In Vivo X Cost 
Availability 
Simplicity 
Ionising 
Delay to diagnosis 
Nil 59,60,89,90
 
Microradiograp
hy 
~10µm Structure In Vitro 
Ex Vivo 
✓ Cost Limited information Embedding, 
sectioning 
78,91
 
Micro CT ~1µm Structure In Vitro 
Ex Vivo 
In Vivo 
X Rapid 
Allows longitudinal 
analysis in vivo 
3-dimensional 
dataset 
Ionising 
Highest resolution not 
safe in vivo 
Nil 48,57,61,75,87
,92,93  
Isotope Bone 
Scan 
~1cm Structure In Vivo X Early In Vivo 
detection 
Non-specific 
Ionising 
Radioisotope 
administration 
94
 
Near Infra-Red 
Fluorescence 
~1mm Structure In Vivo X Gives information on 
process of 
mineralisation 
Relatively poor spatial 
resolution 
Administration of IR 
dye 
81,95,96
 
MRI ~100µm Structure 
Elastography 
In Vivo 
In Vitro 
X Provides multimodal 
data 
Requires highly 
specialised equipment 
Nil for structural 
information 
Mechanical vibration 
for elastography 
97-109
 
Ultrasound ~25µm Structure 
Composition 
Elastography 
In Vivo 
In Vitro 
X Cheap, safe, real-
time, multimodal 
information 
User dependent Nil for structural 
information 
110-118
 
Energy 
Dispersive X-
ray 
Spectrometry 
~1µm3 Composition In Vitro X Elemental analysis 
 
Low efficiency at 
exciting x-ray 
fluorescence 
Slow scan speeds 79,119
 
X-Ray 
Fluorescence 
Spectrometry 
 
10µm Composition In Vitro 
Ex Vivo 
✓/X Femtogram quantities 
of elements 
detectable 
Requires access to 
synchrotron for highest 
resolution data 
Pellet formation for 
bulk XRF, 
embedding for 
mapping 
 
120,121
 
Fourier 
Transform 
Infrared 
Spectroscopy 
(FT-IS) 
 
~10µm 
(1.3µm 
using 
synchrotron
) 
Composition Ex Vivo 
In Vitro 
 
X Chemical bond 
analysis 
Requires access to 
synchrotron for highest 
resolution data 
Nil 92,122-125
 
Raman 
Spectroscopy 
~1µm Composition Ex Vivo 
In Vivo 
In Vitro 
X Non destructive 
No sample 
preparation 
Safe in vivo 
Very large datasets 
when imaging volumes 
Nil 34,61,126-129
 
X-Ray 
Diffraction 
(XRD) 
Atomic 
(WAXS) 
 
Composition Ex Vivo 
In Vivo 
✓/X Can identify mineral 
species present  
Not suitable for live 
cells/tissue 
Ionising radiation 
Destructive at higher 
beam energies 
Grind sample to 
powder 
79,130-133
 
Multi-photon ~0.1µm3 Structure 
Composition 
Ex Vivo 
In Vitro 
In Vivo 
X Tissue penetration 
Resolution 
High signal to noise 
ratio 
Technically challenging 
Photodamage 
Fluorescent labelling 
if needed 
Untreated samples 
can be used 
134-139
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2.1.1 Structural Analysis of Mineralised Tissue 
2.1.1.1 Light Microscopy 
Light microscopy covers a broad range of well-established techniques, most of which 
utilise visible light reflected from or transmitted through a sample (Figure 2-1). This 
enables direct visualisation of tissue and cells as a result of differences in their 
optical properties. While the theoretical resolution of light microscopy is less than 
1µm, this is limited by the wavelength of light and the poor structural contrast of 
biological samples in their unprocessed form.71 Light absorption contrast may be 
increased by selectively staining components of interest with chemical dyes.72  
Histology remains a very popular modality for investigating mineralisation both in HO 
and bone tissue engineering due to its relatively low cost and ability to provide insight 
into the biological response of the surrounding tissue. A significant disadvantage is 
that histological techniques are destructive, as they require the samples to be 
embedded in plastic or paraffin and then to be processed using chemical fixatives 
and dyes. Furthermore, processing of mineralised samples requires either 
specialised cutting techniques or a demineralising step, which is to be avoided if the 
researcher is interested in the mineral content. Histological techniques may be 
combined to provide counterstaining to reveal more than one component of interest. 
While standard hematoxylin and eosin staining may be used, there are many 
specialist histological techniques for imaging mineralisation.140 One of the oldest is 
the Von Kossa method, which uses a silver nitrate-based treatment that selectively 
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Figure 2-1: Examples of light microscope techniques used to visualise mineralised 
tissues. A) Von Kossa staining of a mineralising culture of rat calvarial osteoblasts. 
Black = mineralisation. Reproduced with permission from Zhang et al.133 B) Sanderson 
bone stain of a sample of human combat-related HO. O = osteoid. AO = arteriole. 
Purple = mature bone. Blue = osteoid. White = unmineralised tissue. Reproduced with 
permission from Isaacson et al.78 C) Von Kossa and MacNeal tetrachrome staining of a 
rat proximal tibia. Black = mineralisation. Light blue = marrow contents. Dark blue / 
purple = cartilage. D) Safranin O with alizarin red counterstain of the growth plate. 
Green = mineralisation. Orange = cartilage. Black = cell nuclei. E) White light (upper 
image) and ultraviolet light (lower image) of cortical bone after fluorochrome labelling 
with calcein (green) and alizarin (red) demonstrating osteon formation during the 
period of administration. F) Polarised light microscopy of lamellar bone demonstrating 
varying layers of collagen alignment in the lamellae. Subfigures C-F reproduced with 
permission from Allen and Burr.72 
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stains the mineralised tissue in a sample.73 In a modification of this staining process, 
von Kossa tetrachrome, osteoid is also visualised in blue as compared to the black 
colour of mineral. More recent examples are: Alizarin red staining of mineralisation in 
mesenchymal stem cell (MSC) cultures treated with HO wound effluent, ex-vivo 
samples of HO from rodent burn model using Safranin O, Picrosirius Red, and aniline 
blue, Picrosirius red dye used in mouse Achilles tenotomy model, Masson’s 
trichrome staining in examining ex vivo ectopic bone and osteoid formation in dog 
HO model (ceramic implantation), Masson’s trichrome in human combat-related HO 
samples, and Sanderson’s bone stain used to analyse bone and osteoid formation in 
combat-related HO.34,61,75-78 
Immunohistochemical staining is a refinement of standard histological processing 
that allows identification of proteins relating to the cell biology of tissues. The 
principle of this technique is the conjugation of a dye molecule to an antibody that will 
bind to a specific target protein of interest. Fluorescence microscopy is then exploited 
to image the distribution of the labelled antibody without any interference from 
unlabelled background tissue components, and hence a large increase in image 
contrast can be achieved. The protein target could, for example, be a tissue matrix 
component such as collagen or cell surface markers. Cell markers can indicate cell 
phenotype and stages of cellular processes such as proliferation and apoptosis. This 
offers the possibility to correlate changes in the hard tissue matrix to changes in 
cellular function, which may aid mechanistic understanding of different types of 
mineralisation. A common refinement of this technique is to use one antibody to bind 
to the target and a second, labelled, antibody to bind to the first. In mineralisation 
research, immunohistochemical staining has been used to highlight hypoxia-inducible 
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factor 1-alpha (HIF-1-α) in a mouse tenotomy HO model and in an in vitro 3D MSC 
mineralisation model.48,79 
Examination of the particular cell types within HO or mineralising tissue can also be 
undertaken using selective staining techniques. Osteoclasts can be highlighted by 
tartrate-resistant acid phosphatase (TRAP).93 Immunohistochemical analysis of 
alkaline phosphatase will highlight osteoblast activity.56,74 Staining for lactate 
dehydrogenase can identify osteocytes and indicate viability.141 
Fluorochrome labelling is a technique that provides information on the process of 
mineralisation. A fluorescent dye is injected into a live animal or human and acts as a 
substrate for mineralisation or binds to calcium as it is deposited into soft tissue. The 
tissue/bone sample is retrieved after an appropriate interval and analysed under 
ultraviolet light to reveal the labelled newly deposited mineral. The key information to 
be gained from this technique is the rate and location of new mineral deposition. In 
humans, the antibiotics tetracycline or doxycycline are commonly used as 
fluorochromes. In an animal study on ectopic mineralisation using BMP-loaded HA 
scaffolds, calcein, xylenol orange, and alizarin red have been used to demonstrate 
the rate of mineralisation at different time points.80 
2.1.1.2 Plain Radiography 
Plain radiographs are commonly used in clinical practice for diagnosis and 
surveillance of pathological mineralisation (Figure 2-2B). The sample or patient is 
illuminated with a short pulse of X-rays. The detector collects transmitted X-rays, 
which are attenuated to different extents depending on the elemental composition of 
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the sample. Regional density and thickness of the sample or structures within the 
sample can be inferred. Highly radio-dense matter, such as calcium in mineralized 
tissue, absorbs or scatters the X-rays more than less radio-dense components 
leading to the formation of a “shadow” image on the detector. X-radiation is ionizing 
and therefore potentially damaging to live tissue but controlled and sparing use can 
mitigate the risk to acceptable levels. Ex vivo and in vitro samples of mineralising 
tissue are not adversely affected by the low doses of radiation required to form a 
routine image. Advantages of radiography are its relative low cost, rapid acquisition, 
and suitability for use in vivo. One significant disadvantage is the delay between the 
start of mineralisation and the time that it becomes detectable. For example, after 
head injury, it takes approximately 4-5 weeks for HO to be detected by this method.89 
There is a similar time delay in surveillance of combat-related HO in humans and 
blast-related HO in a rat model.59,60,90 Another disadvantage of plain radiography is 
that the images produced are not spatially resolved in three dimensions making it 
less suitable for quantification of volume of HO or for pre-operative planning. 
Microradiography is used for monitoring calcification ex vivo. The macroscopic 
technique is modified by sectioning the sample, embedding it in a radiolucent 
material, and placing the sample in direct contact with the detector. Isaacson et al 
used this technique to highlight the hypervascularity of HO samples excised from 
civilian trauma patients (Figure 2-2A).78 Despite its relative simplicity, 
microradiography can provide information on calcification with a spatial resolution of 
approximately 10 µm.91  
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2.1.1.3 Electron Microscopy 
Electron microscopy relies upon the short (de Broglie) wavelength of electrons to 
provide higher resolution images than is possible using visible light. Scanning and 
transmission electron microscopy are able to produce structural and chemical 
information relevant to mineralisation research. The structural information is 
discussed here. For the chemical techniques, see sections 2.1.2.1 and 2.1.2.2 below. 
2.1.1.3.1 Scanning Electron Microscopy (SEM) 
SEM is used to provide information on the topography of a sample surface through 
the back-scattering of electrons or the generation of secondary electrons. Secondary 
electron mode is the most common imaging mode found on SEM systems and 
A 
 
B 
 
Figure 2-2: Radiographic imaging of human HO. A) Contact microradiograph 
demonstrating an extensive vascular network. Reproduced with permission from 
Isaacson et al.78 B) Macroscopic clinical plain radiograph of a left femur with extensive 
terminal and medial HO. Reproduced with permission from Potter et al.34 
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involves the production of high energy electrons ejected from the surface atoms of 
the sample upon excitation by the incident electron beam. The intensity of the 
secondary electrons reaching the detector is strongly dependent on the angle of the 
sample plane probed by the incoming beam relative to the plane of the detector and 
therefore samples with large changes in topography will produce large changes in 
image contrast. The fine lateral resolution of this technique (around 1 nm) and a large 
depth of field make SEM particularly suited to imaging three-dimensional engineered 
constructs or trabecular structures within bone. As an example, SEM has shown 
utility in evaluating calcium phosphate coating and biomineralisation of an 
electrospun polycaprolactone model in an in vitro study of ectopic mineralisation.87 It 
has also been used recently to analyse the microarchitecture of calcium phosphate 
ceramics before implantation into rats, rabbits, and dogs as part of an ectopic 
ossification model.76 In addition to the insights gained through transmission electron 
microscopy (TEM), Scaglione et al used SEM to define microarchitecture, and pore 
size and shape of their scaffolds before seeding with MSCs.142 Once the scaffolds 
had been seeded with MSCs but before they were implanted into the murine model, 
they were able to demonstrate that a certain scaffold architecture caused polarisation 
of the cells with subsequent alteration in their bone extracellular matrix deposition 
behaviour.  
Backscattered electron imaging modes detect the reflection of beam electrons 
scattered elastically after interaction with atoms in the specimen interaction volume. 
The image contrast is strongly dependent on the atomic number of the elements 
present within the sample. This relationship enables good contrast to be obtained of 
sample with very small changes in topography (of the order of tens to hundreds of 
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nm) and biological samples, which typically consist of light elements or elements 
close together in terms of their atomic number. This imaging mode is often used to 
identify chemical elements within the sample by analysing the characteristic X-ray 
emission from the elements when irradiated by the incident electron beam.  
Backscattered SEM of ex vivo samples of combat related HO has provided data on 
the maturity of the trabecular structure.78 Surface details over several orders of 
magnitude down to the nanometre scale can be detected which makes it particularly 
suited to studying the lamellar organisation of bone (Figure 2-3A). 
One of the key advantages of SEM is its versatility in terms of rapid image acquisition 
over a huge range of magnifications and choice of systems available to 
accommodate biological samples. Traditionally, SEM samples require sputter coating 
of a thin layer of conductive metal in order to electrically ground the sample during 
imaging and prevent artefacts due to charge build up on the surface. Biological 
samples usually require chemical fixation prior to surface coating. Sputter coating 
processes may physically alter delicate and/or thin biological samples such as 
muscle sections but can be avoided by using a low voltage mode in some SEM 
instruments while maintaining a good lateral resolution and contrast. Alternatively, 
samples can be infused with substances such as osmium tetroxide, which improves 
the bulk conductivity of the sample. Environmental SEM (ESEM) enables 
characterisation of wet uncoated samples by maintaining a suitable pressure around 
the sample. The risk of sample damage from chemical fixation or coating is thus 
avoided but this comes at the penalty of restricted field of view as the electron beam 
becomes increasingly attenuated the further away the sample is. While electron 
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induced damage or chemical changes to samples may be a risk in any form of 
electron microscopy, the use of a gaseous sample environment in ESEM adds a 
further factor to the issue. To date, the precise impact of electron-gas-sample 
interactions are largely unknown, but should be taken into consideration when 
analysing imaging or spectral data. 
For the analysis of samples relevant to bone engineering and bone disease, the 
choice of technique and whether the use of extensive chemical processing methods 
is acceptable depends largely on the nature of the sample and what information one 
wishes to extract from that sample. Samples consisting largely of hard matter such 
as excised bone or bone substitute are likely to be more robust against dehydration 
compared to soft tissues and hence the full range of SEM techniques are available to 
gain high-resolution images of sample microstructure. On the other hand, the impact 
of sample preparation techniques on samples containing a mix of hard and soft 
tissues/materials is likely to be varied. Some reports suggest that chemical fixation of 
cells and soft tissues may induce precipitation within the sample, which is obviously a 
concern if investigating the presence and composition of small mineral or amorphous 
deposits in the soft tissue components of samples.143 
Despite these considerations, SEM offers a powerful tool for studying samples’ 
physical structure and the most promising frontier in this field is the development of 
systems capable of acquiring and co-registering SEM data with optical fluorescence 
and X-ray imaging data. Although, to the best of our knowledge, such an approach 
has been untested on mineralisation samples under discussion in this review, the  
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concept has the potential to remove the number of sample preparation and handling 
steps between imaging with different modalities and hence aid the preservation of 
such samples. 
 
A 
  
B 
  
Figure 2-3: A) Scanning electron microscopy back scattered electron image of a 
sample of blast-related HO demonstrating osteoclast resorption pits (white arrows 
in left image) and osteons (white arrows in right image). Reproduced with 
permission from Isaacson et al.144 B) Left: 2-D transmission electron microscope 
image of a cryosection of a collagen fibril from a mineralising horse tendon. Scale 
bar = 100 nm. Right: computer-generated 3-D reconstruction of the tendon with 
plate-like mineral crystals highlighted in pink. Reproduced with permission from 
Nudelman et al.84  
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2.1.1.3.2 Transmission Electron Microscopy (TEM) 
TEM is an imaging technique used to determine the shape and surface structure of 
thin samples with Angstrom-scale lateral resolution. The physical principle behind 
image contrast in TEM depends on the mode of operation, but the most common 
mode (and the mode used to observe the shape of HA crystals) is called ‘bright-field’ 
mode. In this mode, the electrons can be treated under classical physics principles 
as being occluded or absorbed by the sample. Image contrast is then obtained 
because fewer electrons are transmitted through thicker regions (or regions 
containing elements of higher atomic number) compared to thinner regions, (or 
regions containing elements of low atomic number) which appear as dark and bright 
regions in the image respectively. The image formed at the detector can then be 
regarded as a 2D projection of the volume of the sample irradiated by the electron 
beam. The power of TEM resides in its ability to overcome the diffraction limits 
imposed on light microscopy systems. A generalised approximation of the Abbe 
diffraction limit states that the size of the smallest sample feature resolvable using an 
optical system is approximately equal to half the wavelength of the light. The De 
Broglie wavelength of electrons accelerated by the typical kV voltages used in TEM 
instruments would be under 1nm, which is several hundred times smaller than the 
wavelengths typically used in light microscopy (e.g. 532nm green laser line). It then 
becomes clear that TEM can resolve features in the pm-nm range and achieve 
atomic scale resolution, which cannot currently be achieved with light microscopy 
techniques. Consequently, TEM is suited to elucidating the mechanism of 
mineralisation at the nano-scale due to its ability to resolve individual mineral crystals 
(Figure 2-3B).83,145 The utility of this technique is enhanced by the use of uranyl 
 34 
nitrate staining to reveal the repeating structure of collagen fibrils thus allowing direct 
imaging of the interaction between the mineral and organic components of ectopic 
bone. Scaglione et al used TEM to define the deposition and orientation of collagen 
into HA scaffolds that had been loaded with MSCs and implanted ectopically in a 
murine model.142 This insight allowed them to infer the mechanisms behind the 
observed differences in the bone produced by each scaffold. 
The main drawback to using TEM techniques in general is the extensive sample 
preparation required to produce sectioned samples thin enough to be electron 
transparent and obtain good image contrast. As with any chemical or physical 
sample preparation process, there is the risk of altering the natural physical structure 
of the sample. Although this can be mitigated to an extent by cryofreezing samples, 
this process also requires a specialist TEM setup with a cryostage and the 
appropriate sample preparation equipment close to hand. Given the level of sample 
preparation required and low sample throughput, TEM may lend itself best as an end 
stage nanoscale structural analysis tool for samples known to contain evidence of 
early mineral formation rather than act as a ‘screening process’ to detect mineral in 
bulk samples. 
2.1.1.4 Computed Tomography 
The principle of computed X-ray tomography (CT) involves the use of X-rays to 
illuminate the target and a detector to measure the intensity of the transmitted X-rays. 
The key is that there is relative rotational movement between the sample and axis of 
the radiation such that an image-processing computer can build up a 3D dataset of 
radiodensity within the sample. Calcium phosphate in bone is relatively radiodense  
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compared with surrounding soft tissue so this technique is well suited to detecting 
mineralisation in in vivo, ex vivo, and tissue engineering applications. A potential 
problem with CT is that the dose of ionising radiation received by the sample is much 
higher than with plain radiography due to the need to illuminate from many directions. 
However this does not prevent this technique from being used in clinical practice, in 
vitro culture, or in vivo models. Clinically, CT remains a common modality for the 
classification and diagnosis of HO and pre-operative planning for its removal.147 
Micro CT utilises exactly the same physical principles as clinical CT but at much 
higher resolution (less than 10 µm3).148 Resolution can be optimised by minimising 
the size of the sample so that the source-to-sample distance can be kept as short as 
possible while still keeping the entire sample in the field of view. Porter et al used 
micro CT to monitor cell-mediated mineralisation in a perfusion bioreactor and 
demonstrated that this modality could be used in a tissue engineering application 
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Figure 2-4: Examples of computed tomography in HO research. A) Micro CT 3-D 
reconstruction (left) and axial slice (right) of HO in a mouse Achilles tenotomy model. 
Yellow shading / circles indicates the HO tissue. Reproduced in a modified form 
under Creative Commons Attribution Licence from Zimmermann et al.146 B) Clinical 
CT 3-D reconstruction (left) and axial slice (right) of a human femur after an above-
knee amputation. These images demonstrate severe heterotopic ossification 
extending from the distal femur into the soft tissues of the thigh including the skin. 
Reproduced with permission from Potter et al.31 
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without detrimental effects to the cell culture under study.92 One particular advantage 
of CT is that the dataset can be used to quantify the volume of bone formation in all 
types of mineralising construct including in vitro scaffolds, in vivo lesions, and ex vivo 
samples.48,57,87,93,140 This is because CT can generate high contrast between hard 
and soft tissues meaning that relatively simple image thresholding-based methods 
can be used to segment the mineralised regions for analysis. Ultimately, being able 
to quantify exactly how much bone has been formed or inhibited is the single most 
important question to answer in most translational biomineralisation studies. Another 
major advantage of CT is that it can be used to monitor ossification serially over time. 
This has clear beneficial implications for the numbers of animals or samples required 
for experiments in this field. Two recent studies by Peterson et al demonstrated this 
longitudinal monitoring of HO in mouse in vivo implantation models.61,75 CT is also 
able to demonstrate both surface and cross-sectional detail (Figure 2-4). The 
versatility of this technique in being able to generate striking visual images in addition 
to quantitative information, such as histomorphometric or bone mineral density data 
makes it a very powerful tool in mineralisation research. 
Nano-scale computed tomography has become possible through the use of 
synchrotron beamlines due to the high flux and tight collimation of X-radiation 
possible in such systems.149 However, technical differences in the beam geometry 
between traditional CT systems and synchrotron systems means that the latter use 
phase contrast, rather than beam attenuation, as their underlying physical 
principle.131 This requires an additional step of phase retrieval when converting the 
raw datasets into images. Additionally, synchrotron systems may require additional 
X-ray focussing systems such as Kirkpatrick-Baez optics. The added complexity of  
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synchrotron systems pose challenges but the advantages are also significant, 
including a volumetric resolution in the nanometre range and excellent compositional 
contrast in mineralized tissue (Figure 2-5).150 The high resolution is particularly well 
suited to demonstrate the canalicular network in detail.151 A recent application of 
synchrotron nanotomography has been to define the relationship between canalicular 
network morphology and the spatial distribution of mass density in human bone.152 
This study demonstrated that mineral density is highest near to canaliculi and 
lacunae. This supports the hypothesis that the raw materials for mineralisation are 
supplied from the extracellular fluid via the lacunar canalicular network. Synchrotron 
nanotomography has not previously been used to study samples of HO. 
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Figure 2-5: A) Transverse slice through a synchrotron x-ray nanotomography 
dataset. Empty spaces such as osteocyte lacunae and canaliculi are black. High 
density mineral is white. On = osteonal bone. It = interstitial bone. Cm = cement line. 
Field of view is approximately 100 µm. B) Computer generated 3-D rendering of a 
single osteocyte lacuna with associated canaliculi (pink) adjacent to a cement line 
(green) taken from the dataset in A). Images reproduced under Creative Commons 
Attribution Licence from Langer et al.150 
 
 38 
2.1.1.5 Isotope Bone Scanning 
Isotope bone scanning is mentioned here for completeness as it has become less 
commonly used in clinical practice since the advent of other modalities, such as CT. 
It has not been used extensively in recent research literature for analysis of ectopic 
ossification or bone tissue engineering. The principle of this technique involves the 
administration of a radioisotope (usually technetium-99m conjugated to a 
bisphosphonate) that will localise to areas of metabolic bone activity. The 
radioisotope produces gamma radiation that is detected by a “gamma-camera” 
(Figure 2-6A). This technique is able to detect HO as soon as 2.5 weeks post injury 
but with the caveat that it is highly non-specific. Infection, tumour, thrombosis, and 
fracture can all provide false positive results.94,153 
2.1.1.6 Near Infrared Fluorescence 
Near infrared (NIR) light covers the wavelength range of 700 – 1000 nm and has two 
key properties of relevance to in vivo imaging: i) these wavelengths induce little to no 
auto-fluorescence in biological samples and, ii) tissues generally have a low molar 
attenuation coefficient in the NIR range.95 Good tissue penetration depth and high 
signal to noise ratio can be achieved when transmitting NIR through tissue and NIR-
emitting dyes are therefore excellent reporter molecules for tissue structures for in 
vivo or intra vital imaging. Generally, NIR imaging systems consist of a NIR source in 
transmission or reflection geometry with a sensitive CCD camera or an InGaAs 
detector (for less sensitive measurements but over the full NIR range). NIR dyes can 
be conjugated to chemical species that will highlight sites of mineralisation in a 
manner similar to fluorochrome labelling. Pamidronate has been conjugated with an 
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infrared fluorophore to demonstrate development of ossification in a nude mouse 
model.96 A particular benefit of this technique in the context of monitoring ectopic 
mineralisation is that is it able to demonstrate mineralisation in its very early stages 
(Figure 2-6C).81 The probe in this case was a calcium-chelating agent conjugated to 
an infrared fluorescent dye and this system was able to detect HO five days post 
injury, compared with five weeks for micro CT in the same model. This sensitivity to 
very early ossification could be extremely useful in in vivo experimentation as the 
ability to quantify mineralisation at much earlier time points would have a beneficial 
effect on animal welfare. However, while this technique may be able to detect 
mineralisation much earlier than micro CT, its spatial resolution is much lower and it 
does not produce a three-dimensional dataset. 
2.1.1.7 Magnetic Resonance Imaging 
MRI is a technique widely used in clinical practice and also, to a limited extent, in 
biomaterials science. This technique utilises a constant, strong magnetic field (0.5-
1.5 Tesla in clinical settings) to align the spin axis of hydrogen nuclei parallel to the 
direction of the applied magnetic field.97 A radio-frequency pulse is applied 
perpendicular to the magnetic field, causing the spin axis of the nuclei to tilt away 
from the direction of the magnetic field. Upon cessation of the pulse, the spin axis of 
the hydrogen nuclei realigns to the magnetic field, in a process called relaxation. This 
causes emission of radio frequency energy that is detected by receiver coils. Spatial 
encoding of the data is achieved by employing a secondary gradient coil, which 
manipulates the strength of the magnetic field across the subject such that only 
nuclei within a given ‘slice’ are forced to align with the magnetic field and respond to 
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the radio-frequency pulses. Sequential movement of the slice under analysis along 
the length of the subject then permits the building of a three-dimensional data set. 
Altering the timing, frequency, and intensity of the radio frequency pulses, allows 
encoding of different structural information.  
One of the main benefits of this technique is that it is non-destructive and requires no 
sample preparation. It has the further advantage that it does not expose the sample 
to ionising radiation. These attributes would seem to make it ideal for monitoring 
progression of mineralisation in animal models but the cost, complexity, and long 
scan times have been inhibitory to its routine use. 
Sites of developing HO in humans have been shown to have the following 
characteristic features on MRI: diffuse muscle hyperintensity on T2 weighted images 
(which enhances with contrast), enhancing hyperintense surrounding fascia, and 
non-enhancing foci within the muscles that were later shown to indicate the origin of 
mature HO.98 As HO matures, T1 imaging shows areas within the lesion that have 
low signal intensity (relative to muscle) diminishing while areas isointense to muscle 
increased.99 Signals indicating fat and cortical bone within the lesion become more 
intense. On T2 images, the intensity of the signal, which is initially high, decreases 
with maturity. However, some authors have questioned the specificity of MRI in the 
early stages as it can mimic infection (abscess, osteomyelitis), fat, and tumour.100 
Several groups have published further evidence of the heterogeneity of HO as seen 
on MRI with the only common characteristic linking their cases being a low-intensity 
rim around the lesion, which is contradictory to previous reports.101,102 Further, there 
is evidence that MRI grossly underestimates the presence and extent of ossification 
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with only 10% of bony lesions being detected in one study.99 MRI has been shown to 
be useful in the initial stages of analysis of mineralisation in implanted tissue-
engineered structures but the signal becomes less intense as the mineralisation 
progresses and no additional data is provided that could be generated by simpler 
means.103,104 One method for improving the specificity of MRI for bone mineral is to 
conjugate gadolinium, an MRI contrast agent, to a bisphosphonate.105 The 
bisphosphonate adsorbs onto the surface of HA co-locating the gadolinium. In 
explanted polymeric scaffolds seeded with osteoblasts, MRI sensitivity was improved 
by using a gadolinium-alendronate conjugate marker.106 One of the benefits of this 
technique is that it counteracts the image-degrading effects of ingrowing blood 
vessels in implanted bone constructs in animal models. MRI is also safe and effective 
for use in animal models. Several studies have used MRI to quantify mineralisation in 
bone graft substitute implanted ectopically in a rat model.108,109 Further, MRI 
microscopy has been used to evaluate the mineralisation of tissue-engineered 
phalange constructs implanted into athymic mice (Figure 2-6B).154 
MRI elastography is an experimental technique demonstrating how modalities that 
have previously generated only structural data may be modified to allow analysis of 
material properties of mineralising constructs. As an example, micro MRI 
elastography has been used to infer the tensile strength and elasticity of a 
mineralising tissue engineered osteogenic cell culture.107 The possibility of using a 
non-invasive technique to infer mechanical properties has major implications for 
studying mineralisation in bone graft substitutes that have been populated with cell 
cultures. This is because traditional mechanical testing is incredibly challenging to 
carry out in the sterile environment required for cell culture techniques. Another 
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advantage is that this methodology of mechanical testing is non-destructive and may 
be more appropriate for immature cell-infiltrated scaffolds. 
2.1.1.8 Ultrasound 
Ultrasound is an established imaging modality in clinical practice and provides 
structural information based on tissue transduction and reflection of high frequency 
sound waves. This modality is based on electrically driven high-frequency (>20 kHz) 
oscillation of a piezoelectric crystal in the transducer probe. These oscillations are 
conducted via a coupling gel to the tissue of interest. Inside the tissue they are 
transmitted, refracted, diffracted, or reflected depending on the sound conducting 
properties of the tissue and the interfaces between tissues with differing conductive 
properties. The reflected sound wave is received by the probe and interacts with the 
piezoelectric crystal to generate an electrical signal pulse. The magnitude of this 
pulse and the time taken to travel back to the transducer is recorded and correspond 
to the impedance mismatch at the reflecting boundary between two tissue types and 
the depth of that boundary within the body respectively. In practice, the probe 
consists of an array of piezoelectric crystals, enabling processing of data from a two-
dimensional plane or three-dimensional volume and conversion into an image.110 
Ultrasound has the advantages of being relatively cheap, safe, non-destructive to 
samples, and can provide real-time information. One disadvantage is that it is highly 
user dependent meaning that there is often poor correlation between results obtained 
by different operators.116 In clinical practice, ultrasound has been used to diagnose 
HO before calcification becomes appreciable on plain radiographs or CT.111-115 This 
is possibly due to the change in stiffness of soft tissues observed in what has been 
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termed “pre-HO”.128 HO is recognised using ultrasound by characteristic “zone 
phenomenon”: outer sonolucent muscle zone, highly sound-reflective middle zone of 
mineralisation, and hypoechoic central zone.113 Clinically, the use of Doppler  
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Figure 2-6: A) Radionucleotide bone imaging study taken three hours after injection 
of Technitium-99 into a patient with HO around the hip joint after CNS injury. The 
normal outline of the pelvis and lumbar spine can be visualised. Darker areas 
demonstrate high uptake in the developing HO and pooling within the bladder.  
Reproduced with permission from Orzel et al.89 B) Quantitative proton density (left) 
and T2-weighted (right) magnetic resonance images of mineralisation within an 
engineered phalangeal scaffold. Scale bar = 5mm. White arrowhead = dense bone 
formation. Reproduced with permission from Potter et al.154 C) Ex vivo near infrared 
(left) and microCT (right) images of HO formation in a mouse Achilles tenotomy 
model. The high signal in the near-infrared image is generated by a calcium-chelating 
infrared dye. White ovals = HO. Reproduced with permission from Perosky et al.81  
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ultrasound has a secondary advantage in that as well as being able to diagnose HO, 
it may be used to rule out venous thromboembolism, which is a dangerous and 
common differential diagnosis of early HO in its inflammatory phase. Ultrasound has 
been used to monitor the progression of HO in patients with central nervous system 
injury, showing strong correlation with histological findings.114 This study also used 
the Doppler shift of reflected sound energy to demonstrate vascular ingrowth into the 
new area of ossification. This may be of use in animal models of HO formation and in 
tissue engineering applications when researchers want to monitor scaffold 
implantation.  
Ultrasound also has a role in in vitro mineralisation research. A novel ultrasound 
technique for analysis of mineralisation within a 3D scaffold has been developed.117 
In addition to high-resolution structural information (25 µm), this technique provides 
data on concentration, distribution, and particle size of the mineral phase. 
Mineralisation can be monitored in an animal model using ultrasound.118 
Researchers implanted mesenchymal stem cell-seeded 3D matrices into rats and 
were able to follow the osteogenesis, degradation, and calcification of these 
constructs over time. Ultrasound is relatively uncommon in mineralised tissue 
research but given that it does not rely upon ionising radiation, and requires no 
sample preparation, it may become more common in future. 
2.1.2 Chemical Analysis of Mineralised Tissue 
2.1.2.1 Selected Area Electron Diffraction (SAED) 
This technique is an adjunct to TEM which exploits the fact that de Broglie 
wavelength of a high energy electron beam is within the same order of magnitude as 
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the typical atomic spacing in a crystalline material, leading to electron diffraction by 
the crystal structure.155 A fraction of the incident electrons are scattered at a 
particular angle, which relates to the spacing between atoms in a particular plane of 
the sample, and shows as a series of ordered bright spots in an image. Rotation of 
the sample relative to the incident electron beam enables diffracted electrons from a 
range of angles to be detected sequentially to build a diffraction pattern covering a 
range of crystal planes. This pattern is unique to the composition and structural 
phase of the crystalline material within the sample. A ‘selected area’ of the sample is 
analysed simply by placing a thin metal strip with a small aperture underneath the 
sample to block all electrons except those coming from the region of the sample 
directly above the aperture. A significant advantage of this technique over x-ray 
diffraction is that it can be used to analyse a several hundred nm portion of a sample 
(microns) in contrast to bulk sampling. This is ideal for tissue samples containing 
small amounts of mineral whereas X-ray diffraction usually requires large (mg-1g) 
amounts of the material of interest to generate adequate diffraction patterns. This 
modality can provide information on the identity and spatial distribution of crystalline 
species present in a sample. For example, Hong et al used it to confirm the identity of 
crystals in murine bone as HA (Figure 2-7A).83 Nudelman et al used SAED to 
demonstrate that the initial infiltration of calcium phosphate into mineralising collagen 
fibres is amorphous and that the characteristic diffraction pattern of HA develops 
later.85 In the field of tissue engineering, SAED can be used to investigate the 
interface between implanted bone graft substitutes and host bone. De Aza et al 
implanted bioactive glass/ceramic composites into a murine model and used SAED 
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to demonstrate the presence and crystal orientation of HA in newly deposited 
collagen at the interface region.156 
2.1.2.2 Energy Dispersive X-ray Spectroscopy (EDX) 
This modality is another adjunct to electron microscopy whereby high-energy 
electrons strike a sample causing the ejection of electrons in lower energy shells. X-
ray radiation is emitted as an electron in an outer shell moves to fill the gap. Each 
different element produces a unique series of peaks on an X-ray emission spectrum 
(Figure 2-7B). A major advantage of this technique is that it provides semi-
quantitative evidence to corroborate qualitative interpretation of electron microscopic 
images. For example, this technique has been used to confirm the pattern of calcium 
and phosphorus deposition in mineralising horse-tendon collagen fibrils and the 
distribution of mineralisation on a synthetic collagen sponge.85,157 Data processing 
techniques even allow two-dimensional mapping using this technique. For example, 
Koburger et al used it for phosphate mapping of mineralisation of the engineered 
hard-soft interface and Sasaki et al used it to confirm the distribution of calcium and 
phosphorus in a MSC populated cell scaffold.79,158 Finally, as an example of the 
complementary use of SEM, SAED, and EDX to provide structural and chemical 
information in a mouse model of ectopic mineral deposition, see Kikkawa et al.88 This 
group were able to determine the location of mineral deposition within muscle 
bundles, confirm its identity as a calcium phosphate, and compare the diffraction 
pattern to pure HA. 
Limitations of EDX relate to how the nature of the sample can influence the detected 
emission spectrum. X-ray fluorescence will be emitted in all directions, with a portion  
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of this reaching the detector. A proportion of these X-rays will not leave the sample 
due to scattering events or attenuation and the influence of these effects on the  
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Figure 2-7: A) Left: Transmission electron micrograph of collagen fibrils containing 
crystals (white arrows).  Right: selected area electron diffraction (SAED) pattern of 
the same image field. The EDX diffraction pattern confirms the identity of the 
crystals as apatite and demonstrates a continuous pattern, confirming that the 
crystals have no preferred orientation. Reproduced with permission from Hong et 
al.83 B) Left: Scanning electron micrograph of a filament of mineral-coated 
electrospun polycaprolactone scaffold. Right: Energy dispersive X-ray (EDX) 
spectrum and calcium/phosphate ratio of the coating. Reproduced with permission 
from Vaquette et al.87 
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detected signal depends on the energy of fluorescent X-ray and the density and 
thickness of the material the X-ray must pass through. This can be a particular 
problem in rough samples where thicker regions are likely to attenuate the X-ray 
fluorescence signal more, reducing the signal-to-noise ratio and hence compromise 
accuracy of element identification. With respect to bone mineral research, this could 
pose a particular issue when attempting to characterise ion substitutions. 
2.1.2.3 X-Ray Fluorescence Spectrometry (XRF) 
Similar in principle to energy dispersive x-ray spectrometry (above), XRF can identify 
elements in a sample through the generation of X-ray spectra. However X-rays, 
rather than electrons, are used to excite the sample and such measurements are 
performed in a lab/benchtop scale instrument, often operated under ambient 
conditions. Much finer chemical sensitivity (femtogram quantities) can be achieved 
with this technique compared with energy dispersive X-ray spectrometry, particularly 
if the beam is synchrotron generated.120 Relatively recent advances of this technique 
have included the ability to focus the incident X-rays to a microscale spot and raster 
over the sample surface, enabling elemental mapping with lab/benchtop grade XRF 
instruments. XRF analysis in this manner requires little to no sample preparation and 
fresh tissue samples can be analysed without any noticeable drying due to heating 
from X-ray exposure. Stahler et al used micro-XRF to map abnormal mineralisation 
by demonstrating low calcium and phosphorus signals in chick embryo tibiotarsi.121 
Synchrotron-based XRF measurements and mapping utilise X-ray sources orders of 
magnitude brighter than the X-ray sources typically used in lab grade instruments, 
which further enhances the lower limit of detection of elements. The ability to 
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continuously control the incident X-ray beam energy and spectral resolution opens up 
a more refined subdivision of techniques known collectively under the term of X-ray 
Absorption Spectroscopy. A detailed discussion of such methods is beyond the remit 
of this thesis, but they essentially probe electron scattering effects at energies around 
the X-ray absorption edge of elements as a means of investigating the covalency, 
electronic structure, oxidation state and site symmetry of elements and compounds 
within a sample. Thus such methods go beyond identification of elements and into 
reaction dynamics of elements within their sample environment. 
The application of XRF to bone tissue engineering and HO research has so far been 
limited in scope. Typically, its use has been bulk measurement of calcium phosphate 
ratios in pre-implantation ceramic materials.159,160 However, an example of a more 
advanced application is the use of synchrotron XRF to produce elemental mapping of 
zinc and calcium in a rabbit zinc-doped HA implantation model.161 XRF provided data 
to demonstrate the post-implantation distribution of this element. Thus elemental 
mapping using XRF is demonstrated to be an excellent technique for mapping the 
fate of the constituents of doped or substituted calcium phosphates being used as 
bone grafts. There are currently no published studies using mapped XRF to 
investigate elemental distribution in samples of HO.  
In terms of limitations, care must be taken to consider how the sample topography 
and thickness may influence the XRF spectrum/elemental map in much the same 
way as EDX, albeit to a lesser extent. Some signal will still be lost within the sample 
but this can be partly offset by using the more intense X-ray based sources 
associated with XRF to create more excitation events in the sample per unit time. 
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The depth penetration of XRF depends on the elements under investigation and the 
intensity of the incident beam with general penetration ranging from tens to hundreds 
of µm. As a result, this is still largely a surface based technique in the context of bone 
samples and does not afford depth-resolved chemical mapping. Micro-XRF 
instruments have a very small depth of field and hence only regions of a sample 
surface within a few hundred micron window range of the detector will mapped 
accurately. For samples with large undulations (mm), this could simply be overcome 
by bringing the sample closer or further away from the detector. 
2.1.2.4 Fourier Transform Infrared Spectroscopy (FTIR) 
Infrared (IR) light can be absorbed by molecules within samples to cause stretching, 
twisting and rocking modes of their chemical bonds. The frequencies of light required 
to resonate with such modes are highly dependent on the constituent elements of a 
molecule and, unlike X-ray fluorescence spectrometry, the nature of the bonding 
between those elements. A broadband IR beam incident on a sample may resonate 
with multiple modes of several different chemical bonds creating a spectrum of well-
defined absorption bands unique to the molecule. FT-IR is most commonly used to 
produce spectra for bulk samples but recent advances have meant that it can 
produce two-dimensional mapped data (Figure 2-8A) and even, using the confocal 
principle, a three-dimensional data-set in a non-destructive manner. Using a standard 
IR emission source, spatial resolution is in the region of 10 µm, but this may be 
reduced to 1.3 µm by illuminating the sample with a synchrotron unit.122 FT-IR data 
can provide the following spatially-resolved information for mineralized tissue 
samples: mineral content, carbonate/phosphate content, crystallinity, the type of 
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carbonate substitution, the relative acid phosphate content, and collagen maturity.122 
In bone graft substitute bioengineering, FT-IR has been used to map the spatial 
distribution of HA and poly(D,L-lactide) in a bioglass-loaded composite foam.162 FT-
IR has also been used to demonstrate the evolution of calcium phosphate crystal 
phases in sites of heterotopic ossification in a mouse model.125 This technique has 
yet to be used to analyse the chemical bonds present in human HO but given how 
valuable it has been in providing insights into physiological mineralisation, much may 
be gained by doing so. 
2.1.2.5 Raman Spectroscopy 
Raman spectroscopy has revolutionised the compositional analysis of samples in 
ossification research. Monochromatic laser light is used to illuminate the sample and 
is scattered inelastically by the chemical bonds within molecular species present, 
resulting in a shift in the wavelength of the light.126 A chemical bond between two 
elements produces a unique wavelength shift of the incident light, which is detected 
as peak on a plot of Raman intensity against wavenumber, and hence mineral and 
collagen have distinct patterns of Raman peaks (Figure 2-8B). Depending on the 
species present, Raman spectroscopy is also sensitive to the chemical coordination 
around the bond of interest and orientation of the molecule within the sample matrix. 
Raman mapping can be performed by rastering a diffraction-limited laser spot over 
the sample surface and collecting a Raman spectrum at each point. The integrated 
intensity under a peak relating to a molecule of interest produces a grey level pixel 
value and hence changes in the image intensity representing differences in the 
abundance of that particular molecule across the sample. Lateral resolutions are 
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defined by the Abbe diffraction limits and hence have a theoretical resolution of the 
order of half the wavelength of light used. However, in practice, 1 µm is the limit of 
resolution of this technique and analyte sensitivity is in the nanogram range.127 
Three-dimensional chemical maps can be obtained by raising or lowering the sample 
with respect to the objective lens after rastering each plane in the same way as 
confocal fluorescence microscopy. One major advantage of Raman spectroscopy for 
analysis of biological samples is that there is minimal interfering signal from water, in 
contrast to FT-IR. Additionally, Raman spectroscopy can be considered a 
complementary technique to FT-IR in that it can analyse transitions such as those 
exhibited by centrosymmetric molecules. 
The spectra generated by Raman spectroscopy show peaks specific for molecular 
bond bending, vibration, and rotation. In bone, the ν1 phosphate vibration at 961cm-1 
is the predominant peak with others at 438cm-1 (ν2 phosphate), 589cm-1 (ν4 
phosphate), 1075cm-1 (carbonate substitution), 1256cm-1 (amide III in collagen), and 
1677cm-1 (amide I in collagen).126 Raman spectroscopy has been used to 
demonstrate that ectopic bone in a mouse burn model is compositionally identical to 
normal cortical bone.61 Potter et al used Raman spectroscopy to detect “pre-
heterotopic ossification” in combat-injured muscle by the appearance of mineral 
bands at 961 cm-1.34 The same group undertook a more detailed analysis of combat-
injured tissue using this technique to demonstrate the early deposition of type I 
collagen followed by the appearance of mineralisation.128 The maturation of 
mineralisation was then monitored spectroscopically by the reduction in the ratio of 
amorphous calcium phosphate to HA. This suggests that Raman spectroscopy may 
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have a clinical role in the minimally-invasive detection and monitoring of HO, a 
concept supported by a recent pilot study by Harris et al.163 Evidence that this 
concept is viable in living tissue is provided by Peterson et al who used  
A 
 
 
B 
 
Figure 2-8: A) A sequence of Fourier Transform Infrared Spectroscopy mapped 
datasets of mineralising chick limb-bud mesenchymal cells taken at 12, 14, and 21 
days of culture. The colours represent the ratio of mineral to matrix in the cultures. 
The field of view is 400 x 400 µm. Reproduced with permission from Boskey et al.124 B) 
Raman spectra of normal muscle (solid line), immature HO tissue (dotted line), and 
mature HO tissue (dashed line) taken from human subjects. Shaded regions indicated 
regions where vibrational bands differ significantly. The most prominent feature of the 
mature HO spectrum is the peak at 960 cm-1, which indicates a v1 P-O stretching mode 
due to the presence of mineral in the soft tissue. Reproduced with permission from 
Crane et al.128 
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Raman spectroscopy to detect HO progression in a live mouse model.75 This paper 
reports that HO may be detected as early as 5 days post injury using in vivo Raman. 
Ghita et al have shown that Raman spectroscopy is also a viable technique for 
prolonged in vitro monitoring of mineralising cell culture.129 Over 28 days of culture 
they demonstrated the conversion of amorphous calcium phosphate into HA. 
In terms of future prospects for Raman mapping and spectroscopy in the field of 
bone mineral research and engineering, developments are occurring across the field 
from lab-based research to remote diagnostic use. The development of advanced 
polarisation resolvable systems and cheaper commercially available longer 
wavelength lasers are enabling the orientation of bone matrix components such as 
collagen to be resolved at larger tissue depths. Raman micro-needle based 
spectroscopic methods have been developed by researchers for clinical applications 
to differentiate between healthy and diseased tissues. While the driving force for this 
has been early detection of cancer in a minimally invasive manner, the identification 
of a series of characteristic peaks specific to early HO or normal or sub-optimal bone 
healing may form the basis of utilising such technology in the clinic in time. 
2.1.2.6 X-Ray Diffraction (XRD) 
XRD is a technique that provides information on the crystal structure of a sample 
through the illumination of a sample with of a beam of monochromatic X-rays and the 
analysis of the unique pattern of intensity of X-rays scattered over an angular range. 
Elastic scattering of incident X-rays by a crystalline sample occurs because the 
wavelength of X-rays is comparable to the chemical bond lengths and because the 
atomic arrangement exhibits long range periodic order.130 Importantly, the reflection 
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of X-rays from a crystal plane only occurs when the incident beam is at a precise 
angle to that plane. The detector is moved relative to the axis of the beam to detect 
the summation of radiation diffracted by various magnitudes. The degree of 
crystallinity, size and orientation of crystals, and crystalline chemical composition can 
all be determined by the resulting diffraction pattern. This is of particular interest in 
ossification research as it allows the mineral component of bioengineered or native 
tissue to be analysed. XRD is divided into wide-angle x-ray scattering (WAXS) and 
small-angle X-ray scattering (SAXS), which provide data on atomic and colloidal 
scale structural regularity respectively. The beam of X-rays may be generated by 
conventional means or by a synchrotron facility, which can deliver higher intensity 
radiation with controlled wavelength distribution, lower signal to noise ratio, and 
ultimately greater analytical sensitivity.131 In addition to information on the identity of 
crystalline phases within a sample, the Scherrer method may be applied to XRD data 
to allow calculation of fundamental crystallite size and shape.155,164 The most 
common use for XRD in mineralisation research is simply to compare the diffraction 
pattern of bulk samples of ectopic bone or engineered mineralised tissue to reference 
samples of pure HA or normal bone. For example, Sabou et al used conventional 
XRD to compare the mineral phase of ex vivo human HO with that of normal bone 
and found a high degree of similarity.132 Similarly, Saito et al used XRD to confirm the 
presence of hydroxyapatite after ectopic implantation of a BMP2-derived peptide into 
a murine model.93 Synchrotron XRD has been used recently to demonstrate the 
presence of octacalcium phosphate and dicalcium phosphate dihydrate in an 
osteoblast cell culture model with phase evolution into HA.133 Synchrotron beamline 
XRD is able to detect smaller quantities of crystalline phases in a sample, 
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differentiate more components of mixed samples, and detect biological 
macromolecules. However, for the vast majority of biomineralisation research, 
laboratory XRD is sufficient. 
2.1.2.7 Multi-photon Spectroscopy 
The underlying principles of multiphoton microscopy (MPM) have been understood 
for decades but it is only recently that it has become a commonly used technique in 
the characterisation of biomaterials. The mechanism is that two (or more) long 
wavelength photons can interact simultaneously with electrons in the target sample 
to elevate them to a higher energy level than either could achieve alone.134 As the 
electron returns to its resting state, it emits a photon with a shorter wavelength 
(higher energy) than the excitation photons. This is known as the anti-Stokes effect. 
The difference between coherent anti-Stokes Raman spectroscopy (CARS) and 
standard multiphoton imaging is that in CARS, the excitation photons are generated 
by two different lasers and have different wavelengths. By using longer wavelength 
excitation photons in the near infrared spectrum, it is possible to achieve greater 
fresh tissue penetration (up to 1mm) without any preparation or staining.135,136 This is 
due in part to the reduction in autofluorescence of biological tissues at these 
wavelengths. Omelon et al have used MPM to demonstrate the presence of 
polyphosphates in areas of mouse vertebral bone remodelling.165 This study used a 
fluorescent dye, DAPI, to improve detection of polyphosphates. The differentiation of 
human adipose-derived stem cells into HA-producing osteoblasts has been studied 
using CARS.137 Liu et al used MPM to characterise their engineered polycarbonate 
scaffolds and analyse osteoblastic seeding.138 This study demonstrated how MPM 
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provides greater sample penetration, less photobleaching, and higher signal-to-noise 
ratio than conventional single photon imaging. Villa et al have shown that in vivo 
MPM is possible, by using it to monitor integration and ossification of donor-cell 
impregnated scaffold constructs in mouse calvarial defects.139 MPM in this study 
provided three-dimensional structural information highlighting the spatial relationships 
of osteoblasts, scaffold, and deposited mineral. Furthermore, this study highlights 
another feature of MPM, second harmonic generation, which can be used to image 
collagen in situ without any staining or preparation. This means that MPM can 
provide a full picture of the hard and soft components in an in vivo or in vitro 
mineralisation system. 
2.2 Discussion and Future Directions In Imaging 
2.2.1 Discussion 
Pathological mineralisation in tissues can cause dysfunction in a broad array of organ 
systems. Its effects are dependent upon the anatomical location and can lead to 
significant problems as varied and serious as heart failure, loss of mobility, and 
blindness. HO is an outlier in this spectrum of disease due to the speed, volume, and 
degree of hierarchical organisation it displays. This fascinating problem is currently 
the subject of intense research activity relating to the biological stimuli and processes 
that cause it. However, the chemical and physical processes occurring at tissue level 
remain comparatively under-investigated. This is surprising given that tissue 
mechanics and chemistry are known be able to drive biological processes and cell 
differentiation. For example, work by Engler and Discher has demonstrated clearly 
that mesenchymal stem cells can be made to follow an osteoblastic lineage purely 
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through the stimulus of a stiff culture substrate.166,167 The recent rapid advancement 
of techniques has allowed materials scientists to analyse the physical and chemical 
changes within pathologically mineralised tissue in an unprecedented level of detail. 
Critically, it is through an improved understanding of these material properties that 
new approaches to treating and preventing these conditions will be discovered and 
refined.  
Despite all of the potential benefits that physicochemical analysis of HO tissue might 
bring, the limitations of this approach must be acknowledged. The modalities 
described in this paper are unlikely ever to be able to advance our understanding of 
the upstream biology involved. Meaningful elucidation of the complex interplay 
between tissue damage, inflammation, signalling pathways, and stem cell recruitment 
and differentiation cannot be achieved through observation of the mineral product, no 
matter how careful that observation may be. 
2.2.2 Future Clinical Directions 
One particularly promising experimental technique that could be used in the clinical 
setting in future is percutaneous Raman spectroscopy to diagnose HO earlier and 
with more certainty than is currently possible. The Raman laser light and return signal 
could be delivered transcutaneously via optical fibre within a needle to “interrogate” a 
region suspected of developing the disease. If the signal came back showing 
characteristics of mineral where there should only be soft tissue then this would be a 
strong indicator of HO rather than one of the differential diagnoses such as venous 
thromboembolism or infection. The possibility of using Raman in this way to provide 
an early and highly reliable diagnosis would enable clinicians to target prophylactic 
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therapies to those who needed it rather than exposing entire cohorts of patients to 
the adverse effects of these treatments.  
Another potential use for Raman spectroscopy in this field may be during surgical 
excision. Once HO has matured into fully mineralised bone-like tissue, it is relatively 
easy to identify intraoperatively. In this case the surgeon can be sure that all of the 
tissue has been excised. However, waiting several months for the tissue to reach this 
level of maturity will adversely impact upon the rehabilitation of the patient. One of 
the reasons why surgical excision is not undertaken earlier is that, in its immature 
and only partially mineralised state, HO tissue is challenging to identify with certainty 
and the surgeon has to risk either excessive resection of healthy tissue or inadequate 
resection leading to recurrence. This situation is highly analogous to the dilemma 
faced by surgeons excising tumours. However, intraoperative Raman spectroscopy 
could be used to analyse the resection margins for residual immature mineralisation. 
The surgeon would then be able to operate earlier on in the progression of the 
disease and resect only tissue with developing mineralisation. This in turn would 
enable the patient to start their rehabilitation at an earlier stage with all the attendant 
benefits that this would bring. Given that Raman spectroscopy has already been 
used intraoperatively to confirm resection margins in neurosurgery, there is no 
conceptual reason why this could not be used during HO excision surgery.168 
2.3 Conclusion 
This chapter has demonstrated that there is a wide variety of techniques for 
analysing mineralisation and mineralised tissue. The length scale available for 
physical analysis ranges from a few nanometres to greater than one metre while the 
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chemical analytical techniques can demonstrate elemental composition, bond 
identities, crystallite characteristics, and macromolecular interactions. Also the 
applications are as numerous and diverse as the techniques themselves and include 
identifying the calcium phosphate phase within a single mineralising fibril of collagen, 
quantifying the degree of mineralisation within a cell culture or bioreactor or animal 
model, diagnosing HO in a patient, and visualising the true structure of the lacunar / 
canalicular network inter alia. The challenge for this project, therefore, is in selecting 
the techniques that can provide insights into the structure and formation of HO. In 
part, the nature of the samples will provide a practical limitation on the choice of 
techniques. For example, the samples of HO have already been collected and 
frozen, which means that it is not possible to administer fluorochrome dyes to the 
patients to determine the rate of mineral apposition. Also, cell culture forms no part of 
this work so those techniques adapted to this application will not be used. Nor will 
clinical diagnostic techniques because this is a basic science and in vivo proof of 
concept study. This still leaves many techniques available however, so the two 
questions that will help make the decision as to which to use are: 1) could this help to 
understand the structure of HO in a way that has not been done before and, 2) could 
this demonstrate a chemical property of HO that could be exploited for the purposes 
of prevention or treatment. The first question is based on the fundamental principle 
that bone is an active tissue that remodels according to the forces acting upon it. The 
physical history of the tissue is “written” in its structure. As such, understanding the 
physical structure of HO will provide evidence of the physical forces that have 
shaped it and possibly caused it. The second question is fundamental to the 
development of a chemical means of prevention or treatment of HO. If the identity of 
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the hard mineral component of HO is understood then a therapeutic agent can be 
tailored to attack it preferentially to normal bone. Also, it is not clear whether the 
mineral component of HO forms in the same way as normal bone. Chemical mapping 
of HO mineral and its soft-tissue envelope together may provide clues as to the 
mechanism of formation. 
In summary, this review of mineralised tissue analytical techniques (along with their 
underlying principles, applications, and limitations) has provided the understanding 
required for the physicochemical analysis of HO samples detailed in Chapter 3.  
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3 PHYSICOCHEMICAL ANALYSIS OF HUMAN POST-
TRAUMATIC HETEROTOPIC OSSIFICATION 
3.1 Introduction 
3.1.1 Structure and Function of Normal Bone 
Before one can consider the structure of pathological bone, it is important to 
understand the structure of normal bone. Bone is a hierarchically-ordered composite 
material with levels of organisation from the molecular to the macroscopic scale.120 
By mass, bone is 65% inorganic mineral, 25% organic (cells and proteins), and 10% 
water. The inorganic mineral phase is almost entirely composed of nanocrystalline 
non-stoichiometric (calcium deficient) hydroxyapatite (HA) with various lattice 
substitutions and trace element inclusions.169-171 This so-called “biological apatite” is 
relatively poorly crystalline compared to mineral apatite.172 
The protein content of bone is 90% type I collagen, which provides a matrix into 
which the mineral phase is deposited.173 The direction and arrangement of collagen 
fibres in bone varies according to bone type and anatomical location and is one of 
the causes of anisotropy.174 Non-collagenous proteins make up the remaining 10% of 
the protein content of bone and are grouped into one of the following categories: 
proteoglycans, glycoproteins, small integrin-binding ligand N-linked glycoproteins 
(osteopontin, matrix extracellular phosphoglycoprotein, bone sialoprotein, dentin 
matrix protein-1, dentin sialophosphoprotein, and dentin phosphoprotein), 
osteocalcin, and osteonectin.175,176 
 63 
 
There are three specialised cell populations in bone.177 Osteoblasts are the product 
of mesenchymal stem cell differentiation and their function is to form bone through 
the production and mineralisation of extracellular matrix. Osteoclasts are multinuclear 
bone-resorbing cells descended from a monocyte/macrophage lineage. They resorb 
bone through the formation of a sealed microenvironment into which they actively 
secrete protons, chloride ions, and cathepsin K. Together, osteoblasts and 
osteoclasts form multicellular units to facilitate coupled bone remodelling, which is a 
process controlled by local and systemic signalling systems.178 During the process of 
bone formation, some of the osteoblasts become trapped in lacunae and change 
Figure 3-1: Hierarchical structure of bone from whole bone to crystal lattice structure. At the 
macroscopic level, a whole bone is composed of mesh-like trabecular bone surrounded by a 
shell of dense cortex. At the sub-millimetre scale, both trabecular and cortical bone have a 
lamellar sub-structure where the mineralised collagen fibrils are arranged in layers. The 
identity and distribution of bone cells relate closely to lamellar organisation at this length 
scale. At the sub micron scale, hydroxyapatite is seen to coat and infiltrate collagen. At the 
nanometre scale there is structuring of the hydroxyapatite crystal orientation and crystal 
lattice composition. Reproduced with permission from Burr and Akkus.176 
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morphology to become osteocytes. These specialised cells form an interconnected 
network throughout the bony tissue and are thought to have multiple roles including 
calcium sensing, remodelling control, and strain detection.179  
Vertebrates form normal bone through two main mechanisms: intramembranous 
ossification (disorganised woven bone is remodelled into the mature lamellar version) 
and endochondral ossification (mineralisation of a cartilage template by 
osteoblasts).180 Multicellular functional units consisting of coupled osteoblasts and 
osteoclasts constantly remodel developing and mature bone in response to local 
strain.181,182 This is known as Wolff’s law, which plays a crucial role in driving the 
observed organisation of bone at multiple length scales.14 Bone functions as a 
mechanical scaffold for weight bearing and is an effector mechanism for muscle 
contraction.183 It also acts as an endocrine organ, storing calcium and phosphorus, 
and a haematopoietic organ generating blood components.184 Finally, bone has a 
protective function to prevent damage to crucial organs such as the brain and heart. 
3.1.2 Current Understanding of the Structure of Human HO 
3.1.2.1 Macroscopic 
On the whole organism length scale, one important feature of HO is that some 
anatomical sites are more prone to HO development than others. As described in 
Chapter 1, HO forms most commonly around the hips and, in the context of traumatic 
amputations, the distal end of the residual femur. 
At the macroscopic level, HO has a highly variable morphology (Figure 3-2).185 This 
makes it challenging to make generalisations about, but there are some common  
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Figure 3-2: 3-D computed tomography reconstructions of the residual femora of 
patients with combat-related amputations and HO. These images illustrate the variable 
morphology and disordered architecture of HO on a macroscopic scale. A: inverted 
dome (convex side pointing downwards) shape of HO extending from the distal 
femoral residuum. Also, note the islands of HO not attached to the orthotopic bone. 
Characteristically, the growth of HO on the medial side is more extensive than that on 
the lateral side. B: There is HO developing from the end of the residual femur in this 
case but the morphology is different, with extensions growing distally rather than 
proximally and no preference for the medial side. There is also a large volume of HO at 
the level of the mid-portion of the residual femur in the posterior compartment. There 
are also small islands of HO. Reproduced with permission from Isaacson et al.186 
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patterns described in the literature. For example, in the simplest of terms, HO may be 
attached to, or separate from, normal bone. This forms the basis of a classification 
system that was derived from MRI scans of a non-blast trauma series of patients and 
describes HO as intramuscular (separate from normal bone), periosteal (attached to 
normal bone), or intermediate (associated with the insertion site of muscles into 
bone). Another morphological description in paraplegic patients divided cases into 
those with HO “needles “ or “blades”.187 In post-surgical cases of HO around the hip, 
the most commonly used morphological classification system was derived by 
Brooker, who used the degree of bony bridging across the joint as the key indicator 
of severity.188 CT scanning has allowed a more nuanced appreciation of the 
morphology of HO around the hip but the classification system that results is still very 
simple and merely describes which side of the joint is affected.147 Similarly, HO in the 
residual stumps of blast amputees can form a wide variety of shapes but the 
classification system that has been developed is simply a description of the amount 
of HO as a proportion of the width of the residuum.22 
A common theme of these classification systems is simplicity. Highly complex 
structures are reduced to a handful of categories based on simple parameters such 
as location or size. This is possibly due to the fact that these are clinical classification 
systems and so only a few parameters have clinical importance. Also, different 
morphological parameters are clinically relevant at different sites. Near a joint, the 
extent to which the HO interferes with movement is most important whereas in a 
residual limb stump, the relative diameter of HO is most important as it will guide 
prosthetics management. However, while these systems do have clinical utility, they 
do not provide fundamental insights into the condition. In the literature there are no 
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studies that quantify morphology more completely than these simple classification 
systems or compare morphology over time or between aetiologies. 
3.1.2.2 Micro to Nano Scale 
In the millimetre to micron length scale, HO also displays a disordered architecture. 
All of the structures found in normal bone are present but their spatial arrangement is 
abnormal. This was demonstrated by Isaacson et al, who used microradiography, 
SEM, and histology to demonstrate vascular channels, Haversian systems, mixed 
cancellous and cortical morphology, active remodelling, bone marrow, and adipose 
cells.78 They also noted highly variable distribution of mineralisation within samples. 
In fact, the same group discovered such a significant variation in the degree of 
mineralisation within their samples that they hypothesised that the HO had been 
seeded by chips of normal bone displaced into the soft tissue during the injury.144 As 
with their previous study, they describe HO as displaying a hybrid of cortical and 
cancellous morphology but they do not characterise it any further. 
Crane et al. used histological techniques to assess human HO bone and described it 
as hypercellular and disorganised.128 They also report identifying cement lines and 
marrow elements but reported that they saw no evidence of osteoclasts or 
remodelling activity. Histological data presented by Rangnathan et al.50 have been 
interpreted as evidence that maturation of HO bone is more advanced at the 
periphery of the lesion compared to the centre but the rationale for this conclusion is 
not explored. It could equally be concluded from the published images that the 
peripheral portions of the lesion were tending towards a cortical morphology while the 
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central portions were predominantly trabecular; which would be more in keeping with 
other data. 
Beyond these qualitative descriptions, there has been no attempt to quantify the 
structure of human HO at this length scale. Also, notably, there has been no 
published work using micro or nano tomographic techniques to examine the 3-D 
structure. 
3.1.2.3 Molecular Scale 
Chantraine et al.189 excised HO from patients with spinal cord injuries and used 
atomic absorption spectroscopy on processed and finely ground samples to 
determine the calcium and phosphorous content as 40-236 mg/cm3 and 28-113 
mg/cm3 respectively. They did not provide any data on how the calcium and 
phosphorous were chemically bound. Sabou et al.132 also analysed processed and 
finely ground HO samples and used X-ray diffraction to confirm that the mineral 
component was crystalline hydroxyapatite. They used manual peak matching to 
confirm the presence of hydroxyapatite but did not provide any data on the presence 
of any secondary phases. There was no data on the crystal lattice parameters or, 
due to the sample preparation, on crystallite orientation. 
In addition to their histological data described in 3.1.2.2 above, Crane et al.128 used 
Raman microscopy to investigate the chemical species present in HO and confirmed 
that the predominant mineral phase was the same carbonated hydroxyapatite 
(“biological apatite”) as found in normal bone. They were also able to provide 
information on different mineral species present such as amorphous calcium 
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phosphate (through deconvolution of the 960 cm-1 v1 phosphate band) and the 
degree of carbonation of the hydroxyapatite (1070 cm-1 v1 carbonate band). This work 
does not provide any quantification of the absolute amounts of amorphous calcium 
phosphate or carbonate, nor does it provide any spatial distribution data for the 
chemical species. Indeed, there are currently no published data on the spatial 
distribution of chemical species in HO. 
3.2 Methods 
3.2.1 Samples 
Samples of heterotopic ossification were harvested from patients undergoing 
excision surgery at the Queen Elizabeth Hospital, Birmingham, United Kingdom. All 
patients gave their full consent for their tissue and data to be used for research 
purposes. All of the patients developed HO secondary to major traumatic injuries. 
The demographic details of the patients are included in Table 3-1. 
All tissue transfer and handling was done with reference to the Human Tissue Act 
2004 and local regulations. Ethical approval was acquired from the North West 5 
Research Ethics Committee. The samples were frozen immediately after removal 
and transferred to the Human Biomaterials Resource Centre (HBRC) at the 
University of Birmingham. After release from the HBRC, the samples were kept at 
minus 80°C until required for sectioning or analysis. Sample preparation varied 
according to the individual techniques and is described in greater detail below. 
Throughout this chapter, sample numbers and patient numbers will be synonymous; 
i.e. sample 1 is from patient 1 and so on. Where there is more than one sample per 
patient, this is indicated by a suffix letter. 
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3.2.2 Plain Radiograph Methods 
Upon receipt of the samples from the HBRC biobank, contact radiographs were 
performed as a screening investigation to establish the degree of mineralisation. 
These were taken using a Faxitron LX-60 (Faxitron X-ray LLC, Lincolnshire, USA) 
with exposure time of 10 s and beam voltage 25 kV. Contact radiograph images were 
digitised using the Agfa CR-30X radiography imaging system. Photographs of the 
samples were taken at the same time for comparison. 
3.2.3 Micro Computed Tomography (MicroCT) Methods 
Samples from patients 3 - 6 were thawed at room temperature for 1 hour and each 
was then cut into 3 smaller samples using hand tools. These were sealed in 
radiolucent cellulose tubes with wet tissue paper to prevent drying during scanning. 
Scanning was performed using a Bruker Skyscan 1172 microCT scanner (Bruker, 
Coventry, United Kingdom). The scan settings used were as follows: near camera 
position, tube voltage 70 kV, tube current 100 µA, 180o rotation, rotation step 0.4o, 
frame averaging 3, exposure time 950 ms, pixel size 3.51 µm, camera size 2000 x 
1332 pixels, 0.5 mm aluminium filter. Each sample scan lasted for approximately 43 
minutes. Scans were reconstructed using NRecon (software version 1.6.10.2, Bruker 
microCT) with the following settings: beam hardening correction 30, smoothing 3, 
ring artefact reduction 10. Reconstructed datasets were processed using CTan 
(version 1.15.4.0, Bruker microCT) as follows: 3-D automatic Otsu adaptive 
thresholding, 2-D black despeckling with 9 pixel limit, 3-D black despeckling with 100 
voxel limit, and 3-D white despeckling with 100 voxel limit. The data were analysed 
using the 3D object tool in the same programme. Details of the algorithms used to 
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generate the quantitative data may be found at: http://bruker-
microct.com/next/CTAn03.pdf. Tissue mineral density (TMD) calibration was 
performed with proprietary hydroxyapatite phantoms (Bruker) using the same 
scanning and reconstruction parameters as for the samples. Once calibration had 
been completed, TMD was calculated by binarising the dataset and then producing a 
VOI mask with which to selectively measure the greyscale values of the mineralised 
parts of the sample. 3-D reconstructions were created using CTvox (version 3.0.0 
r1114 (64 bit), Bruker microCT). 
3.2.4 Scanning Electron Microscopy (SEM) Methods 
A different subset of samples was used for SEM. Samples designated for surface 
topographical investigation were incubated in hypochlorite solution overnight to 
remove any non-mineralised tissue. They were then mounted directly onto aluminium 
conductive stubs using adhesive conductive carbon discs, and sputter coated with a 
50 nm coating of gold. These were studied using a Hitachi TM3030Plus (Hitachi 
High-Technologies Europe GmbH) in secondary electron (SE) mode with a beam 
voltage of 10 kV. Samples designated for cross-sectional analysis were treated in 
hypochlorite solution for 1 hour and then embedded in epoxy (EpoFix Low Viscosity 
Resin, Struars Ltd, Rotherham) under vacuum. They were then ground and polished 
before being mounted on conductive aluminium stubs as above. Conductive copper 
tape was used to prevent charging of the samples but no gold sputter coating was 
applied. They were studied using the same electron microscope in backscattered 
electron (BSE) mode with a beam voltage of 15kV. 
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3.2.5 Synchrotron X-Ray Diffraction (SXRD) Methods 
Samples were thawed at room temperature for 1 hour and then embedded in optimal 
cutting temperature (OCT) compound (VWR Chemicals, Leuven, Belgium) under 
vacuum (20 kPa) using a Struers CitoVac (Struers Ltd, Rotheram, United Kingdom). 
After refreezing at -80°C overnight, the samples were equilibrated to -18°C and then 
cut into 100 µm sections using a Leica cryotome fitted with a tungsten carbide blade. 
Sections were mounted on glass microscope slides and allowed to dry in ambient 
conditions for 72 hours. 
SXRD measurements were carried out on the I22 beamline at the Diamond Light 
Source (Oxford Harwell Campus, Didcot, UK). An incident X-ray energy of 14 keV 
was used (equivalent to a wavelength (λ) of 0.8856 Å) with a beam size of 10 µm2 
defined using vacuum tube collimation slits. Tissue samples were mounted normal to 
the impinging X-rays in transmission geometry onto a travelling sample stage to allow 
movement in two orthogonal directions perpendicular to the X-ray beam for SXRD 
mapping. 
A wide angle X-ray scattering (WAXS) geometry was used to study the 
hydroxyapatite phase, by placing a 2D area detector (Pilatus P3-2M, Dectris, Baden-
Daettwill, Switzerland) with a 1475 x 1679 pixel resolution (172 µm2 optical pixel size) 
270 mm behind the sample to give a q range of 0.1 - 4.7 Å-1. SXRD maps were 
collected in high and low resolution modes corresponding to measurement 
increments (along each row of a mapped area) of 12.5 and 50 µm respectively, by 
moving the sample relative to the beam in an x and y direction, with each 
measurement having an exposure time of 15 s. A photo-diode was mounted on to the 
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beam stop to simultaneously record the attenuation of the direct beam to correct the 
data for varying transmission.  
To aid data analysis, further measurements were taken for the direct beam, empty 
sample containers and water to allow diffraction patterns to be corrected for 
background and normalisation effects. Instrument parameters such as the X-ray 
wavelength, sample to detector distance and the peak shape profile were accurately 
determined using a lanthanum hexaboride (LaB6) standard sample (Sigma Aldrich, 
Dorset, UK). 
Diffraction data were normalised and background corrected using the DAWN 
software package (version 2.1, DAWN science).190 Texture parameters, such as the 
direction and magnitude of the preferred orientation were obtained by integrating the 
intensity around the Debye ring of the (002) Bragg reflection over 360° and plotted 
against the azimuthal angle. Preferred orientation was determined as this reflection is 
perpendicular to the C axis of the hydroxyapatite unit cell. Peaks were fitted with a 
Gaussian shape to calculate the deviation angle φ of the crystallite axis with respect 
to the vertical axis.191 
Note that scanning and data processing were undertaken with the assistance of Mr 
Slobodan Sirovica (PhD Researcher, Aston University, Birmingham) and Professor 
Owen Addison (School of Dentistry, University of Birmingham). 
3.2.6 X-Ray Fluorescence (XRF) Methods 
An initial attempt to investigate HO using XRF was performed on a single subsample 
of tissue from patient 2. This sample was defrosted for 1 hour from -80 to room 
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temperature and underwent no further preparation. More detailed XRF examination 
was performed on subsamples from patients 2, 3, 4, and 6. These samples were 
defrosted and vacuum embedded in OCT before being sectioned to 100 µm 
thickness in a cryostat using a tungsten carbide blade. Sections were air-dried on 
glass slides. 
Elemental maps of the HO samples were generated using a Tornado M4 micro-XRF 
system (Bruker Nano Gmbh, Berlin, Germany) fitted with a Rhodium micro focus X-
Ray tube and a polycapillary lens. The X-ray tube voltage was set to 50 kV and a 
tube current set to 300 µA. XRF spectra were collected pixel by pixel while the 
microfocus beam was rastered over the sample. Elemental maps were generated 
progressively in real time by gating around the phosphorous Kα1 (2.0137 keV), 
calcium Kα1 (3.692 keV) and sulphur Kα1 (2.30784 keV) X-ray emission lines in the 
spectra, creating an image where pixel intensity represented X-ray detector pulses 
integrated under an elemental peak at each measurement point on the sample. 
Maximum pixel intensity for each element was normalised to the peak pulses/eV 
value for that element across the whole sample. The instrument was set to map the 
selected area twice to generate a single averaged map for each element. 
Maps were generated with a pixel resolution of 15 x 15 µm and a measurement time 
of 60 ms per pixel. The chamber pressure was lowered to 50 mbar in order to 
maximise sensitivity to the phosphorus signal, which can be attenuated by air. In a 
preliminary experiment, brightfield images of test samples (at x10 and x100 
magnification) subjected to incremental vacuum pressures of 1000 mbar, 500 mbar, 
200 mbar, 100 mbar, and 50 mbar did not reveal evidence of vacuum distortion. 
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Note that scanning and data processing for the XRF and Raman spectroscopy 
investigations were done with the assistance of Dr Richard Williams (School of 
Chemical Engineering, University of Birmingham, UK). 
3.2.7 Raman Spectroscopy Methods 
The sample from patient 4 (Figure 3-17C) that had undergone XRF analysis was 
reinvestigated using mapped Raman spectroscopy. Raman maps of the samples 
were collected with a confocal Raman microscope (Alpha300r, Witec, Ulm Germany), 
with a 785nm 250 mw diode laser (XTRA II, Toptica photonics, Munich, Germany) 
and a spectrograph (Acton SP2300, Princeton instruments, Trenton, NJ, USA) fitted 
with a 300 g/mm 750 nm blaze grating. 
Raman maps were generated by rastering the beam over the samples via a 20x 
(numerical aperture = 0.45) objective lens with a 50µm step size and accumulating 3 
spectra with an integration time of 1 second at each point. The laser power was 
measured at 60 mW (standard deviation 0.06 mW) at the back aperture of the 
objective lens. The data were collected and saved using the WITec control version 
1.6 software (WITec, Ulm, Germany). 
Spectral data cubes were pre-processed to remove cosmic rays using the instrument 
associated software (Witec Project v2.10, Witec, Ulm, Germany), exported in .SPC 
format. The .SPC files were imported into MATLAB (MATLAB 2016b. Mathworks, 
Natick, Massachusetts, USA), baseline corrected using an adaptive iteratively 
reweighted penalised least squares method,192 and vector normalised. Least squares 
regression was used for fitting of individual Gaussian curves to each peak. 
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Octacalcium phosphate (OCP) was represented by the P−O stretching mode (v1) of 
the PO4 group between 953-956cm-1. Hydroxyapatite was represented by the 
symmetric stretching mode (v1) of the PO4 group (P−O bond) between 958-961cm-1. 
Collagen was represented across all maps by the amide I peak spanning 1620-1650 
cm-1. To best visualise the relative amounts, distribution of, and association between, 
mineral and collagen throughout the samples RGB image maps were produced by 
integrating over the sum of peaks of interest. 
3.2.8 Nano Computed Tomography (NanoCT) Methods 
Samples from patients 3, 4, and 6 were thawed, embedded in OCT, and sectioned as 
described in 3.2.5 (above). 100 x 100 x 4000 µm batons were cut from these sections 
by hand using a scalpel with visualisation via an optical microscope. These were then 
mounted onto aluminium sample-holding stubs. NanoCT was performed under 
vacuum at the ID16A beamline at the European Synchrotron Radiation Facility 
(ESRF) in Grenoble, France according to standard protocols.150 This beamline uses 
Kirkpatrick-Baez X-ray optics to produce a moderately monochromatic focused beam 
(ΔE/E ~1%). Beam energy was set to 17.05 keV. The detector was the FReLoN HD 
E230-84, which is an ESRF-developed charge couple device. Sample areas of 
interest were scanned at multiple spatial resolutions to allow an overview followed by 
a closer interrogation of sub volumes of interest. Overview scanning generated a 
voxel size of 120 nm (giving a cylindrical volume of interest with diameter and height 
245.76 µm). High resolution scanning generated a voxel size of 50 nm (cylindrical 
volume of interest diameter and height of 102.40 µm). Raw image data was collected 
at four different focus-to-sample distances for each rotation step (20.13, 20.99, 
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24.45, and 31.62 mm). Focus to detector distance remained constant at 1208 mm. 
Image reconstruction was performed as described previously.150 Briefly, the raw data 
generated during scanning were in the form of magnified Fresnel diffraction patterns. 
These data underwent alignment, phase retrieval, and tomographic reconstruction to 
obtain the 3D distribution of the real part of the complex refraction index decrement, 
which is proportional to the electron density.193 From this information, 3-dimensional 
mass density distribution may be ascertained. As the raw data were generated using 
hard synchrotron radiation, propagation and dynamical effects within the sample are 
negligible. Retrieved phase maps were converted to tomographic reconstructions 
using a filtered back projection algorithm (PyHST, ESRF). All reconstructed output 
images were 2048 x 2048 pixels in size. The output images were in the form of a 
stack of 2048 2-D greyscale cross sections. These data were thresholded and 
processed using CTan (version 1.15.4.0, Bruker microCT) to remove the canaliculi 
and any other features (such as Haversian canals etc.) apart form the osteocyte 
lacunae themselves (see Figure 3-19 C and D).  
Note that scanning and data retrieval were undertaken with assistance from Dr 
Alexandra Pacureanu (ESRF, Grenoble, France) and Professor Owen Addison 
(School Of Dentistry, University of Birmingham, UK). 
3.3 Results 
3.3.1 Plain Radiograph Results 
Radiographs show the marked heterogeneity of the samples in terms of the quantity 
and distribution of the radio-dense mineral phase (Figure 3-3). Samples 1, 5A, and 7 
have no areas of high X-ray attenuation and are comprised of soft tissue only. 
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Sample 2 is predominantly composed of soft-tissue X-ray density with small islands 
of high attenuation material distributed in bands throughout. Sample 3 has a central 
area with cortical morphology surrounded by soft tissue containing islands of mineral 
similar to those seen in sample 2. Samples 4A-C are the most abundant and are 
relatively homogeneously trabecular in morphology at this macroscopic scale. These 
samples are comprised of multiple smaller fragments, which would be consistent with 
piecemeal removal during surgery. Sample 5B is entirely cortical and appears to be a 
piece of orthotopic rather than heterotopic bone. Sample 6 has mixed cortical and 
trabecular morphology with little soft tissue envelope. 
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Figure 3-3: Contact radiographs and photographs of all of the samples of human HO. 
It is clear that there is a great deal of variability with cortical, cancellous, and hybrid 
morphologies demonstrated to different degrees within and between samples. Scale: 
each radiograph / photograph is 5cm across.  
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3.3.2 MicroCT Results 
MicroCT 3-D reconstructions of samples 3 to 6 are shown in Figure 3-4 and Figure 
3-5. Samples 3A-C are neither classically cancellous nor cortical in morphology but 
are a hybrid of both. Channels approximately 50 µm in diameter can be seen opening 
onto the surface of the samples in an irregular distribution. The surfaces of the 
samples are textured with pits and depressions of approximately 500 µm diameter. 
Channels of 1 mm diameter are seen to perforate the samples. Sample 4A is almost 
entirely trabecular. There is a clear graduation in trabecular size from left to right 
across the sample ranging from a few tens of microns to a few hundred microns. 
Sample 4B demonstrates a predominantly plate-like morphology with plate thickness 
of 150-300 µm separated by unmineralised gaps of similar width. Sample 4C has a 
trabecular central volume bounded by a perforated cortical shell of 80-300 µm 
thickness and, as seen in sample 4A, the trabeculae demonstrate variable size in a 
graduated pattern with thickest trabeculae adjacent to the cortical shell and thinnest 
trabeculae further towards the central volume. Samples 5A-C appear to be normal 
cortical bone. They demonstrate regularly arranged osteons and larger channels, 
presumably vascular in nature. Samples 6A-C have cortical shells of 200-1500 µm 
thickness adjacent to trabeculae. The trabeculae in sample 6A appear similar to 
those in normal bone whereas those in 6B and 6C are more disordered and even 
plate-like. A 500 µm diameter perforating channel is visible in 6B, which is consistent 
with a vascular structure. The tissue mineral density (TMD) and quantitative 
morphometric parameters of these datasets are shown in Figure 3-6 and Figure 3-7 
respectively. 
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3A 
 
 4A 
 
3B 
 
 4B 
 
3C 
 
 4C 
 
Figure 3-4: MicroCT 3-D reconstructions of HO samples from patients 3 and 4. 3A-C: 
cancellous and cortical hybrid morphology. 4A: variation of trabecular size. 4B: plate-like 
morphology. 4C: trabecular volume bounded by cortical shell. 
Arrowheads = plate-like morphology. White circles = osteons. Black circles = vascular 
channels. Distance between “ticks” on the bounding cuboid = 500 µm in all images. 
 83 
5A 
 
 6A 
 
 
5B 
 
 6B 
 
5C 
 
 6C 
 
Figure 3-5: MicroCT 3-D reconstructions of HO samples from patients 5 and 6. 5A-C: normal 
cortical bone appearance with osteons and vascular channels. 6A-C: coarsely trabecular 
volume bounded by cortical morphology of variable thickness.  
White arrows = cortical morphology. White circles = osteons. Black circles = vascular 
channels. Distance between “ticks” on the bounding cuboid = 500 µm in all images. 
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Figure 3-6: Tissue mineral density (grams of 
hydroxyapatite / cm3) for samples of human HO. This 
measure is insensitive to morphology. Error bars = 
SD. 
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Figure 3-7: Quantitative morphological analysis of the microCT datasets shown in 
Figure 3-5. 
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3.3.3 SEM Results 
SE SEM topographic images of HO from patient 4 are shown Figure 3-8 and Figure 
3-9. The images show the mineralised portion of the HO sample after soft tissue 
removal using sodium hypochlorite. The low magnification images demonstrate a 
predominantly hybrid morphology that is neither truly cortical nor trabecular. There 
are multiple channels opening onto the surface of the sample (Figure 3-8 A and B). 
These range in diameter from 30-80 µm. There is also extensive scalloping of the 
surface. These depressions are approximately 10-20 µm across and are consistent 
with osteoclast resorption pits. They form confluent patches on the surface of the HO 
but are not seen in all areas. In certain areas of the sample, the fractured surface can 
be seen (Figure 3-8 A and C). Higher magnification images show the osteoclast 
resorption pits in more detail. In a number of areas near these resorption pits, there 
are deeper depressions in the surface that contain multiple roughly spherical forms, 
which are approximately 1 µm in diameter. In the highest magnification view, these 
spherical objects can be seen to be formed from plate-like subunits that are 
approximately 0.5 µm in their longest dimension (Figure 3-9D). 
BSE SEM images of samples of HO from patients 3, 4, and 6 are shown in Figure 
3-10, Figure 3-11, Figure 3-12, Figure 3-13, and Figure 3-14. At low magnification, 
disordered trabecular (Figure 3-10A), hybrid (Figure 3-13A), and disordered cortical 
Figure 3-11A) morphology can be seen. There is also a region that has a plexiform 
appearance (Figure 3-11B). Across all the samples, there is a common appearance 
of disordered core regions containing a high density of osteocyte lacunae with little or 
no obvious organisation. These core regions are bounded by highly organised 
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lamellar bone, which is more sparsely populated with osteocyte lacunae. There is a 
sharp delineation between the ordered and disordered regions. The lacunae in the 
lamellar regions demonstrate a high degree of alignment with the lamellae and each 
other. Another finding is that the lacunae in the core regions appear larger and more 
rounded than those in the lamellar regions, which have a flatter and more elongated 
appearance in the direction of the lamellae. The lamellar regions are distributed both 
circumferentially around the Haversian canals and linearly at the surface of the 
samples. The lamellar regions are also darker than the disordered core regions. This 
darker appearance corresponds to a lower mean atomic number (Z) of the atoms in 
the lamellar regions compared to the disordered core regions. 
Like in the SE images, shallow pits can be seen on the surface of the HO (Figure 
3-10C). These are approximately 20 µm across and are found in a confluent group. 
At high magnification, osteocyte canaliculi can be visualised. These appear more 
numerous in the organised lamellar regions and are arranged at right angles to the 
orientation of the lamellae. The repeating wave-like pattern in Figure 3-14D is 
consistent with the previously described “twisted-plywood” orientation of collagen 
fibres.194 
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This lends weight to a central conclusion of this chapter; that while HO appears to be 
macroscopically disordered, below a certain length scale it is highly ordered. In other 
words, the fundamental constituents of and processes within HO are normal but lack 
coordination and direction above the micron to millimetre length scale. One 
hypothesis may be that the lack of insertion of muscles into HO, and the subsequent 
atypical loading that the tissue is therefore subjected to, could be the cause of the 
observed disorder. A clear demonstration of just how ordered and normal HO bone 
can be on a small length scale is shown in Figure 3-14D. This demonstrates the 
highly ordered arrangement of collagen fibres in a “twisted plywood” configuration, 
which has been described at length in the normal bone literature.194 
3.3.4 SXRD Results 
C-axis length for the HA component of each sample was determined to be follows: 
sample 3: 6.86 Å (SD 0.0047), sample 4: 6.86 Å (SD 0.0047), sample 6: 6.87 Å (SD 
0.0035). Spatially resolved data for beam transmission, hydroxyapatite c-axis length, 
and orientation / texture are presented in Figure 3-15. Crystal orientation in each 
sample has the appearance of a dominant orientation with individual regions of 
variability. There is a correlation between areas with low transmission and areas of 
high pixel-by-pixel variation in orientation. 
Hydroxyapatite was the only crystalline calcium phosphate phase detected in the 
samples. 
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Figure 3-15: Synchrotron X-ray diffraction mapping of samples of HO from patients 3 
(row A), 4 (row B), and 6 (row C). Representative beam transmission maps (left), 
hydroxyapatite c-axis length maps (middle), and texture / orientation maps (right) for 
each sample. Transmission intensity is inversely related to tissue mineral density and 
is represented by an arbitrary scale. 
 
A 
 
B 
 
C 
 
 97 
3.3.5 XRF Results 
The image generated from the sample of HO from patient 2 shows several 
trabeculae with co-localised calcium and phosphate signals (Figure 3-16). 
Additionally, there are several areas of calcium signal without any appreciable 
phosphorus signal. In some cases, these calcium-rich areas are not connected to the 
trabeculae and thus form islands. 
Figure 3-17 shows XRF maps from patients 2, 3, 4, and 6. Sample 3 (subfigure A) is 
largely unmineralised as demonstrated by a high sulphur signal from proteins in the 
soft-tissue extracellular matrix. There are several islands of co-localised phosphorus 
and calcium. There are also islands of high calcium signal without phosphorus. In 
samples 2 and 4 (subfigures B and C) the co-localised calcium and phosphorus 
signals form a recognisable, albeit disordered, trabecular pattern that is to be 
expected in HO. In several places, a calcium signal can be seen extending into the 
surrounding soft tissues. 
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Figure 3-16: 	   Sample of HO from patient 2. A: photograph of the 
sample taken using the optical microscope in the XRF scanner. The 
sample has undergone no preparation since removal from the 
patient. B: XRF image of the area within the dashed white box in A. 
Calcium rich islands are indicated by dotted white ellipses. Two of 
these calcium rich islands do not appear to be connected to the 
mineralising projections. Red = calcium. Green = phosphorus. Yellow 
= co-localised calcium and phosphorus. 
A" B"
 1 mm 
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3.3.6 Raman Spectroscopy Results 
Raman maps for hydroxyapatite (HA), octacalcium phosphate (OCP), and collagen in 
a sample of HO from patient 4 can be seen in Figure 3-18. OCP is shown to be 
highly co-localised with HA (subfigures B and C). These maps also correlate well with 
the distribution of colocalised calcium and phosphate (yellow areas in subfigure A) in 
the XRF map except in the lower right quadrant of the map. In this quadrant, there is 
a diffuse HA/OCP signal that does not correspond well to the structured calcium and 
phosphorus seen in a trabecular pattern in the XRF image. 
Subfigure D shows that collagen occupies the sample outline as the HA/OCP signal 
but that within this boundary, there is an inverse relationship in signal. Areas rich in 
HA/OCP show lack of collagen and vice versa. This is confirmed in the composite 
image where the map is either dominantly yellow (indicating colocalisation of HA and 
OCP) or blue (indicating predominance of collagen) with no areas of white, which 
would indicate the co-localisation of all three molecules. 
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Figure 3-18: A: XRF map of a sample of HO from patient 4, indicating the region of 
interest for Raman mapping. B-D: Maps showing the relative distribution 
Hydroxyapatite (HA), Octacalcium Phosphate (OCP), and Collagen within the region of 
interest. Brighter pixels indicate higher concentration. E: composite of subfigures B-
D. Yellow area indicates colocalisation of HA and OCP. Blue area indicates mineral-
poor soft tissue matrix. 
HA OCP 
Collagen Composite 
1"mm" 1"mm"
1"mm"1"mm"
A"
" "
B"
D"
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E"
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3.3.7 NanoCT Results 
Figure 3-19A and B were formed by summing information from 200 slices of the 
datasets. These cross-sectional images show that the osteocyte lacunae are highly 
aligned with each other and with the lamellar structure within which they reside. They 
have a typically flattened lozenge shape, which can be approximated to an ellipsoid. 
There are abundant canaliculi emerging from each osteocyte lacuna and these 
branch multiple times and form a densely connected network with canaliculi from 
other osteocytes. The canaliculi are also highly aligned with each other, with their 
primary axis of alignment being at right angles to the axis of alignment of the long 
axis of the lacunae. 
Striations within the inter-lacunar tissue are also visible. These match the orientation 
of the long axis of the lacunae. Within and between these striations are bright flecks, 
which represent lower density material or porosity. 
Three-dimensional reconstruction of processed data reveals the 3-dimensional 
morphology of the osteocyte lacunae and their alignment with the lamellar structure 
of the samples. In Figure 3-19C, the long axes of the lacunae align themselves along 
lamellae around a Haversian canal (digitally removed from the image). In Figure 
3-19D these same lacunae are viewed along an orthogonal plane to reveal that their 
intermediate and short axes also demonstrate a high degree of alignment. 
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Figure 3-19: Processed nanoCT images of HO from patient 6. A: 200-slice (24 µm) 
maximum intensity image at 120 nm per pixel resolution. The elongated osteocyte 
lacunae are highly aligned with each other. Canaliculi are visible extending at right 
angles to the axis of orientation of the lacunae. Haversian systems are partially visible 
at the bottom right and top of the image. B: 200-slice (10 µm) maximum intensity 
image at 50 nm per pixel resolution. In addition to the osteocyte lacunae and 
canaliculi, alignment of the extracellular matrix can be seen as alternating dark and 
lighter striations running from the top right to the bottom left of the image. Within and 
aligned to these striations, there are low-density (bright) features, which could 
represent collagen fibres. C: 3-D reconstruction of processed dataset after removal of 
all features except osteocyte lacunae. Note how the lacunae are arranged around a 
Haversian canal (removed) D: Orthogonal view of same dataset as in C. Note the high 
degree of alignment of the osteocytes with each other. In all of these images, bright 
pixels/voxels represent low density regions (porosity) and dark pixels/voxels 
represent high density regions (mineralised tissue). 
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Figure 3-20: 200-slice Z projections of maximum greyscale values from nanoCT 
datasets. A & B = patient 3. C & D = patient 4. E & F = Patient 6. Scale bar = 10 µm. 
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The bright flecks in the inter-lacunar tissue are also of interest. As they are brighter 
than the mineralised background they must have a lower mean Z value. They may 
possibly represent collagen-rich regions or nano-scale porosity. Unfortunately, these 
data do not contain any compositional information (other than mean Z) so it is not 
possible to determine the nature of these observed structures any further. 
3.4 Discussion 
3.4.1 Plain Radiograph Discussion 
All 7 of the patients from whom the HO was excised were male and had been 
exposed to major trauma. The mechanism of injury was blast in 5/7 and blunt force 
trauma in 2/7. All except one patient had an amputation; either caused by their 
mechanism of injury or performed surgically in the course of their treatment.  
Looking at the macroscopic radiographic appearance of the samples, it is striking 
how variable the morphology is. Within the subset of samples containing obvious 
mineralisation, regions of cortical, trabecular, and hybrid morphology are clearly 
visible. 
Samples 1 and 7 do not contain any mineralised tissue detectable by contact 
radiographs. It is unclear why these samples were included in the cohort. It is 
possible that they were suspected of being “pre-HO” but these data are not available. 
Also, sample 5 may not be HO at all. Its macroscopic appearance is that of a portion 
of the distal fibula, which may have been removed during a stump refashioning 
operation. This is consistent with the clinical information that the patient had a below-
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knee amputation. Despite the hypothesis that this sample was not HO, it was still 
subject to microCT scanning as detailed in 3.2.3. 
The heterogeneity and small number of samples means that any statistical analysis 
or quantitative comparison of the samples with each other or even with normal bone 
is unlikely to be of value. Also, the variable morphology and quantity of the samples 
means that they are not all suitable for all the various analytical modalities available. 
3.4.2 MicroCT Discussion 
MicroCT investigation of HO has revealed a wide variety of morphological features. 
As in normal bone, osteons, vascular channels, cortical volumes, and trabecular 
volumes are all present. However, the disordered arrangement of these anatomical 
elements in relation to each other sets this tissue apart from normal bone. 
Additionally, these features demonstrate variability over short length scales, which is 
unlike normal bone. For example, there is a distinct graded increase in size of 
trabeculae in samples 4A and 4C over a few mm and a similarly variable cortical 
shell thickness in samples 6B and 6C.  
Another interesting feature is the hybrid morphology seen in samples 3A and 3C. 
This is neither typically cortical nor trabecular but contains elements of both. The 
samples are largely solid but contain channels (300-500 µm in diameter) and 
extensive surface texturing including depression and ridges with approximately 300-
500 µm feature size. There is also evidence of osteons opening onto the surface of 
this hybrid tissue, as seen inside the white circles in Figure 3-4 A and C. 
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Sample 4B demonstrates an entirely novel architecture that has not previously been 
described in the context of HO. This sample is dominantly plate-like in its morphology 
with mineralised and unmineralised layers approximately 150-300 µm in depth. This 
structuring is reminiscent of distorted fibrolamellar or plexiform bone, which is not 
usually present in adult humans except in response to injury or inflammation, and 
even then only rarely.195 
Samples 5A-C are clearly different to the other samples. They are almost entirely 
cortical, with highly regular Haversian canals of 40-80 µm in diameter. This provides 
support to the hypothesis that this sample is normal bone. It may be tempting to use 
this as a form of control tissue but there are two significant reasons not to do so. 
First, the macro and micro scale morphology look normal but this cannot be 
definitively proven one way or another. Second, the very idea of control tissue is 
problematic in the context of HO. It has been demonstrated (above) that HO bone 
can be morphologically similar to normal bone (cortical and cancellous), to at least 
one type of pathological bone (plexiform bone), and to a hybrid of any of these put 
together. So it would be hard to justify what type of normal bone one would choose 
as a control. Additionally, bone morphological parameters vary between different 
bones, making it even more challenging to justify what could be considered a valid 
control. The lack of consensus on this issue has led to the decision not to use sample 
5, or any other tissue, as a control for any of the physicochemical techniques. 
Further, given the strong suspicion that sample 5 is normal bone, its quantitative 
morphological results will not be discussed below. 
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It is important to note that the aim of this work is not to compare the samples against 
one another, merely to observe what morphology is available to be observed. 
Therefore, no statistical significance testing has been performed on these data. Mean 
values and standard deviations for each patient have been derived from the 
subsample data. 
Tissue mineral density was notably constant within and between samples (Figure 
3-6). This may be partly explained because, unlike bone mineral density (BMD), TMD 
is insensitive to morphology of the samples because it is calculated from the 
mineralised portion of the dataset only (as defined by the binarisation process). In 
contrast, BMD is highly sensitive to the morphology of the samples because it 
averages the density values for the entire volume, including any soft tissue, vascular 
network, marrow elements, and other porosity. BMD has merit when one is interested 
in bone that conforms to normal trabecular morphology because it provides a 
clinically meaningful result but is of highly questionable relevance to HO. In contrast, 
TMD is particularly suitable for samples that do not fit standard morphological models 
and gives a clearer indication of the density of the mineral component only. What is 
surprising is how similar the TMD results are across the patients: 0.95 g/cm3 (SD 
0.05), 0.91 g/cm3 (SD 0.01), and 0.97 g/cm3 (SD 0.02) for patients 3, 4, and 6 
respectively. 
In contrast to the quantitative TMD data, the rest of the quantitative morphological 
data must be interpreted with extreme caution. The sample volumes used in this 
experiment were necessarily small due to the nature of the samples themselves. 
Figure 3-7A shows that the samples were only a few cubic millimetres in volume. The 
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relevance of this is that any calculated parameter will be highly influenced by small 
variations in the samples and may therefore provide information that is more to do 
with random sampling effects than being truly reflective of the tissue itself. In normal 
bone, it is important that a large sampling volume is used in order to improve the 
signal to noise ratio in the data. This is a reasonable approach when the architecture 
of the tissue being sampled is relatively homogeneous, such as orthotopic trabecular 
or cortical bone. However, given the highly variable morphology of the HO samples, 
even over short length scales, it is not clear that sampling larger volumes would be 
meaningful. 
An additional limitation of these quantitative data is that many of the algorithms used 
to generate them rely upon models developed for bone that is clearly trabecular or 
cortical. It is not clear how meaningful the data generated by these algorithms will be. 
There are plans to develop new methods of quantifying the morphology of HO bone 
(personal communication) but, until that time, the current tools are all that are 
available. The quantitative data are included despite the sampling and quantification 
challenges because there are currently no published data whatsoever about the 
microCT-derived histomorphometric parameters of HO. Providing this information will 
be a starting point from which a greater understanding of the structure can be built 
over time. 
Drawing conclusions from the quantitative results is challenging as there is such 
variation between (heights of bars) and within (magnitude of error bars) samples. 
Thus, perhaps the key conclusion to draw from these data is that there is not yet a 
satisfactory method for quantifying morphology of HO on this scale. This conclusion 
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supports a shift away from using current bone histomorphometric parameters and 
supports the development of new tools for quantifying the morphology of HO. 
3.4.3 SEM Discussion 
The topographical images generated by SE SEM confirm the qualitative findings of 
the microCT investigation, which are that HO can be morphologically similar to 
cortical bone, trabecular bone, a hybrid between the two, and even plexiform bone.  
Additionally, these images reveal extensive surface pitting, which is interpreted as 
evidence of osteoclast remodelling. 
BSE SEM images reveal a wealth of detail that is not available from the SE SEM or 
microCT investigations. The most striking finding is that the internal structure is 
sharply divided into two types of tissue and that this appears to be independent of the 
external morphology. There is a core tissue that is densely populated with large, 
unaligned osteocyte lacunae. This is surrounded by a more organised tissue that has 
a classically lamellar structure with fewer, more highly aligned, osteocytes. The 
delineation between these two tissue types is clearly defined with no evidence of 
intermediate tissue types. Not only is this subdivision of internal structure constant 
across the samples, but the spatial distribution of the tissue types is also constant. 
Ordered lamellar bone is present around Haversian canals and on the surface of the 
samples. Taken with abundant evidence of osteoclast remodelling of the surface of 
HO, this finding provides a key insight into how HO forms: the primary structure is 
likely to be the disordered core tissue, which is replaced through remodelling by the 
ordered lamellar bone. 
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Another finding that is common to all samples is that the lamellar regions appear 
darker than the intervening disordered regions. In BSE SEM, the higher the mean 
atomic number (Z) in a region, the more electrons are scattered and the brighter it 
appears. Thus Z must be higher in the disordered regions than the lamellar regions. 
It is unclear why this is the case and would certainly be of interest for a potential 
future examination of these samples. 
The clusters of approximately 1 µm diameter spheres visible in the SE SEM images 
(Figure 3-9) are also of interest. These appear similar to what has been described in 
the literature as calcospherites or mineralisation clusters.196 It is significant that these 
calcospherites are seen close to sites of resorption but nowhere else. This is strong 
evidence that local resorption and mineralisation are coupled, as in normal bone 
remodelling. Thus the disordered macroscopic and millimetre-scale architecture is 
not driven by uncoupled remodelling. Instead, the remodelling process is working 
normally but is being directed in a disordered manner. 
3.4.4 SXRD Discussion 
In general, the maps in Figure 3-15 show a correlation between areas with low 
transmission, shorter c-axis length, narrowness of the full-width half maximum 
(FWHM) 002 value, and variability in the lattice orientation. One interpretation of the 
correlation between areas with low transmission and areas of variable orientation is 
that these areas represent the disordered core regions seen in cross-sectional SEM 
imaging. Their central distribution in the sample fits this interpretation. Also, they 
were seen to be brighter on BSE SEM, indicating a higher mean Z value, which 
would account for lower X-ray transmission seen in the synchrotron data. What is 
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less clear, however, is why these areas demonstrate low FWHM values and shorter 
c-axis values. The FWHM value is an indicator of the magnitude of crystalline 
alignment and c-axis values are dependent on a number of values including lattice 
substitutions and local conditions at the time of formation. It seems paradoxical at 
first that there should be a high magnitude of crystallite alignment (low FWHM) in 
areas demonstrating disorder. However, if one examines the direction of alignment in 
these areas, one can see that there is a high degree of variation between pixels. So 
the picture is more nuanced than first appears: there is disordered alignment at 
longer length scales, but a high degree of order at shorter length scales. With respect 
to the c-axis parameter, the maps show shorter lengths in the core regions and a rim 
of longer lengths at the peripheries (although an exception is that there is a region of 
the rim of sample 3 that has a shorter than average c-axis). Without further data, this 
finding is challenging to explain. However, the strength of this effect is not great, with 
less than 1% difference between the longest and shortest c-axis lengths in any map.  
Put together, the conclusion from these data is that core regions have high mineral 
density, locally (<50 µm length scale) highly aligned crystals with short c-axis lengths, 
and poor alignment on longer length scales (>50 µm). 
3.4.5 XRF Discussion 
There is currently no published mechanistic data on mineralisation in HO so the 
finding of calcium-rich islands in developing HO is highly significant. This suggests 
that rather than synchronous deposition of calcium and phosphorus species to make 
hydroxyapatite, some other mechanism is occurring. It is conceivable that a calcium 
salt is deposited with a counter ion that is not detectable using XRF. Possibilities 
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could include organic acids such as lactate, oxalate, or carbonate. It is possible that 
this salt then transforms into an orthophosphate phase. This hypothesis is supported 
by the presence of a calcium-rich leading edge in the more mature samples of HO, 
suggesting that the tissue grows through a “calcium first” mechanism. Also, in the 
most mature specimen (3 years between injury and excision) there is no calcium-rich 
leading edge, suggesting that the growth of the mineralised tissue has ceased and it 
has become quiescent. This fits the clinical picture where HO grows rapidly over the 
course of months to years and then stabilises and stops progressing. It might be 
argued that embedding the samples in OCT could have caused some kind of soluble 
calcium phase to be washed out of the mineralised portion of the samples into the 
soft tissue giving the observed calcium-rich regions. However, these regions were 
also seen in Figure 3-16, in which the sample had undergone no preparation or 
manipulation of any kind so it makes this explanation much less likely and supports 
the calcium-first hypothesis. 
Another finding that fits with the clinical experience is that there is separation 
between the mineralised and unmineralised portions in the most mature specimen 
(Figure 3-17D). While this may be a processing and sectioning artefact, it illustrates 
that the interface between mature HO and soft-tissue is weak, a fact that is confirmed 
by excising surgeons who report that mature HO simply peels out of its soft-tissue 
envelope. Quantitative measurement of the sulphur signal (a surrogate measure of 
protein) shows that there is progressive loss of organic content within the mineralised 
portion of the samples as they mature. 
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In summary, the XRF studies have generated novel hypothesis relating to the 
mechanism of mineralisation in HO and the maturation process, including an 
explanation for clinically observed phenomena. 
3.4.6 Raman Spectroscopy Discussion 
The extensive OCP signal is the most interesting finding from the Raman mapping 
experiment. Raman spectroscopic evidence of OCP in bone formation has only ever 
been shown in animal studies, and then only as a point spectrum rather than as 
spatially resolved data.197 Its colocalisation with HA is important because it is thought 
to occur as a preliminary phase in mineralisation.198 Thus, if HA forms from an OCP 
precursor phase, it is unsurprising that areas rich in OCP will also be rich in HA. 
These data support the hypothesis that OCP is a significant precursor to HA 
formation in HO. This is relevant because OCP is much more soluble than HA and 
would therefore make developing HO bone more amenable to chemical dissolution 
than formed bone. 
3.4.7 NanoCT Discussion 
These are the first nanotomography datasets of HO bone ever recorded. At this 
scale, what is most remarkable about the tissue is how ordered it is. The long axes of 
the lacunae are predominantly determined by the lamellar orientation while the short 
and intermediate axes are determined by another factor that is not obvious from 
these data. For example, in Figure 3-19C, the long axes of the lacunae are seen to 
follow the lamellae around a Haversian canal (not shown in this image). In Figure 
3-19D, which is an orthogonal view of the same dataset, there is a striking degree of 
alignment of the short axis of the lacunae, which all lie on the same plane. It would 
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be of great value to know what the orientation of the samples was in the body so that 
the factors determining the alignment of these axes could be understood in greater 
detail. One hypothesis is that while the lamellar structure of the bone determines the 
long axis alignment of the lacunae, gravity or a chemotactic gradient may determine 
the alignment of the short and intermediate axes. 
3.5 Discussion and Conclusions 
This study is the first time that human HO has been analysed by nano tomography or 
any of the spatially-resolved chemical modalities (XRD, XRF, and Raman). It is also 
the first time that microCT has been used to quantify the histomorphometric 
parameters or mineral density of human HO. 
One of the most striking findings of this study is that HO demonstrates different 
degrees of order depending on length scale. For example the SEM and microCT data 
support previous reports of disordered hybrid cortical-cancellous morphology on the 
millimetre-micron length scale and there is further evidence of disorder when 
interpreting the crystallite orientation data from the SXRD. However, in contrast to 
this disorder, the nano-tomography demonstrates that the osteocyte lacunae are 
highly aligned in planes with canaliculi oriented at 90o, forming ordered connections 
between these planes. This finding generates a question that cannot be answered 
with these data: what processes contribute to order or disorder at each length scale? 
Another feature that we have detected (using SEM) that has been noted before144 is 
the presence of osteoclast resorption pits, indicating that HO is continuously being 
remodelled. Further evidence for this remodelling is demonstrated by the presence of 
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discontinuous osteons, showing that existing structures were not simply enlarged but 
partially reabsorbed and new Haversian systems laid down in their place. 
Previous reports have suggested that HO may have a mature leading edge of well-
corticated bone with an inner core of immature bone.78,199 However, we have shown 
using XRF elemental mapping that there are islands of calcium within the soft tissue 
surrounding the edge of the main HO mass. This would suggest that rather than 
enlarging through pure remodelling, there is some de novo mineralisation process 
acting around the HO mass with eventual consolidation of this new bone as the mass 
enlarges. Looking at this process more closely, our XRF data has provided evidence 
that the mechanism of mineralisation in HO may be a unique “calcium first” process. 
The mineral islands forming at the periphery are initially highly calcium-rich and only 
approach a more normal calcium/phosphate stoichiometry as the HO tissue matures. 
This is highly unusual and contrary to the accepted mechanism of mineralisation 
whereby calcium and phosphate are deposited together from the outset. 
Due to the heterogeneity of the samples, small sample number, and the nature of the 
analytical modalities, this work was designed to be predominantly descriptive rather 
than quantitative in its approach. Few statistical analyses were appropriate. Also, it is 
important to note that this work is not designed to be a quantitative comparison with 
normal bone and therefore no “control” tissue has been examined. Given that HO is 
not a disease of physiological bone but a new and separate entity, it would be 
challenging to justify which type of normal bone and from what anatomical location 
one should choose to compare HO against. 
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It is also important to note that all of our samples and the focus of this work relate to 
HO secondary to high-energy trauma. It is uncertain whether or not these findings 
may be generalisable to HO caused by other aetiologies. Indeed, it has not been 
demonstrated that HO generated as a consequence of different aetiologies has a 
common pathophysiology, structure, or physicochemistry. 
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4 DEVELOPMENT OF A NOVEL HETEROTOPIC 
OSSIFICATION THERAPY 
4.1 Introduction 
Many of the clinical problems caused by HO are due to the mechanical effects of 
bone forming in abnormal anatomical locations. If it were possible to prevent this 
formation, or disperse it once it had formed, then it may be possible to reduce the 
clinical impact on the patient. However, as discussed in Chapter 1, a fundamental 
problem with attempting to inhibit the biological processes involved in HO formation 
is that the signalling network involved may allow more than one way for the 
pathological end result to occur. This is particularly true when attempting to inhibit a 
disease such as HO where the mechanism, signalling networks, and cell populations 
are so poorly understood. The central aim of this work was to overcome this 
challenge by developing a novel treatment capable of targeting the mineralised 
component of bone. It was hypothesised that a non-toxic agent could be developed 
that was able to dissolve hydroxyapatite and / or directly inhibit its formation. This 
agent would also require a means of delivery to the site of formation of HO. The 
desired properties of such a treatment would be as follows: ability to dissolve 
hydroxyapatite under physiological conditions, specificity for HO without affecting 
normal bone, non-toxic, temporally controllable action, and ability to be delivered 
percutaneously. 
This chapter details the search for, and development of, a polyphosphate treatment 
for HO. In this study, the demineralising effects of polyphosphate on hydroxyapatite 
monoliths and pathological bone samples were determined. The mechanism of this 
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process was investigated using micro X-ray fluorescence (micro-XRF). The potential 
to regulate the demineralising activity was evaluated through controlling local pH and 
through the exposure of polyphosphate to alkaline phosphatase (ALP). Finally, the 
effect on samples of human post-traumatic HO was evaluated using microCT to 
determine the change in mineralised volume. 
A modified version of this chapter was published in the Journal of Materials 
Chemistry B.200 
4.1.1 Polyphosphates as Potential HO Therapy 
During the 1960s, there was great research interest in the potential role of 
polyphosphates in regulating biomineralisation. Fleisch et al.201 found that the 
addition of minute (10-6 to 10-7 M) concentrations of polyphosphates were able to 
inhibit calcium phosphate crystallisation. Fleisch et al took this work further in 1966 
by investigating the ex vivo biological effect of polyphosphates on chick femur 
mineralisation.202 Incubation in the presence of polyphosphates for 6 days inhibited 
mineralisation as analysed histomorphometrically and by using X-ray diffraction.  
Despite being shown to be effective inhibitors of calcium phosphate crystal formation, 
polyphosphates subsequently received little attention as inhibitors of 
biomineralisation. Ultimately, this body of research led to the development of 
bisphosphonates, which are chemically similar to pyrophosphate except that the 
central oxygen atom is replaced by a carbon atom with two side chains. Rather than 
inhibiting mineralisation in the manner of polyphosphates, bisphosphonates have the 
opposite effect and reduce demineralisation through inhibition of osteoclast activity. 
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In the dental research literature, polyphosphates have been investigated due to their 
anti-caries effect, which occurs through increasing the resistance of hydroxyapatite 
(HA) to acid dissolution and the chelation of calcium ions in order to prevent tartar 
formation.203 In 1983, McGaughey undertook detailed mechanistic work to attempt to 
understand the interaction between HA and a range of polyphosphates.204 This work 
showed that hexametaphosphate (HMP) is an effective agent for the dissolution of 
HA. The author’s conclusions about the molecular mechanisms are, however, 
debatable. Given the size and mass:charge ratio of the polyphosphate molecules, 
their direct incorporation into the hydroxyapatite lattice is improbable. More recently, 
Rao and Kannan demonstrated the efficacy of HMP in dispersing HA in aqueous 
solution.205 Whatever the mechanism, these papers provide evidence that HMP can 
dissolve HA, a mineral that is normally incredibly insoluble. 
In 2001, Cini et al.206 investigated the use of polyphosphates to dissolve calcium 
pyrophosphate, a mineral that causes the condition pseudogout. They demonstrated 
that hexametaphosphate could dissolve this mineral in in vitro and ex vivo samples of 
pathologically calcified human meniscal tissue. Although this work related to the 
effect of HMP on calcium pyrophosphate rather than HA, the results are encouraging. 
This work demonstrates that hexametaphosphate can accelerate the dissolution of a 
biologically formed calcium phosphate from within a collagenous matrix (the 
meniscus) and that this reagent is relatively benign to both chondrocytes and the 
biological component of the menisci. This gives real weight to the idea that this agent 
might be used to disperse hydroxyapatite from the collagen template found in 
heterotopic ossification. 
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Put together, the data from the 1960’s studies into mineralisation control, the dental 
literature, and the more recent experiments on calcium pyrophosphate, suggested 
the hypothesis that a polyphosphate may be the agent required for treating and 
dissolving HO. 
4.2 Methods 
4.2.1 Experimental Outline and Rationale 
The first step in developing an HA-dissolving treatment was to compare the relative 
effectiveness of a variety of polyphosphates in order to identify the most promising 
candidate to take forward for further development. A simple screening experiment 
was undertaken whereby pellets of HA were incubated in a range of polyphosphates 
and their mass was monitored over time to determine the degree of dissolution. In 
order to gain a greater understanding of the interaction between the reagents and 
HA, the residual pellets at the end if this experiment were examined with XRF. 
Using the mass-loss of pellets of HA over time was found to be an effective but slow 
method of determining the HA-dissolving ability of the polyphosphates. In order to be 
able to determine the HA-dissolving ability of HMP under a variety of conditions, a 
more rapid experimental technique needed to be developed. HA sol was chosen as 
the target for dissolution to achieve this faster turn-around time. HA sol is chemically 
identical to solid HA but is physically dispersed as a nanoparticular solid phase in a 
continuous liquid water phase. This makes dissolution much more rapid as the 
surface-to-volume ratio is vastly increased compared to sintered monoliths. A novel 
method was developed whereby light transmission through HA sol was used to 
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determine the degree of dissolution. This method was then used to determine the 
effect of pH and alkaline phosphatase (ALP) on the ability of HMP to dissolve HA. 
In order to determine whether or not HMP was able to dissolve HA in a biological 
setting, post-mortem rat femora were used as a target material and mechanical 
testing was used to measure the effect. 
As a final test of efficacy, samples of human HO were incubated in HMP or control 
media and the effect on the mineralised volume was assessed using microCT. 
In order to investigate the potential of polyphosphates to act as a prophylaxis for HO, 
a further experiment was undertaken. HA synthesis was attempted in the presence of 
a variety of polyphosphates, and the products were analysed using XRD. 
4.2.2 HA Pellets and Dissolution 
Disc-shaped pellets of HA were formed by isostatically pressing 400 mg of HA 
powder (Sigma-Aldrich, Gillingham, UK) with 100 µL of deionised water (diH2O) at 2 
kN for 5 seconds. These were sintered at 600 oC for 1 hour. After cooling in ambient 
conditions, pellets were weighed and incubated at room temperature (20 oC) in 50 ml 
of a 0.1 M solution of each of the following reagents: sodium pyrophosphate 
decahydrate (Na4P2O7·10H2O), sodium tripolyphosphate (Na5P3O10), trisodium 
trimetaphosphate (Na3P3O9) (all Sigma-Aldrich), and sodium HMP (Na6P6O18) 
(Fisher, Loughborough, UK) (Figure 4-1). Ethylenediaminetetraacetic acid (EDTA) 
(C10H16N2O8) (Sigma-Aldrich) was used as a positive control. Before incubation, each  
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reagent was adjusted to pH 7.4 (physiological pH) with 0.1 M NaOH or 0.1 M HCl. 
There were triplicate repeats of each condition. The pH-adjusted media were 
replaced every 3.5 days. The pellets were removed from solution every 3.5 days, 
surface fluid removed with absorbent paper, and weighed. After 21 days the pellets 
were recovered (except for the EDTA group, which had dissolved completely) and 
dried overnight at 80 oC before being analysed by micro XRF to examine the surface 
chemistry. 
4.2.3 XRF 
Elemental maps of the recovered and dried HA pellets were generated using a 
Tornado M4 micro-XRF system (Bruker Nano Gmbh, Berlin, Germany) fitted with a 
 
Figure 4-1: Schematic structural diagrams of the ionic forms of the polyphosphates 
under investigation in this chapter. Pi = orthophosphate. PPi = Pyrophosphate. LTPP = 
Linear tripolyphosphate. CTMP = Cyclical Trimetaphosphate. HMP = 
Hexametaphosphate. 
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Rhodium micro focus X-Ray tube and a polycapillary lens. The X-Ray spot size from 
the polycapillary lens was 25 µm. All samples were analysed under ambient 
conditions with an X-Ray tube voltage of 50 kV and a tube current of 400 µA. The X-
rays were rastered over the sample surface with a step size of 100 µm and an XRF 
spectrum was collected at each point with an acquisition time per pixel of 2.5 ms. 
Elemental maps were then generated in real time by gating around the phosphorus 
Kα1 (2.0137 keV) and calcium Kα1 (3.692 keV) X-ray fluorescence emission peaks in 
the XRF spectra, creating an image where pixel intensity represented detected X-ray 
counts per second per eV from each measurement point on the sample. Pixel 
intensity increased monotonically with X-ray counts with maximum pixel intensity 
normalised to the highest count rate per eV for a given element across the whole 
sample. The instrument was set to map samples three times to generate a single 
averaged map for each element. 
4.2.4 Sol Optical Density Method Calibration 
In order to demonstrate that the transmission of light through hydroxyapatite (HA) sol 
may be used to quantify the concentration of available HA in sol form, the following 
calibration process was performed. HA sol was synthesised as described by Afshar 
et al.207 Briefly, this involves adding 0.3 M orthophosphoric acid dropwise to an equal 
volume of 0.5 M calcium hydroxide under agitation and close pH control, being 
careful not to let the pH drop below 10. After synthesis, the HA sol was allowed to 
age overnight at 40oC. 
The concentration of HA per ml of sol was determined as follows. Triplicate volumes 
of 3ml of pure sol were centrifuged at 3900 rpm for 10 minutes, the supernatant 
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decanted, and the tubes containing the residual centrifuge pellets dried at 80oC 
overnight. The mean dried pellet mass was 79.3 g (standard deviation 0.265 g). Thus 
each ml of pure HA sol yielded 26.43 mg of dried HA. Concurrently, a volume of the 
same batch of HA sol underwent serial dilution with deionised water. Triplicate repeat 
volumes of 245 µL of each dilution were transferred to a 96-well plate and optical 
density (OD) was measured at 650 nm using a Glomax 9301-010 plate reading 
spectrophotometer (Promega, Wisconsin, USA). The resulting calibration curve is 
shown in Figure 4-2. 
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 By using the chart trend line fitting function on Microsoft Excel (Microsoft 
Corporation, Redmond, Washington, United States), equations relating high (>0.5) 
and low (<0.5) OD values to HA concentrations were generated (see insets in Figure 
4-2). These equations were used to convert OD data to g / L values on the Y-axes of 
Figure 4-5 and Figure 4-6. 
 
Figure 4-2:  Calibration curve showing the relationship 
between optical density (at 650nm) and the concentration 
of HA Sol. Error bars are +/- standard deviation. HA = 
hydroxyapatite. Insets: Reversing the axes and dividing 
the data into points greater than or less than an OD value 
of 0.5 allows best-fit lines to be drawn and equations 
formulated to describe the relationship between optical 
density and HA concentration. Note the exceptionally 
high R2 values. HA = hydroxyapatite. OD = Optical 
Density. 
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4.2.5 pH Control of HA Dissolution by HMP 
HA sol was prepared as described above and was added to serial dilutions of HMP in 
a 96-well plate. Each concentration was conducted in triplicate. diH2O was added to 
each well to give a constant final well volume of 245 µL. A Glomax 9301-010 plate 
reading spectrophotometer (Promega, Wisconsin, USA) was used to measure light 
transmission through the sample at 650 nm as a quantitative determination of the 
degree of dissolution. Results were normalised to a diH2O blank. This experimental 
method was repeated with adjustment of the pH to 6.2, 7.4, and 9.6 using 0.1 M HCl 
or 0.1 M NaOH as required. 
4.2.6 Alkaline Phosphatase Control of HA Dissolution By HMP 
3.6 mL of undiluted HA sol was dissolved completely in 25 mL 0.1 M HMP (adjusted 
to pH 7.4 using 0.1 M NaOH). The resulting solution was optically clear on 
macroscopic examination. 2 mL aliquots of this stock solution were incubated at 37 
oC for 9 days with addition of either 400 units (in 200 µL) of bovine ALP (Sigma-
Aldrich) for the experimental samples or 200 µL diH2O for the control samples. The 
optical density of the solution was measured at day zero and day nine using a plate-
reading spectrophotometer (see above). Each condition was conducted in triplicate 
and the results compared using a two-tailed Student’s t-test. 
4.2.7 Residual Mass Method 
The OD method of assaying the concentration of HA sol is novel and, as such, 
needed to be validated to ensure it is reliable. The calibration data presented above 
provided reassurance that this methodology was robust but this was not sufficient in 
itself to prove reliability. Therefore, to support the conclusions drawn from the data, 
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these experiments were repeated. Instead of determining the concentration of HA sol 
through light transmission, direct determination of the HA concentration was 
performed. For the pH experiment, 1.5 ml aliquots of HA sol were added to 10 ml 
HMP at varying concentrations and the pH was adjusted to 6.2, 7.4, or 9.6. These 
samples were agitated for 4 hours, centrifuged at 3900 rpm, residual pellets dried 
overnight at 80oC, and then weighed to determine the HA pellet mass. All conditions 
were carried out in triplicate. The ALP experiment was repeated exactly as outlined 
previously, but instead of measuring the OD of the samples, the residual mass 
method was used to measure the amount of undissolved HA per sample. Triplicate 
repeats were performed. 
4.2.8 Post-Mortem Rat Tibiae 
Three pairs of tibiae were harvested immediately post mortem from male Lister 
hooded rats of 275-325 g bodyweight. The left-sided tibiae were incubated in 50 mL 
1% w/v gellan (Gelzan CM, Kelco, Atlanta, USA) loaded with 0.1 M HMP. Right-sided 
tibiae were incubated in 50 mL 1% w/v gellan only. The gellan was used as an inert 
delivery vehicle in this experiment (Figure 4-8A). All samples were incubated at room 
temperature (20 oC) for 6 days. Destructive 4-point bending was performed on all of 
the samples using a Bose Electroforce 5500 mechanical tester (Bose / TA 
Instruments, Minnesota, USA). Testing parameters were as follows: upper points 4.0 
mm apart, lower points 10.4 mm apart, displacement ramp 0.02 mm/s, non-
destructive displacement limit 0.2 mm, destructive displacement limit 2.0 mm (see 
Figure 4-8B for details of the test set-up). Data from the mechanical testing were 
analysed using WinTest 7 software (Bose). Stiffness was calculated as the gradient 
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of the linear elastic region of the force-displacement curves. Yield force was identified 
as the force corresponding to the upper limit of the elastic region of the force-
displacement curves. Maximum force was taken as the maximum recorded force 
during destructive testing. A two-tailed paired t-test was used to compare the 
stiffness, yield force, and maximum load to failure for each pair of tibiae. 
4.2.9 Human HO 
Samples of human HO excised from a single patient who had suffered civilian poly-
trauma were retrieved from the Human Biomaterials Resource Centre at the 
University of Birmingham. These were incubated in 5 mL of either 0.1 M HMP 
(adjusted to pH 7.4 with 0.1 M NaOH) or diH2O as a control for 7 days. Before and 
after incubation, these samples were wrapped in parafilm and placed inside a 
polystyrene sample tube. These were scanned using a Bruker SkyScan 1172 X-ray 
micro computed tomography (microCT) scanner (Bruker, Coventry, UK) with the 
following settings: no filter, camera position near, pixel size 4.96 µm (voxel size 
120.32 µm3), rotation step 0.2o, camera resolution 4000 x 2664 pixels, exposure time 
400 ms, frame averaging 6, current 70 µA, voltage 70 kV. The scans were 
reconstructed using NRecon software (version 1.6.10.2, Bruker microCT) and 
analysed using CTAn (version 1.15.4.0, Bruker microCT). Three-dimensional models 
were generated using a double time cubes algorithm. Models were visualised with 
CTvol (version 2.3.1.0, Bruker microCT). The same scanning, reconstruction, and 
post reconstruction processing settings were used for the samples before and after 
incubation. 
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4.2.10 Inhibition of HA Synthesis 
HA synthesis (as above)207 was undertaken in the presence of 10-3 M of each of the 
potential inhibiting reagents: pyrophosphate, linear tripolyphosphate, cyclic 
trimetaphosphate, EDTA, and HMP. The reaction products were aged for 1 hour then 
centrifuged (4000 rpm for 10 minutes) and washed with diH2O three times. The 
product was dried overnight at 80 oC and finely ground. X-ray diffraction patterns 
were generated using a Bruker D8 diffractometer (2θ 5-80o) and analysed using 
Bruker EVA diffrac.suite software (version 3.1). The raw diffraction data was baseline 
corrected but not smoothed. Reference data for HA (PDF 00-009-0432) and calcium 
hydroxide (Ca(OH)2) (PDF 00-044-1481) were obtained using the software program 
PDF-4+ with database version 4.4103 (International Centre for Diffraction Data). 
4.3 Results and Discussion 
4.3.1 HA Pellet Mass Loss 
Incubation in HMP reduced the mean mass of HA pellets by 30.2% over 504 hours 
(Figure 4-3). The EDTA positive control reduced the mass of pellets by 95.0% in the 
same time period. diH2O water control, cyclical trimetaphosphate, linear 
tripolyphosphate, and pyrophosphate had no effect on HA pellet mass over the same 
time period. 
HMP was clearly the most effective polyphosphate at dissolving HA. As such, the 
other reagents were excluded from further dissolution experiments. They were, 
however, included in the synthesis-inhibition experiment (below). 
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4.3.2 HA Pellet XRF Maps 
Element maps illustrating the resulting changes in surface chemistry as a result of 
incubation in the polyphosphates for 21 days are shown in Figure 4-4. diH2O, HMP, 
linear tripolyphosphate, and cyclical trimetaphosphate all showed no change in Ca:P 
ratio over the period of the study. 
 
Figure 4-3:  Mass loss of hydroxyapatite pellets over time 
incubated in various potential dissolving agents. This 
demonstrates the potent dissolving ability of 
hexametaphosphate. Ethylenediaminetetraacetic acid 
(EDTA) was used as a positive control. diH2O =  
deionised water, CTMP = cyclic trimetaphosphate, LTPP 
= linear tripolyphosphate, PPi = pyrophosphate, HMP = 
hexametaphosphate HMP. Error bars are +/-SEM. 
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The pellets incubated in pyrophosphate, however, showed an increased phosphorus 
signal distributed heterogeneously across the surface of the pellet. This suggests that 
there is adsorption of pyrophosphate ions onto the surface of the samples. There are 
no images for the pellets incubated in EDTA as these were dissolved completely. 
The finding that the HMP group did not cause any change in the Ca:P ratio compared 
with deionised water controls is significant. This is because an increase in 
phosphorus signal relative to calcium signal would be expected if the mechanism of 
dissolution was initial incorporation of the terminal phosphate group of HMP into the 
HA matrix (as McGaughey proposed).204 
The lack of change in Ca:P ratio, coupled with the monotonic rate of dissolution was 
more consistent with a solution-mediated rather than surface-mediated mechanism. 
Certainly, HMP has a very strong affinity for Ca2+ ions, forming a 1:1 complex with a 
high thermodynamic stability constant.208 Thus it is possible that HMP is complexing 
any available Ca2+ ions from the hydroxyapatite matrix and forming a highly stable 
Ca-HMP complex in solution. Indeed, HMP has such a high affinity for cations that it 
has been demonstrated to dissolve kaolin and kaolinite by complexing the aluminium 
cations in these minerals.209 
The finding that incubation of HA pellets in pyrophosphate caused an increase in the 
surface phosphorus signal on micro-XRF suggests adsorption to the surface of the 
pellet, which is consistent with previous reports in the literature.210 
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Figure 4-4:  Micro X-ray fluorescence mapping of calcium and 
phosphorus on the surface of pellets of hydroxyapatite after 21 
days of incubation in the following potential dissolving agents: 
deionised water (diH2O), cyclic trimetaphosphate (CTMP), 
linear tripolyphosphate (LTPP), pyrophosphate (PPi), 
hexametaphosphate (HMP). Note that for each dissolving 
agent, this figure shows the micro-XRF data for different 
elements on the surface of a single pellet. There were, in fact, 
triplicate repeats under each condition and the changes shown 
here were typical for all repeats. 
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4.3.3 Effect of pH and ALP using the Optical Density Method 
At every concentration of HMP, higher pH values reduced the amount of HA sol 
dissolved (Figure 4-5). For an HMP concentration of 0.1125 M, the available HA in 
sol form in the samples at pH 6.2, 7.4, and 9.6 was 0.15, 13.3, and 23.4 g/L, 
respectively (note: control samples of sol had 26.43 g of HA per L). This pH-
controlled effect was demonstrated across a range of concentrations of HMP 
spanning four orders of magnitude. This may prove to be a key mechanism by which 
the activity of HMP can be targeted towards the sites of pathological bone formation 
in HO. This is because hypoxia is thought to be a key step in the biological pathway 
for HO formation, and hypoxia leads to local low pH in tissues through switching 
toward anaerobic respiration and the generation of lactate.57,211 Therefore, in sites 
where pH is low and HO is most likely to develop, HMP will also be most potent at 
dissolving HA. While these data provide compelling evidence that pH controls the 
HA-dissolving ability of HMP, they do not provide any mechanistic explanation for the 
relationship.  
Addition of ALP to a solution of HA sol dissolved in HMP caused HA to precipitate out 
of solution as demonstrated by a change from clear to turbid over 9 days. The mean 
HA concentration in the ALP group increased from 1.08 to 11.8 g/L (p = 0.00) 
whereas that of the control group fell from 1.13 to 0.94 g/L (p = 0.007) (Figure 4-6). 
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ALP is an exophosphatase found in many tissues that can cleave the terminal 
phosphate group from polyphosphates. As demonstrated in Figure 4-3, shorter chain 
length polyphosphates have little or no HA-dissolving ability. Therefore, the increased 
turbidity in the presence of ALP is interpreted to be due to HA precipitating out of 
solution as the solvent (HMP) is cleaved. The importance of this is that it 
demonstrates that ALP-mediated degradation is a feasible mechanism for the 
inactivation of HMP over time in the body. It would not be desirable to deliver an 
 
Figure 4-5:  Demonstration of the effect of varying the pH 
and concentration of HMP on the amount of available HA 
in sol form. Lower amounts (in g/L) of available HA sol 
indicates higher amounts dissolved by the HMP. 
Dissolving ability is increased with increasing 
concentration and decreasing pH. Error bars are  +/- 
SEM. 
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 agent with HA-dissolving activity into the body without the possibility of limiting its 
duration of action. It is noted that, in contrast to the ALP group, the HA concentration 
of the control group decreased. This may represent further dissolution of any 
undissolved HA sol over the incubation period. 
 
Figure 4-6:  Change amount (in g/L) of available HA in sol 
form in a nearly- saturated solution of HA dissolved in 0.1 
M hexametaphosphate after incubation with either alkaline 
phosphatase (ALP) or control (diH2O) for 9 days. Error bars 
are +/- SEM. * = p < 0.05.  
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4.3.4 Effect of pH and ALP Using the HA Residual Mass Method  
The results of these experiments are presented in Figure 4-7. These data are 
strikingly similar to the OD-derived data and therefore support the conclusions drawn 
using the optical density methodology. 
A 
 
B 
 
Figure 4-7: Repetition of pH and ALP control experiments using an alternative assay 
method (residual mass of HA). A: The effect of pH and concentration of HMP on the 
mass of undissolved HA. Increasing pH is associated with greater mass of 
undissolved HA suggesting that HMP is less effective at dissolving HA at higher pH. 
Error bars are +/- SEM. B: Change amount (in g / L) of available HA in sol form in a 
nearly-saturated solution of HA dissolved in 0.1 M hexametaphosphate after 
incubation with either alkaline phosphatase (ALP) or control (diH2O) for 9 days. 
Error bars are +/- SEM.  (* p =  0.00) 
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4.3.5 Post Mortem Rat Tibiae 
Incubation of rat tibiae in gellan loaded with HMP caused a reduction in stiffness and 
maximum load to failure. Stiffness was 49% lower in the HMP/gellan group compared 
to gellan-only controls (p = 0.001). Maximum load to failure was 41% lower in the 
HMP/gellan group compared to gellan-only controls (p = 0.03) (Figure 4-8C). There 
was no significant difference in the yield force between the two conditions. The 
reduction in stiffness of the bone is consistent with the dissolution of hydroxyapatite 
from the bone matrix.212,213 Interestingly, the yield force was unaffected by incubation 
in HMP. As the yield force is determined by the collagenous component of bone, this 
finding suggests that HMP is able to dissolve HA from within the bone composite 
structure without affecting the collagen component.174,214 Another notable finding 
from this experiment was that gellan was able to form a stable gel in the presence of 
HMP. As discussed below, HMP has unpredictable effects on many hydrogels and 
prevents gelation in nearly all of them. Thus the finding that 1% gellan will form a set 
gel in the presence of 0.1 M HMP is significant, particularly given that no cross-
linking agent was added. 
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A 
 
C 
 
B 
 
 
Figure 4-8: A: Rat tibia incubated in 1% gellan containing 0.1 M HMP. B: 4-point 
mechanical testing of tibia. C:  Results of 4-point mechanical testing of rat tibiae after 
incubation in either 1% gellan alone or 1% gellan loaded with 0.1 M HMP for 6 days. 
Incubation in HMP caused a significant reduction in the stiffness and maximum load 
to failure compared to paired controls. Error bars are  +/-SEM. * = p < 0.05. 
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4.3.6 Human HO 
By using the same scanning, reconstruction, and processing protocols for the 
samples before and after incubation, micro-CT imaging and volume analysis 
demonstrated that HMP caused the demineralisation of samples of human HO at 
physiological pH. The bone volume of the HO sample incubated in 0.1 M HMP at pH 
7.4 for 7 days decreased from 11.6 mm3 to 3.43 mm3, a reduction of 70.4%. The 
bone volume of the control sample changed from 9.34 mm3 to 8.76 mm3, a reduction 
of 6.2%. Three-dimensional models of the mineralised component of the HO samples 
are shown in Figure 4-9. The sample incubated in HMP appears grossly attenuated. 
In contrast, the sample incubated in diH2O appears largely unchanged compared 
with its pre-incubation state. With n = 1 for each experimental condition, these results 
must be interpreted with caution. However, due to the precious nature of the samples 
and the encouraging results obtained using other forms of HA, it was decided not to 
repeat this experiment. The conclusion from this experiment is that HMP is able to 
dissolve human HO. 
4.3.7 Inhibition of Hydroxyapatite Synthesis 
X-ray diffraction (XRD) patterns generated from unsintered reaction products are 
shown in Figure 4-10. The patterns generated in the control sample and in the 
presence of cyclic trimetaphosphate, EDTA, linear tripolyphosphate, and 
pyrophosphate match the reference standard of HA with no detectable secondary 
phases. In contrast, the pattern generated by the sample synthesised in the presence 
of HMP has additional peaks that match the reference standard for Ca(OH)2, one of 
the reaction precursors. This suggested that HMP inhibited the formation of HA, as 
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Figure 4-9: Three-dimensional surface-rendered models of the mineralised volumes of 
samples of heterotopic ossification (from patient 4). Before (A) and after (B) 
incubation in 0.1 M HMP at pH 7.4 for 7 days. Before (C) and after (D) incubation in 
diH2O at pH 7.4 for 7 days. The sample incubated in HMP is clearly attenuated after 
incubation whereas the control sample shows little change. Scale bar = 1 mm.  
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Figure 4-10:  X-ray diffraction patterns of the products of HA synthesis. In the 
presence of hexametaphosphate, the peaks associated with HA are diminished or 
missing and an increased amount of unreacted calcium hydroxide (Ca(OH)2) precursor 
is detected, suggesting inhibition of hydroxyapatite crystallisation. The other reagents 
had no measurable effect compared to control (no added polyphosphates). PPi =  
pyrophosphate, LTPP =  linear tripolyphosphate, EDTA =  ethylenediaminetetraacetic 
acid, CTMP =  cyclic trimetaphosphate, HMP = hexametaphosphate.  
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previously reported elsewhere.201,202,204 Given that HMP was able to reduce the 
reaction yield of HA precipitated in a super-saturated solution, it is possible that in 
vivo, it could inhibit the formation of HA in ectopic bone.169 
4.4 Conclusions 
This chapter has detailed the process by which a novel therapy for preventing and 
treating HO was discovered and developed. Literature review revealed that 
polyphosphates (hexametaphosphate in particular) had been used experimentally in 
humans in the 1960s and had shown interesting mineralisation controlling effects in 
vitro. This led to the hypothesis that a polyphosphate may be developed into a 
therapy by which trauma-induced HO may be inhibited or even dispersed. The 
results demonstrate that HMP can dissolve HA in inorganic and biological settings, 
that this effect is controllable through alteration in pH and through the action of ALP, 
that ex vivo human HO is attenuated by its action, and that HA formation can be 
inhibited in the presence of small concentrations of this simple polyphosphate. 
Existing clinical prophylaxis and current innovations in this field focus on the 
upstream biological pathways. However, chemical means of dissolving the final 
product, hydroxyapatite, could be an effective way of addressing this problem and 
the data presented here show this to be a possibility. If efficacy is proven in the 
condition of HO, this opens the possibility of broadening the application to other 
diseases of extra-skeletal mineral deposition. 
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5 HYDROGEL FORMULATION ENGINEERING 
5.1 Introduction 
5.1.1 Requirements of a Delivery Vehicle 
The simplest way to deliver a dissolving or inhibiting therapy to the site of HO 
formation would be to inject an aqueous solution. However, this delivery method 
would provide little control over the anatomical site of action. This is undesirable 
because there is a risk that orthotopic bone could be damaged. To prevent this, a 
delivery vehicle would be required, which could deliver the therapeutic payload to the 
desired location and deliver a sustained dose. In general, drug delivery systems need 
to have certain basic properties (Table 5-1).215 In addition to these general 
requirements of delivery vehicles, this project demanded additional specific 
requirements as described in Table 5-2. 
In summary, a safe and injectable vehicle was required to carry HMP to the site of 
HO formation, release it at the correct location in an effective timescale, prevent it’s 
spread to normal bone, and then degrade or disperse safely. 
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Table 5-1: Basic Properties of Drug Delivery Systems 
Biocompatibility 
 
Defined as being non-toxic, non-injurious, and non-
immunogenic in a specific application216 
 
Stability Sufficient to allow a reasonable shelf life 
Degradability Ability to be metabolised and / or cleared from the body but 
still able to maintain its structure and function in vivo for an 
appropriate amount of time. 
 
Cost Effectiveness It should be reasonably cheap and available. 
 
 
Table 5-2: Delivery vehicle properties specific to the application of dissolving and 
inhibiting HO 
Injectability (shear-thinning 
rheological behaviour) 
 
To allow minimally invasive delivery to the site of 
HO formation. 
 
Compatibility with 
Polyphosphates 
The delivery vehicle must not adversely interact with 
polyphosphates or require divalent cations in order 
to function (due to the potent chelating ability of 
some polyphosphates e.g. hexametaphosphate). 
 
Appropriate Mechanical 
Properties: 
In order to withstand the forces of the surrounding 
tissues in vivo that would act to disperse the delivery 
vehicle. 
 
Appropriate Drug Release 
Properties 
It would be desirable for the vehicle to be able to 
control the release of HMP in order to prolong the 
duration of action. 
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5.1.2 Hydrogels as Delivery Vehicles 
Hydrogels are versatile, safe, and effective materials for a wide range of biomedical 
applications so they were chosen for the delivery of HMP in this project.217,218 
Hydrogels are hydrophilic polymeric or co-polymeric networks that can absorb 
thousands of times their own dry mass of water. This gives them a density very close 
to that of water and viscoelastic mechanical properties close to that of biological soft 
tissue.219 These properties make them useful drug delivery agents. Hydrogels are 
incredibly versatile due the high degree to which their mechanical and chemical 
properties can be controlled. Manipulation of their mechanical properties allows them 
to be made into almost any shape or formulation including viscous liquids, 
microparticles, solid slabs, coatings, and films. Hydrogels have been used as contact 
lenses, pharmaceutical capsules, implant coatings, and dermal patches inter alia.215 
Gelation in hydrogels occurs due to multiple different types of intermolecular bonding, 
which are responsible for the ultimate macromolecular structure and mechanical 
properties. Hydrogels are described as “physical” (or “reversible”) if the polymer 
network is bound by molecular entanglement, hydrophobic forces, ionic bonding, 
stereo-complexation, or hydrogen bonding. These bonds can be broken through 
alteration of the pH, heating, stress, or shear. This causes a return to a liquid state; 
hence the name “reversible”. One common subgroup of physical hydrogels are 
known as “ionotropic gels” and these require a multivalent ion of the opposite charge 
to the polyelectrolyte to form crosslinks; e.g. calcium-alginate. Gelation in these gels 
can be reversed through the application of an alternative ion that competes with the 
cross-linker for access to the binding sites.  
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Hydrogel bonding can also be “chemical” (or “permanent”) when the structure is 
dependent upon covalent bonds between polymer chains. Chemical bonding may 
occur directly between polymer chains through functionalisation with reactive groups 
or may require the addition of small-molecule reactive species.220,221 Hydrogels 
formed through intermolecular covalent bonds tend to be more robust and stable 
over time due to resistance of the chains to diffusing away from one another. Some 
hydrogels exhibit both types of bonding, with the predominant type being dependant 
on the physical and chemical conditions. 
Hydrogels may be synthetic or derived from natural sources. Natural hydrogels have 
the advantages of being more degradable, abundant, renewable, non-toxic, and 
cheaper than synthetic hydrogels.222 Sources for natural hydrogel polymers include 
bacteria (gellan223), seaweed (alginate224), bovine or porcine collagen (gelatin225), 
and crustacean shells (chitosan226). Examples of synthetic and natural hydrogels are 
given in Table 5-3. 
5.1.3 Degradability 
Hydrogel degradability can occur through enzymatic digestion or hydrolysis. Cross-
linked hydrogels may also dissolve when the polyvalent cations holding the network 
together are replaced by monovalent cations from body fluid.227 In cases where 
hydrogel networks disperse in this way, the ultimate fate of the component parts will 
depend upon whether the host is able to excrete or further degrade them. 
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Table 5-3: Types of Hydrogel Polymers (modified from Hoffman 2012215) 
Naturally-Derived Hydrogel Polymers 
Anionic Polymers hyaluronic acid, alginic acid (alginate), pectin, 
carrageenan, chondroitin sulphate, dextran sulphate, 
gellan 
Amphipathic Polymers collagen, gelatin, fibrin 
Cationic Polymers chitosan, poly-l-lysine 
Neutral Polymers dextran, agarose, pullulan 
Synthetic Hydrogel Polymers 
Polyesters  PEG-PLA-PEG, PEG-PLGA-PEG, PEG-PCL-PEG, 
PLA-PEG-PLA, PHB 
Other Synthetic 
Polymers  
PEG-bis-(PLA-acrylate), PEG±CDs, PEG-g-P(AAm-co-
Vamine), PAAm, P(NIPAAm-co-AAc) 
Abbreviations: CD, cyclodextrin; PAAc, poly(acrylic acid); PAAm, polyacrylamide; PEG, 
poly(ethylene glycol); PCL, polycaprolactone; PHB, poly(hydroxy butyrate); PLA, poly(lactic acid); 
PLGA, poly(lactic-co-glycolic acid); PNIPAAm, poly(N-isopropyl acrylamide); PVamine, poly(vinyl 
amine). 
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5.1.4 Formulation Engineering Aims 
The aims of the formulation engineering work were to formulate and characterise an 
injectable hydrogel delivery vehicle for HMP. The objectives required to achieve this 
aim were as follows: identification of suitable hydrogel polymers through literature 
review; determination of whether injectable hydrogels can be formed from these 
polymers with HMP included in their formulation; optimisation of the formulation and 
processing conditions to give the best product (as defined by homogeneity and 
injectability); characterisation of the mechanical properties and drug release 
behaviour of the product; determination of whether the product can be used to 
dissolve biological apatite (bone). 
The work in this chapter was carried out in collaboration with Miss Emma Jones and 
Mr Tom Robinson, who were undertaking a final-year chemical engineering Masters 
project under the supervision of the author. 
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5.2 Methods 
5.2.1 Hexametaphosphate Compatibility Screening 
Synthetic hydrogels were excluded on the grounds of either cost, complexity of 
synthesis, or lack of local experience. The literature was then reviewed to provide a 
selection of naturally derived hydrogels that were then considered for further testing. 
Table 5-4 summarises the key features of these gels. 
Gelatin was excluded because it required chemical cross-linking at body temperature 
(37oC). Therefore, agarose, alginate, gellan, and pectin were chosen for further 
screening to establish their suitability as a delivery vehicle for HMP. 
A screening experiment was conducted to observe the compatibility of the selected 
hydrogels with HMP. Divalent cations are commonly used to crosslink these gels but, 
as HMP has a potent capacity for chelating these ions, it was decided to observe the 
behaviour of these gels without adding crosslinking agent. 
With the exception of pectin, gel concentration and method of synthesis was taken 
from local laboratory protocols. A concentration of HMP of 0.1 M was chosen as this 
corresponds to the value used in the HA-dissolving work above. The gels were 
synthesised as described in Table 5-5 and observed the next day after being left to 
cool overnight at room temperature (Table 5-6 and Figure 5-3). 
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Table 5-4: Summary of properties of naturally occurring hydrogels 
 
 Advantages Disadvantages  
Gelatin Biocompatible, biodegradable, 
and non-immunogenic 
 
Weak gelation above 35 
°C, must be chemically 
cross-linked 
228,229 
Gellan Biocompatible and 
biodegradable 
Gelation possible before or 
after injection 
Relatively expensive 
Few studies investigating 
gellan for drug delivery 
230-232 
Agarose Non-toxic, doesn’t form 
damaging by-products, has 
high gel strength 
Has significant history of use 
in tissue engineering 
Thermoresponsive – gels 
with decreasing 
temperature 
233 
Alginate Relatively low cost, 
biocompatible, non-toxic, can 
be injected 
Compatible with HMP 
Requires purification 
Partial oxidisation required 
to speed degradation 
Cross-linked by calcium 
(which is sequestered by 
HMP) 
224,234,235 
Pectin Non-toxic (widely used in food) 
Tuneable cross-linking kinetics 
May be used with 
polyphosphates 
Slow gelation kinetics 236 
Chitosan Used as a drug delivery 
system 
Non-toxic, biodegradable, 
sterilisable, easily chemically 
modified, low cost, and 
renewable 
Poor mechanical 
properties. 
Hard to control pore size. 
May dissolve if physically 
cross-linked 
237,238 
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Table 5-5: Summary of methods of synthesis of hydrogels used in screening 
experiments 
Polymer w/v Experimental Method Reference 
Agarose 
(Fisher Scientific, 
Loughborough) 
1% Control: Add 0.5 g agarose 
to 50 ml DiH2O 
Test: Add 0.5 g agarose to 
50 ml 0.1 M HMP 
Heat and stir to 80 – 90 °C  
Local 
Laboratory 
Protocol 
Alginate 
“Alginic Acid, Sodium 
Salt” (Sigma-Aldrich) 
2% Control: Add 1.0 g alginate 
to 50 ml DiH2O 
Test: Add 1.0 g alginate to 
50 ml 0.1M HMP 
Heat and stir to ≤65 °C 
Local 
Laboratory 
Protocol 
High Acyl Gellan  
“Kelcogel HA” (CP Kelco, 
Atlanta, USA) 
1% Control: Add 0.5 g high acyl 
gellan to 50 ml DiH2O  
Test: Ad 0.5 g high acyl 
gellan to 50 ml 0.1 M HMP 
Heat and stir (T ≤ 80 °C) 
Local 
Laboratory 
Protocol 
Low Acyl Gellan  
“Kelcogel LA” (CP Kelco) 
1% Control: Add 0.5 g low acyl 
gellan to 50 ml DiH2O 
Test: Add 0.5 g low acyl 
gellan to 50 ml 0.1 M HMP 
Heat and stir (T ≤ 80 °C) 
Local 
Laboratory 
Protocol 
Pectin 
(Fisher Scientific)  
2.4% Control: Add 1.2 g pectin to 
50 ml DiH2O 
Test: Add 1.2 g pectin to 50 
ml 0.1 M HMP 
Stir at room temperature 
236 
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5.2.2 Varying HMP and Gel Concentration Under Temperature and pH 
Control 
The next step was to test whether the gels would be stable at body temperature 
(37oC) and at neutral pH (7.0). It has been demonstrated (above) that HMP is more 
effective at dissolving HA at lower pH levels so the delivery vehicle should be 
designed to optimise effectiveness. However, if the pH is too low, this may cause 
pain and inflammation at the site of injection. Thus a balance has to be struck 
between HA-dissolving potency and safety. A pH value of 7.0 was chosen as it is the 
lowest pH that is likely to be found in muscle under physiological conditions and 
therefore represents this optimal balance.239 Another aim of this stage in testing was 
to examine the effect of altering the concentrations of HMP and the polymers to see 
whether there is an upper limit to the amount of HMP that can be loaded into these 
gels before gelation is compromised. A higher HMP concentration would mean that 
less volume would needed to be injected to deliver the same molar quantity. 
Reducing the injected volume is desirable because large volume injections can 
cause pain and discomfort. 
HMP was dissolved in 20 ml aliquots of diH2O to make concentrations of 0.5, 1.0, or 
1.5 M. These were heated to 60 oC and stirred. High acyl gellan was added to each 
of these aliquots and allowed to dissolve to give final concentrations of 0.25, 0.50, 
0.75, 1.00, or 1.25% w/v. All samples were pH adjusted to 7.0 (+/- 0.1) using 1 M 
NaOH or HCl. The samples were then left to set for 12 hours at room temperature 
(20 oC) before being placed into a 37 oC incubator for another 12 hours. Gels were 
observed after this time. 
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Preliminary testing demonstrated that agarose had a tendency to form 
inhomogeneous gels if the simple method appropriate for gellan was used. Empirical 
testing demonstrated that, to produce a homogenous gel in the presence of HMP, the 
following general method was required. Two 10 ml of aliquots of diH2O were heated 
and agitated and made up with twice the desired final concentration of HMP and 
agarose. These two solutions were then combined in a single vessel under 
continuous heating and agitation to produce a 20 ml solution with the required final 
concentrations of agarose (0.5, 1.0, 1.5, 2.0, or 2.5% w/v) and HMP (0.05, 1.0, or 1.5 
M). As with the gellan samples, these were then pH adjusted, allowed to set for 12 
hours under ambient conditions, and then placed into an incubator at 37 oC for a 
further 12 hours before being observed. 
5.2.3 Injectability 
For the delivery vehicle and HMP to be able to act upon the HO within a patient, it 
would need to be injected into the site of developing ectopic mineralisation. It would 
not be suitable to administer the drug systemically (e.g. intravenously) as it might be 
toxic or damage orthotopic bone. As such, it was desirable to test the injectability of 
the HMP-loaded gels. This was performed using a combination of needle and syringe 
sizes that would be typical for this kind of application (as judged by the author, who is 
a clinician with extensive experience of performing injections into soft tissue). The 
aim was to attempt to inject the optimised combinations of polymer and HMP and 
observe the outcome qualitatively. This would provide data on how the materials 
behaved under the high-shear environment of a syringe and needle and how it felt in 
the hand of the end user. 
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Agarose (2.5%) and high acyl gellan (1.25%) gels containing 0.1 M HMP were 
synthesised as described above, except that they were aspirated into 5ml syringes 
(BD Discardit II syringe (Becton Dickinson)) while still hot (>60 oC). These were left to 
cool under ambient conditions (20oC) overnight. A 19 G (inside diameter 0.686 mm, 
length 38.1 mm) needle (Terumo, NJ, USA) was attached to each syringe and the 
contents expelled by compressing the plunger manually. There were triplicate 
repeats of each experimental condition. 
5.2.4 Rheology 
In order to provide more quantitative information on the handling properties of the 
HMP-loaded gels, oscillatory rheological testing was performed. This allows a formal 
description of the viscoelastic properties of the systems under test. The reason for 
this is that this application requires the loaded delivery vehicle to be liquid enough to 
be injectable but then return to a more solid-like state once in situ so that it releases 
its payload in the desired location. In rheological terms, the material needs to be 
shear-thinning. This means that it is viscous (able to flow) under high shear 
conditions but then demonstrate predominantly elastic (solid-like) behaviour in a low 
shear conditions. Oscillatory rotational rheometry is able to measure the storage 
modulus (G’) and the loss modulus (G”) of a soft solid material and use the ratio of 
these terms to establish the viscoelastic behaviour under different shear conditions. 
Before formal rheometry of a material can be undertaken, the linear viscoelastic 
range (LVR) must be determined. This is the range of strain values over which the 
internal structure of a material remains intact and determines the range of strain 
values that can be used to derive the viscoelastic parameters G’ and G”. 
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Rheometry was performed on an AR-G2 rheometer (TA Instruments) with a 40 mm, 
2° cone and a flat base plate. All experiments were carried out at 37 °C.  Parameters 
were taken from the protocol by Zuidema et al.240 
5 ml of each loaded gel (2.5% agarose or 1.25% high acyl gellan containing 0.1 M 
HMP) was injected through a 19G needle onto the plate of a rheometer and the 
normal force was allowed to decay to zero. Strain sweeps were performed at 1 Hz 
over a strain range of 0.0001 - 0.28, with 3 s conditioning and 3 s sampling duration 
per strain setting. This was performed in triplicate for each gel. The results (Figure 
5-1) demonstrate an upper limit to the LVR of 0.01 strain. 0.005 was chosen as the 
fixed strain value during the frequency sweep experiments. 
Frequency sweeps were performed, in triplicate, using a gap of 1000 µm, zero 
normal force, 0.005 strain, a range of 1 – 100Hz, 3 s conditioning time, and 3 second 
sampling per frequency. 
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Figure 5-1: Strain sweep for post-injection 1.25% high acyl gellan containing 0.1 M HMP. 
Above a strain of 0.01 (vertical dashed line), G’ and G” deviate significantly from their stable 
values. Therefore, the upper limit of the linear viscoelastic range of strain is 0.01. Error bars 
are +/- SD. 
 
Figure 5-2: Strain sweep for post-injection 2.5% agarose containing 0.1 M HMP. Above a 
strain of 0.01 (vertical dashed line), G’ and G” deviate significantly from their stable values. 
Therefore, the upper limit of the linear viscoelastic range of strain is 0.01. Error bars are +/- 
SD 
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5.2.5 Release Assay 
One of the key properties of a delivery vehicle is its ability regulate the release of the 
active ingredient over time. This allows intermittent administration of the loaded 
carrier rather than continuous infusion. As such, it was desirable to determine the 
HMP-release characteristics of these gels. The most significant challenge to 
performing a release study on vehicles containing HMP is that there is no assay 
specific for HMP concentration. There is, however, a simple colourimetric assay for 
orthophosphate concentration. As such, it was decided that the HMP concentration 
would be determined through hydrolysis of the HMP into orthophosphate followed by 
assay of orthophosphate. The experimental method was based on the dialysis 
method described by D’Souza.241 Briefly, “parcels” of dialysis tubing were loaded with 
gels and placed in a volume of isotonic phosphate-free buffer at 37oC. The dialysis 
tubing pore size prevented the gels from dispersing in the buffer but allowed free 
movement of water and HMP. Aliquots of buffer were taken at intervals, the HMP 
content hydrolysed to orthophosphate, and the orthophosphate concentration 
measured using the colourimetric assay. In this manner, HMP release over time 
could be estimated. 
Dialysis tubing (Medicell International) with a permeability range of 12-14 kDa 
was formed into parcels and filled with 1.5 ml of 1.25% high acyl gellan or 
2.5% agarose with and without HMP loading. These were suspended in a 
vessel containing 50 ml of tris-buffered saline (TBS) and the temperature was 
controlled at 37oC. The TBS had been prepared by adding 6.05 g of TRIZMA® 
base (Sigma-Aldrich) and 8.76 g of sodium chloride to 800 ml deionised water. The 
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pH was adjusted to 7.6 and deionised water was added to give a final volume of 1 
litre with a pH of 7.4 and osmolality of 0.2998 Osm/kg. 200 µl aliquots of the TBS 
media were sampled at timepoints 15, 30, 45, 60, 90, 120, 180, 240, 300, 1440, and 
2880 minutes. The vessels were agitated intermittently to ensure adequate mixing 
and to avoid sampling error. Each experimental condition was carried out in triplicate. 
The 200 µl samples were each diluted in 4 ml deionised water. 500 µl aliquots of 
these diluted solutions were then hydrolysed by addition of 200 µl of 4 M HCl and 
incubated at 37oC for 72 hours. This HMP hydrolysis method is modified from 
McGaughey et al.204 After this period, 1 µl of each hydrolysed sample was added to 
199 µl of deionised water in the wells of a 96-well plate. 30 µl of a colourimetric 
phosphate assay dye (Sigma-Aldrich) was added to each well, and the plates were 
incubated in the dark at room temperature for 30mins. They were subsequently read 
on a GloMax® Microplate Multimode Reader (Promega) at 650 nm. 
5.2.6 Biological Apatite-Dissolving Ability of HMP Loaded Gels 
As a final check to ensure that the gel vehicles did not prevent the HA-dissolving 
effect of the HMP payload, they were tested on samples of rat trabecular bone. 
Four tibiae were harvested, post mortem, from adult male Lister rats. The proximal 
trabecular volume of each tibia was dissected out intact using hand instruments. The 
samples’ mineralised volumes were quantified using microCT before and after 
incubation in HMP-loaded (0.1 M) and control (no payload) gels (1.25% high acyl 
gellan and 2.5% agarose). MicroCT scanning was performed using a Bruker 
SkyScan 1172. Reconstruction was performed using NRecon version 1.6.10.2 
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(Bruker) and the mineralised volumes determined using CTAn version 1.15.4.0 
(Bruker). Scanning, reconstruction, and analytical processing parameters were 
identical for the pre and post-incubation steps. 
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5.3 Results 
5.3.1 Hexametaphosphate Compatibility Screening 
Table 5-6: Observations on compatibility testing of hydrogels with HMP 
 
Control With HMP 
Gelation Observations Gelation Observations 
Agarose  Yes Set gel  
Cloudy white – 
translucent  
Yes Less stiff than the 
control gel 
Cloudy white – opaque 
Alginate  No Liquid 
Pale brown - transparent 
No Liquid  
Very pale brown - 
transparent 
Gellan – 
high 
acyl  
Yes Set gel 
White – opaque  
Yes Set gel - less stiff than 
control sample  
White – opaque 
Gellan – 
low acyl   
No Fluid gel 
Colourless 
Yes Set gel  
White – opaque 
Brittle 
Pectin  No Liquid 
Formed two separate 
layers: Opaque cream-
coloured lower layer. 
White, foam like upper 
layer.  
No Liquid 
Formed two separate 
layers: Opaque cream-
coloured lower layer. 
White, foam like upper 
layer. 
 
Agarose Alginate High acyl 
Gellan 
Low Acyl 
Gellan 
Pectin 
Figure 5-3: Initial results of hydrogel synthesis in the presence of 0.1 M HMP 
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5.3.2 Varying HMP and Gel Concentration Under Temperature and pH 
Control 
 
 
 
  
Table 5-7: Summary of results of high acyl gellan and HMP combined in various 
concentrations at pH 7.0 after 12 hours at 37oC 
[HMP] 
(M) 
 High Acyl Gellan Concentration (% w/v) 
0.25 0.50 0.75 1.00 1.25 
0.05 Gel at  
37 oC? 
No No No Yes Yes 
Notes White 
translucent 
viscous liquid 
White 
translucent 
viscous liquid 
White opaque 
more viscous 
liquid 
White, opaque 
homogeneous 
deformable 
gel. 
White opaque 
homogeneous 
gel. Self- 
supporting.  
Trend Increasing gel stiffness and opacity    
0.10 Gel at  
37 oC? 
No No Partial Yes Yes 
Notes White 
translucent 
viscous liquid  
White opaque, 
more viscous 
liquid 
White opaque 
partially gelled 
liquid 
White, opaque 
homogeneous 
deformable 
gel. Low 
stiffness.  
White opaque 
homogeneous 
gel. Self- 
supporting. 
Deformable. 
Trend Increasing gel stiffness and opacity   
0.15 Gel at  
37 oC? 
No No No No No 
Notes White 
translucent 
heterogeneous 
low-viscosity 
fluid  
White opaque 
heterogeneous 
low-viscosity 
fluid. 
White opaque 
heterogeneous 
low-viscosity 
fluid. 
 
White, 
opaque, 
heterogeneous 
low-viscosity 
fluid. 
 
White, 
opaque, 
heterogeneous 
low-viscosity 
fluid. 
 
Trend Increasing heterogeneity and opacity   
 
 163 
 
 
5.3.3 Injectability 
Mild filter pressing occurred with the agarose gels, but all of the contents could be 
expelled and there was no blockage of the needles. The contents of the syringes 
were “chopped” as they were injected, forming multiple small pieces. Post-injection, 
these formed a mass of chopped gel that would, for example, adhere to an upturned 
surface. The post-injection agarose gels exhibited moderate syneresis. 
Table 5-8:  Summary of results of agarose and HMP combined in various 
concentrations at pH 7.0 after 12 hours at 37oC 
[HMP] 
(M) 
 Agarose Concentration (% w/v) 
0.5 1.0 1.5 2.0 2.5 
0.05 Gel at  
37 oC? 
Yes Yes Yes Yes Yes 
Notes Translucent 
homogeneo
us gel 
Translucent 
homogeneous 
gel 
Translucent 
homogeneous 
gel 
White opaque 
homogeneous 
gel 
White opaque 
homogenous 
gel 
Trend Increasing gel stiffness and homogeneity 
0.10 Gel at  
37 oC? 
Yes Yes Yes Yes Yes 
Notes Translucent 
homogeneo
us gel 
Translucent 
homogeneous 
gel 
White opaque 
homogeneous 
gel 
White opaque 
homogeneous 
gel 
White opaque 
homogeneous 
gel 
Trend Increasing gel stiffness and homogeneity 
0.15 Gel at  
37 oC? 
No No No No No 
Notes Translucent 
viscous fluid 
White opaque 
viscous fluid 
 
White opaque 
viscous fluid 
 
White opaque 
viscous fluid 
 
White opaque 
viscous fluid 
 
Trend Increasing gel stiffness and homogeneity 
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Gellan was easier to inject than agarose. There was no filter pressing. The gel did 
not chop as it was injected but extruded smoothly and then coalesced into a single 
mass that appeared no different to pre-injection gel. The injected gel was also able to 
adhere to an upturned surface. 
5.3.4 Rheology 
Frequency sweep results for post-injection 1.25% high acyl gellan and 2.5% agarose 
loaded with 0.1 M HMP are shown in Figure 5-4 and Figure 5-5. Under low and 
intermediate shear rates, G’ is dominant. At very high shear rates (approaching 500 
radians/s) the trend changes with G’ starting to diminish and G” to increase. In the 
case of high acyl gellan, the G” and G’ cross. With agarose, they values do not cross 
but the trend is that they are converging. As with the strain sweeps, the absolute 
values of G’ and G” for agarose are approximately 20 times greater than those for 
gellan. 
5.3.5 Release Assay 
Release assay results are shown in Figures 5-6 and Figure 5-7. 
5.3.6 Biological Apatite-Dissolving Ability of HMP Loaded Gels 
3-Dimensional reconstructions of the mineralised volumes of the samples pre- and 
post-incubation are shown in Figure 5-8. Mineralised volumes are given in Table 5-9. 
 
 165 
 
 
Figure 5-4:  Frequency sweep for post-injection 1.25% high acyl gellan containing 0.1 
M HMP. G’ (storage modulus) predominates until high angular frequency indicating 
that an elastic, rather than viscous physical character is dominant except under high 
shear conditions. Error bars are +/- SD. 
 
 
Figure 5-5: Frequency sweep for post-injection 2.5% agarose containing 0.1 M HMP. G’ 
(storage modulus) predominates indicating that an elastic, rather than viscous 
physical character is dominant except under high shear conditions. Error bars are +/- 
SD. 
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Figure 5-6: Phosphate release as a surrogate indicator of HMP release from 1.25 % high acyl 
gellan control containing no HMP (grey dashed line), aqueous solution of 0.1 M HMP (black 
dotted line), and 1.25% high acyl gellan loaded with 0.1 M HMP (black solid line). Error bars = 
SD. 
 
Figure 5-7: Phosphate release as a surrogate indicator of HMP release from 2.5 % agarose 
control containing no HMP (grey dashed line), aqueous solution of 0.1 M HMP (black dotted 
line), and 2.5% agarose loaded with 0.1 M HMP (black solid line). Error bars = SD. 
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Figure 5-8: 3-Dimensional reconstructions of microCT scans of trabecular rat bone 
samples. It is clear that the samples incubated in gels containing HMP were highly 
attenuated compared to controls. Agarose control = 2.5 % agarose, no HMP. Agarose / 
HMP = 2.5% agarose containing 0.1 M HMP. Gellan control = 1.25% high acyl gellan, 
no HMP. Gellan / HMP = 1.25% high acyl gellan containing 0.1M HMP. 
 
 
 
 
 
Table 5-9: Mineralised volumes of samples of rat tibia before and after incubation in 
gels. Agarose control = 2.5 % agarose, no HMP. Agarose / HMP = 2.5% agarose 
containing 0.1 M HMP. Gellan control = 1.25% high acyl gellan, no HMP. Gellan / HMP 
= 1.25% high acyl gellan containing 0.1M HMP. 
 Agarose Control Agarose / HMP Gellan Control Gellan / HMP 
Day 0 2.85 4.37 2.04 1.79 
Day 7 3.17 2.25 1.89 0.47 
% Change +11.1 -48.6 -7.35 -73.7 
 
1 mm 
  Agarose Control               Agarose / HMP           Gellan Control          Gellan / HMP 
Day 0 
Day 7 
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5.4 Discussion 
5.4.1 Hexametaphosphate Compatibility Screening 
The purpose of this screening experiment was to assess whether or not commonly 
used natural hydrogels could be synthesised in the presence of 0.1 M HMP and the 
absence of crosslinking agents. Pectin and alginate could not form gels under the 
experimental conditions outlined above. Agarose and gellan (both high and low acyl) 
formed gels in the presence of HMP. Interestingly, low acyl gellan (1% w/v) did not 
form a gel in isolation but did so in the presence of HMP. Thus HMP acted as a 
crosslinking agent. This is surprising because the literature reports that divalent 
cations are required to crosslink low acyl gellan and it is unclear how HMP, an 
intensely anionic molecule that actively chelates divalent cations, can act as a 
crosslinker. Low acyl gellan (1% w/v) was rejected because it formed a brittle gel in 
the presence of HMP meaning that it would not be suitable for injection. Thus, having 
rejected the other candidates, agarose and high acyl gellan were selected for further 
testing as they were able to form set, but non-brittle, gels containing 0.1 M HMP in 
the absence of divalent cationic crosslinking agents.  
The key limitations of this experiment were that each gel was tested at only a single 
concentration, HMP concentration was also fixed at a single value, and the pH was 
not controlled. These limitations were a consequence of keeping this step as simple 
as possible. Despite the simplicity of this screening step, it was successful in 
providing sufficient justification to reject all but two of the gels, which was important 
because time and resources did not allow for more detailed investigation of a greater 
number of candidate vehicles. 
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5.4.2 Varying HMP and Gel Concentration Under Temperature and pH 
Control 
Both high acyl gellan and agarose demonstrated similar behaviour with respect to 
increasing polymer and HMP concentration. Neither were able to form gels in the 
presence of the highest HMP concentration (0.15 M). Both formed stiffer and more 
opaque gels at higher polymer concentrations but this is not surprising. A higher 
polymer concentration would provide more opportunities for crosslinks and thus a 
stiffer gel. What is encouraging about these data is that both polymers can form gels 
in the presence of 0.1 M HMP at 37oC at pH 7.0 and this means that these materials 
could be stable in vivo when loaded with HMP. 0.1M HMP has been shown to be a 
sufficiently high concentration to dissolve solid sintered pellets of HA so it is likely to 
be sufficient to dissolve unsintered biological apatite. 
Of the gellan samples, a combination of 0.1 M HMP and 1.25% high acyl gellan was 
the most suitable to take forward for injectability testing. This is because it 
demonstrated qualitatively optimised mechanical properties with a high HMP 
concentration. The optimal agarose combination was 0.1 M HMP and 2.5% agarose. 
This not only represented an optimised combination of HMP concentration and 
qualitative mechanical properties but also demonstrated the best homogeneity of the 
agarose samples, as determined by macroscopic observation. See Figure 5-3 for an 
example of an homogeneous agarose gel. Homogeneity is important, as it is 
desirable that any one unit of volume of the vehicle should carry the same dose of 
active ingredient as another. 
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5.4.3 Injectability 
Both agarose (2.5%) and high acyl gellan (1.25%) gels containing 0.1 M HMP could 
be injected through a 19G needle. High acyl gellan performed better than agarose as 
it was easier to inject and the post-injection material had remarkable self-healing 
properties. Despite being a firm deformable gel, it was able to be injected and then 
return to a single cohesive mass with the same appearance. Whether the chopping 
phenomenon demonstrated by agarose is clinically significant is not clear from this 
experiment. However, the filter pressing and “weeping” of the injected gel could lead 
to burst release of the HMP, which is in the aqueous phase. 
As this experiment was subjective, it was decided that external validation of the 
findings would add rigor. As such, a surgeon (not the author) was recruited to repeat 
the injections and give their observations. They were blind to the contents of the 
syringes but understood the potential application of this system for the treatment and 
prevention of HO. The surgeon provided comments that support the above 
observations in that they preferred the handling properties of gellan/HMP and was 
concerned about the chopping and syneresis demonstrated by the agarose/HMP. 
5.4.4 Rheology 
The frequency sweeps provide information on the behaviour of the materials under 
different shear-rates , which correspond to different mechanical environments in use. 
Both gels demonstrated a dominantly elastic, rather than viscous, property over 
almost the entire frequency range. The values of G’ and G” for high acyl gellan are 
approximately 20 times lower at each shear rate than the values for agarose. This 
means that its stiffness is much lower than agarose, which matches the qualitative 
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findings above. The conclusion from the relationship between G’ and G” for both gels 
is that they will not demonstrate viscous flow except under a high shear load. This is 
ideal as this was one of the desired properties of a delivery vehicle for this 
application. 
These rheology data do have significant limitations however. First, the agarose 
samples demonstrated some syneresis upon being compressed by the cone and 
plate geometry of the rheometer. This would cause the gel to have a higher polymer-
to-water ratio and may go some way to explain why the values for G’ and G” were so 
much higher than for high acyl gellan. The second limitation of this technique is slip. 
The moist surface of the gels may provide a fluid layer between the main bulk and 
the cone or plate of the rheometer. As such, the rotational oscillations of the cone will 
not be fully transferred to the gel. As the rheometer calculates the results based on 
an assumption of perfect transfer of shear from the cone to the material under test, 
this may lead to erroneous results. However, it is important to note that the aim of 
this experiment was not to provide a perfect characterisation of the rheological 
properties of the gels; it was to establish whether the gels displayed broadly viscous 
or elastic behaviour under a range of shear conditions. To that end, these 
experiments have been successful. 
5.4.5 Release Assay 
It is challenging to draw conclusions from the release assay data for a number of 
reasons. First, there appears to be a significant experimental artefact affecting all 
results between 100 – 240 minutes. Results during this period are elevated and then 
return to lower values. Whilst this may be due to the release and then reabsorption of 
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free phosphate for this time period, it is more probable that it is an artefact due to the 
sampling process or the colourimetric phosphate assay. Second, some of the results 
are nonsensical. For example, Figure 5-6 shows that at the 1440 and 2880 minute 
timepoints, free phosphate in the no-HMP group was higher than in either the 
aqueous HMP or gellan HMP groups. Confidence in these data is, therefore, low. It is 
suspected that the noisiness of these data and the likely experimental artefacts are 
due to the following factors. First, the number of individual physical operations 
required to make each measurement from start to finish is exceptionally high. 
Accumulations of errors at each stage can reinforce or counteract each other 
unpredictably. This probably accounts for the high variability in the values and error 
bars. Second, unhydrolysed HMP was found to interfere with the phosphate assay 
(unpublished data). No method was used to confirm the completeness of hydrolysis 
of HMP so it is possible that some remained intact and interfered with the assay. 
Third, while the use of laboratory glassware was limited to essential items only (with 
disposable plastic ware being used in its place as far as possible), it was not possible 
to eliminate its use completely. It is recognised that glassware may have residual 
phosphate residue on its surface due to routine washing. No steps were taken to 
remove this residue and there is a risk that this may have interfered with the result. 
In conclusion, the release study experiment has not provided data of sufficient 
reliability to draw any meaningful conclusions. However, reporting this finding here is 
of value because it suggests that the methods described here are flawed and that an 
alternative method should be sought by those who seek to measure HMP release 
from hydrogels in future studies.  
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5.4.6 Biological Apatite-Dissolving Ability of HMP Loaded Gels 
The dissolution of samples of trabecular rat tibiae using HMP-loaded gels was a 
simple test of effectiveness. With n = 1 for each experimental condition, the intention 
was not to characterise the effect fully, but simply to check that the gels don’t abolish 
the HA-dissolving ability of HMP. Given the dramatic reduction in mineralised volume 
of the samples exposed to HMP-loaded gels after 7 days, the conclusion is that the 
gels do not abolish this ability. Control gels, without HMP loading, were included to 
gain an indication of the effect of incubating the samples in a gel in the absence of 
HMP. The small measured change in mineralised volume (+/- ~10%) is probably 
within the bounds of experimental error for this method and probably does not 
indicate a real effect. Multiple repetitions of each experimental condition would be 
required to investigate this effect further but this was of secondary importance to the 
main aim of this experiment, which was satisfied with a single sample per condition. 
5.5 Discussion 
Hydrogels seem ideal candidates for delivery of HMP into the soft tissues to prevent 
and treat HO. They meet many of the required criteria for drug delivery in general 
and this application in particular (Table 5-1 and Table 5-2). However, attempting to 
synthesise these gels in the presence of HMP revealed significant problems with 
compatibility. One of the key problems was that many of the gels require crosslinking 
with divalent cations such as calcium. HMP chelates calcium with very high affinity, 
which means that its presence prevents gelation in crosslink-dependent gels. 
Interestingly, HMP appeared to act as a crosslinking agent itself for both high and low 
acyl gellan. The mechanism for this observation is unclear as, under these 
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conditions, HMP is highly negatively charged whereas the usual crosslinkers are 
positively charged. 
Agarose and high acyl gellan were identified, through screening steps, to be 
compatible with HMP at a range of concentrations. Further steps identified optimal 
gel concentrations and these combinations of gel / HMP were taken forward for 
mechanical testing including injectability and rheology. Subsequently, an attempt was 
made to quantify the HMP-release characteristics of the gels but this did not generate 
meaningful results. Finally, it was shown that high acyl gellan and agarose loaded 
with HMP were able to dissolve the mineralised portion of samples of rat bone. This 
test was a surrogate for using these loaded gels on human HO, as these samples 
were too precious. 
The results of this formulation engineering work show that 1.25% gellan is preferable 
to 2.5% agarose. This is because agarose required a subjectively large amount of 
force to inject and demonstrated significant filter pressing and syneresis. Also, some 
of the agarose / HMP preparations demonstrated a tendency to separate into two 
phases over time (although this was not studied in detail). 
In terms of further work, sterilisation is one of the critical steps that will need to be 
studied and optimised if these gels are to be translated into clinical practice. Another 
important consideration for a delivery vehicle that has not been addressed with this 
research is degradation. There is a notable lack of studies that provide information on 
the breakdown and ultimate fate of hydrogels. As such, translation of a hydrogel 
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delivery vehicle into the clinic would require detailed analysis of how the vehicle is 
degraded and how the components are excreted from the body. 
5.6 Conclusions 
It is possible to formulate injectable hydrogels containing HMP. Gellan and agarose 
are promising candidates for further development in future but significant issues 
remain unresolved. These include a greater understanding of the mechanism of 
degradation of the vehicle, means of sterilisation, and optimisation of an assay for 
HMP activity that would allow release characteristics to be measured. 
Finally, it is important to note that this work was performed concurrently with the in 
vivo testing described in detail in the next chapter. The results of this formulation 
engineering work were, therefore, not available at the start of the animal model work.   
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6 ANIMAL MODEL OF HETEROTOPIC OSSIFICATION 
6.1 Animal Models of HO 
While mathematical modelling of HO is currently in development, animal modelling 
remains the mainstay of research in this area.242 A variety of different models have 
been developed that vary by their fidelity, reliability, welfare severity, logistical 
burden, and relevance to different forms of HO. Each model type is suited for a 
particular purpose or type of research and choosing an appropriate model requires 
an understanding of the advantages and disadvantages of each. 
6.1.1 Types of Model 
6.1.1.1 Injury 
Trauma models are considered to be the most representative of acquired heterotopic 
ossification as they can reproduce the condition without the need for genetic 
modification or administration of osteogenic agents. An early and well-known study 
by Michelsson et al.243 used repeated cycles of manipulation followed by 
immobilisation of rabbit knee joints as the traumatic stimulus. This method reliably 
produced ectopic ossification but it is difficult to see how this relates to acute trauma 
and the welfare considerations are significant. Also, whether or not the ectopic bone 
is excessive fracture callus or true heterotopic bone is unclear, a fact the authors 
concede in a follow-up paper.244 
In order to develop a more clinically relevant model, Schneider et al.245 performed hip 
surgery on rabbits with and without additional muscle injury to study the prophylactic 
effects of radiotherapy on HO. One criticism of the Schneider method is that bone 
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reaming debris was left in situ whereas in hip surgery in humans, care is taken to 
wash any debris away. The concern is that these reamings may seed the local soft 
tissue with bone-forming cells and that this may be the cause of the observed ectopic 
bone formation. This is theoretically possible in traumatic or post-operative HO, 
where injuries to bone could lead to this seeding. However, the consensus (see 
Chapter 1) is that most types of HO, including traumatic and post-operative, form 
through recruitment or induction of bone forming cells rather than direct seeding of 
tissues. 
6.1.1.2 Implantation / Injection 
In these models, a foreign material or structure is implanted into an animal in an 
ectopic site to induce bone formation. This foreign material most often consists of 
bone morphogenic protein (BMP) infiltrated into some form of scaffold.54,246 There are 
many variations of this model including implantation of inert microporous calcium 
phosphate particles,247 osteogenic cells,248 or BMP-encoding genetic material.249 
Criticism of the implantation models includes the artificially high local levels of BMP, 
which brings into question the validity of the system. Further, local trauma caused by 
the implantation of the materials could induce HO at the site anyway, or even 
stimulate an inflammatory response, which is known to promote HO formation. 
6.1.1.3 Genetic 
Genetic models rely on creating animals with modified BMP production or signalling. 
A key example is the mutation in the ACVR1 gene that codes for a BMP receptor, 
leading to constitutive activation and a fibrodysplasia ossificans phenotype.250 Other 
examples of genetic mutations being used to attempt to induce ectopic bone 
 178 
formation include BMP inhibitor knockouts,251 BMP overexpression,252 and BMP 
downstream signalling modification.253 Genetic modification of animal models has 
been described as having little relevance to human acquired heterotopic 
ossification.254 Even when the intention is to study genetic forms of HO, only one of 
the genetic models phenotypically resembles the human version of the disease even 
remotely.252 
6.1.1.4 Blast 
A trauma model with clear clinical relevance is the application of blast injury to rats. 
The first published example of this came from Tannous et al.90 who used explosive 
charges to induce hind or forelimb amputations in Sprague-Dawley rats. The main 
criticisms of this method are that the blast injury caused a high mortality rate amongst 
the animals, and reliability in generating HO was low. A refined version of this model 
was developed by Polfer et al.255 whereby the blast was delivered by a pneumatic 
shock tube rather than explosive. This study showed that while blast exposure alone 
is not enough to produce HO, it potentiates the disease in the context of superadded 
muscle injury and surgical amputation. This model was particularly well designed in 
that it allowed the relative contribution of blast and amputation to be elucidated. 
6.1.1.5 Achilles Tenotomy 
The Achilles tenotomy model has grown in favour as a means of generating HO due 
to its simplicity, reliability, and the fact that no genetic manipulation or exogenous 
osteogenic factors are required. The development of ectopic bone formation at the 
site of Achilles tenotomy was first described in rats by Buck in 1953 in a study on 
tendon healing.256 It was subsequently shown to occur in mice also, and the model’s 
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reputation for reliability was advanced by McClure in 1983, who showed that 100% of 
the mouse models in a study had developed HO after 10 weeks.257 Interestingly, this 
study was investigating the effect of bisphosphonates on HO and concluded that they 
had no effect. Also, the study noted that after 5 weeks, only 60% of the models had 
developed HO. More recently, Lin et al. used the Achilles tenotomy in rats to show 
that it develops via an endochondral ossification mechanism.258 This study 
demonstrated the same temporal progression of HO as McClure, with 60% of the 
models having radiographic evidence of HO at 5 weeks and 100% at 10 weeks. Thus 
it has been demonstrated in several studies over several decades that this model 
behaves reliably. 
In terms of simplicity, this model compares favourably with many other models. The 
only intervention required is the tenotomy operation itself, which takes only a few 
minutes and requires only basic surgical and anaesthetic equipment that is found in 
most animal research laboratories. This is in stark contrast to the blast models, for 
example, which require large amounts of highly specialised equipment, engineering 
support, and attract a significant health and safety burden. 
Finally, from an animal welfare point of view, the Achilles tenotomy model is also 
favourable when compared to other techniques. The papers mentioned above 
describe the animal models as tolerating the tenotomy well, with no discernable 
impact on function after recovery from the operation. Again, this is in contrast to 
some of the other methods such as the Michelsson manipulation model.243 
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Interestingly, it has been shown that the addition of a burn injury increases the speed 
and magnitude of HO development in the murine model.47,81 This is interesting in that 
it shows that inflammation can potentiate HO. However, it was felt by the author that 
the addition of burn would cause excessive animal welfare issues and was 
unnecessary for the requirements of this project given the reliability of the tenotomy-
only method. 
It is clear from published studies that the Achilles tenotomy model is the simplest, 
most reliable, and best tolerated method of generating ectopic bone formation. 
Whether or not it produces HO through the same biological and biochemical 
networks as human post-traumatic HO is irrelevant to this study. This is because, as 
discussed in previous chapters, the novel therapeutic approach that underpins this 
work is the direct dissolution and inhibition of formation of HA. Thus, in order to test 
the efficacy of such a treatment, it is irrelevant what pathways were involved in 
creating the ectopic bone. What is important is that the model is reliable, so that if no 
HO is detected, it must be due to an effective treatment rather than an ineffective 
model. 
6.2 Aims 
These animal experiments were performed with two main aims. The first aim was to 
set up the Achilles tenotomy HO model in our institution in order to have a reliable 
means of producing HO in vivo. The second aim was to use this model to prove the 
concept that HMP can be used to inhibit the formation of HO in vivo. Secondary aims 
included: quantitative evaluation of the effect of HMP on orthotopic bone, basic 
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evaluation of toxicity of HMP when injected parenterally, and evaluation of the 
suitability of alginate as a delivery vehicle in vivo. 
6.3 Methods 
6.3.1 Animal Licencing and Regulation 
In order to gain authorisation to perform the required animal experiments for this 
project, the author applied for and obtained a personal and project licence as laid out 
in the Animals (Scientific Procedures) Act 1986. Note that the project licence is held 
by Dr Zubair Ahmed. Briefly, the personal licence allows the holder to perform 
specified procedures on specified species. The project licence defines the 
experimental protocols that can be undertaken on the specific species. Formal 
University Ethical Committee approval was sought and gained, as was Home Office 
approval. The University of Birmingham biomedical services unit (BMSU) already has 
an establishment licence to allow animal experimentation to be carried out. The 
design and conduct of all experiments were undertaken with full regard for the 
principles codified by the National Centre for the Replacement, Refinement, and 
Reduction of Animals in Research (NC3Rs). All animal work was conducted within 
the BMSU in accordance within the terms of the granted licences, ethical approvals, 
and the law. 
6.3.2 Achilles Tendon Model Development 
At the time of performing these experiments, no animal model of HO was being 
undertaken in the UK so the author set up the model de novo using information from 
the literature.48,81,258 In total, nine adult male Sprague-Dawley rats (Charles River UK, 
Ltd., Margate, UK) were used to establish the model. The aim was to determine the 
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reliability of the model and quantify the baseline burden of HO after Achilles tenotomy 
at various timepoints. This would allow comparison with subsequent batches of 
animals that would receive either control or active injections of the novel HO-
dispersing agent.  
This model development stage was performed as three sequential batches of three 
rats. The rationale was that, if the tenotomy or subsequent HO were found to be 
excessively distressing, only a small number of animals would be affected and 
modifications to the protocols could be made for future experiments. All animals 
underwent unilateral right-sided Achilles tenotomy (see below). The first batch of 
three animals were killed 5 weeks after the procedure. The second and third batches 
were killed at 10 weeks after the procedure. 
Right-sided unilateral Achilles tenotomy was performed on all animals as follows. 
Preoperatively, the rats were weighed and received 0.2 ml of buprenorphine 
subcutaneously. Induction and maintenance of general anaesthesia was achieved 
through inhaled isoflurane. The animals were placed prone on a warmed operating 
table and hair was removed from the dorsum of the right hind limbs using electric 
clippers. After confirmation of adequate depth of anaesthesia and application of 
sterile drapes, a 5 mm longitudinal midline incision was made over the distal Achilles 
tendon using surgical scissors. Blunt dissection was performed to deliver the Achilles 
tendon into the wound. This was cut transversely using a scalpel blade. After 
confirmation that the tendon had been completely sectioned, the wound was closed 
with two interrupted sutures of 4-0 undyed vicryl rapide (dissolvable co-polymer 
containing 90% glycolide / 10% L-lactide, Ethicon, New Jersey, USA). To prevent 
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wound dehiscence, surgical wound adhesive was used to augment the wound 
closure (see Figure 6-1 for operative photographs). 
Post-operatively, the animals were housed individually for 24 hours and allowed 
access to food, water, and oral opioid analgesia as required. After this time, the 
animals were group-housed in batches of three with ad libitum access to food, water, 
and environmental enrichment. No animals were given any form of non-steroidal anti-
inflammatory medication at any stage throughout the study. 
At the appropriate time-point (5 weeks or 10 weeks after tenotomy), the animals were 
killed using the approved schedule-one method of inhaled rising CO2 concentration. 
The right and left hind limbs were harvested through sharp dissection and 
disarticulation at the femoro-acetabular joint (hip). Subsequently, the hind limbs were 
disarticulated at the tibio-femoral joint (knee). Care was taken to preserve the soft 
tissue distal to the tibio-femoral joint. 
Harvested limbs were placed into 60 ml sample pots and stored at -80 oC until 
needed for microCT analysis. Limbs were fully defrosted and allowed to equilibrate to 
room temperature before scanning. 
All limbs were scanned using a Bruker Skyscan 1172 microCT scanner (Bruker, 
Coventry, United Kingdom). The scan settings used were as follows: near camera  
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position, tube voltage 75 kV, tube current 100 µA, 180o rotation, rotation step 0.6o, 2 
frame averaging, exposure time 400 ms, pixel size 21.5 µm, camera size 1000 x 666 
pixels. Each sample scan was double width and lasted for approximately 90 minutes. 
Scans were reconstructed using NRecon (software version 1.6.10.2, Bruker 
microCT) with the following settings: beam hardening correction 50, smoothing 3, 
ring artefact reduction 4. Reconstructed datasets were processed (adaptive 
thresholding followed by despeckling) and analysed using the 3D object tool in CTan 
(version 1.15.4.0, Bruker microCT). All scanning and reconstruction parameters were 
kept constant across all samples except for the movement artefact compensation, 
which was manually adjusted to optimise the data for each sample. 
Scan datasets were processed to remove normal bone and scanning artefacts in 
order to quantify the volume of extra-skeletal mineralised tissue (HO) in the limbs. 
Reconstructed datasets were processed and analysed using the CTan software 
(version 1.15.4.0, Bruker microCT). First, a volume of interest was hand-drawn 
A B C D 
    
Figure 6-1: Photographs of unilateral Achilles tenotomy operation. A: blunt dissection 
underneath the Achilles tendon. B: Sharp sectioning of the tendon using a scalpel. C: 
Confirmation that the tendon has been completely divided. D: Two sutures to close the 
surgical wound. 
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around the HO leaving a margin of normal soft tissue. Subsequently, the processing 
steps and parameters were as follows: adaptive thresholding (median-C) in 3D space 
using round kernel radius 3 pixels (70 < threshold < 255), 2D white despeckle < 9 
pixels, 3D white despeckle < 300 voxels, 3D analysis. 
6.3.3 Testing Hexametaphosphate in vivo 
As discussed in the concluding remarks of the last chapter, the formulation 
engineering work was performed concurrently with these animal experiments. Ideally, 
the formulation work would have been concluded before the animal experiments 
were started but limitation of time and resources precluded these circumstances. 
Decisions had to be made about the nature of the carrier vehicle, dose of HMP, and 
frequency of injections based on what limited objective information was available and 
certain obvious limitations. The first limitation was that the project licence stipulated a 
maximum frequency of injection of once per week. Given the length of time that the 
animal models would be run for, a pragmatic decision was made to perform the 
injections once every two weeks. Second, there is a limit to the volume that an adult 
male Sprague-Dawley rat can tolerate having injected into its hind limb. 
Experimentation on cadaveric models suggested that approximately 400 µl could be 
injected into the site of the Achilles tenotomy before feeling any significant 
resistance. Therefore, in order to introduce a significant margin for error, the volume 
of injection was limited to 200 µl. As the volume and frequency of administration were 
limited, it was decided to use an HMP concentration of 0.2 M rather than the 0.1 M 
that had been used for the majority of the in vitro work. This was to increase the 
chance of the animal model showing a positive result, which would reduce the total 
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number of animals required in the course of proving this concept. Finally, 1% 
uncrosslinked alginate was chosen as the delivery vehicle because, out of the choice 
of hydrogels, alginate has the most substantial evidence of use in vivo.224,259,260 1% 
uncrosslinked alginate is a viscous liquid rather than a gel. This was a deliberate 
choice as it represented a compromise between being viscous enough to limit its 
spread away from the target area while still being able to pass through a 0.2 µm filter 
for sterilisation. This is in contrast to the agarose and high-acyl gellan vehicles 
developed in Chapter 5, which could not be passed through such a filter. Sterilisation 
of these gels remains an unresolved issue.  
In total, 12 adult male Sprague-Dawley rats were used for this stage. The 
experimental protocol was performed on two sequential batches of six animals. In 
each batch, three of the animals were in the control arm of the protocol and three 
were in the active treatment arm of the protocol. The experiment was performed in 
batches so that, should there be adverse effects due to the injections, the number of 
animals affected at any one time would be limited. Unilateral right-sided Achilles 
tenotomy was performed on all animals as described above. After 24 hours in 
individual recovery cages, the animals were housed in two cages with three animals 
per cage. The online randomisation tool random.org was used to determine which 
cages would receive the control (200 µl of 1% alginate) or treatment (200 µl of 1% 
alginate / 0.2 M HMP). Subcutaneous injections were administered at 2, 4, 6, and 8 
weeks post Achilles tenotomy. All animals were killed at 10 weeks post tenotomy. 
Harvesting of hind limbs, MicroCT scanning, and data processing were carried out as 
described above. 
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Injections were manufactured no more than 24 hours before each round of 
administration to avoid any potential problems with shelf stability or bacterial 
contamination. Disposable sterile tissue culture plastic, autoclave-sterilised 
glassware, and a cell culture laminar flow hood were used to provide aseptic 
conditions in which to prepare the control and therapeutic injections. For the control 
injections of carrier vehicle, 25 ml of sterile water for injections (Gibco Life 
Technologies, Paisley, UK) was agitated and heated to 60oC then 0.25 g alginate 
(alginic acid sodium salt from brown algae, Sigma-Aldrich, Darmstadt, Germany) was 
added and allowed to dissolve fully to produce a 1% alginate solution. The pH of this 
solution was adjusted to 7.1 < pH < 7.4 using 2 M NaOH solution that had been 
passed through a 0.2 µm filter (Minisart, Sartorius Stedim Biotech, Göttingen, 
Germany). This pH-adjusted uncrosslinked 1% alginate was then passed through a 
0.2 µm filter and 0.2 ml aliquots were loaded into 1 ml syringes. For the active 
injections, 1% uncrosslinked alginate was made as above. 3.06 g of SHMP (Sigma-
Aldrich) was then dissolved in this solution during heating and agitation. This was pH 
adjusted, passed through a 0.2 µm filter, and loaded into 1 ml syringes in the same 
manner as the control solution. All syringes were stored at 4oC in a laboratory 
refrigerator until 1 hour before use. 
Injections were administered at 2, 4, 6, and 8 weeks after Achilles tenotomy. All 
animals were given 0.2 ml buprenorphine subcutaneously 30 minutes before 
administration of the experimental preparations. The author gave the injections to all 
animals and was blind as to whether the animal was from the control group or the 
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therapeutic group. The author was also blind as to whether the syringes contained 
the blank carrier vehicle (200 µl of 1% alginate) or the active therapeutic load (200 µl  
of 1% alginate / 0.2 M HMP). The injections were administered via 30-gauge needles 
(HSW Fine-Ject, Sigma-Aldrich) into the right hind limbs at the site of the Achilles 
tenotomy (Figure 6-2). 
6.3.4 Bone and Tissue Mineral Density of Orthotopic Bone 
Bone mineral density (BMD) of trabecular bone and tissue mineral density (TMD) of 
cortical bone adjacent to the site of injections were quantified in order to determine 
 
Figure 6-2: Injections of control or HMP-
loaded gel into the site of HO formation. 
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whether the injections had any effect on orthotopic bone. The reconstructed microCT 
datasets that had been collected to quantify the HO volume were reused for this 
purpose but the post-reconstruction processing differed. For BMD, the vertical limits 
of the volume of interest was defined as being from 30 to 130 slices (641 to 3418 µm) 
above the distal tibial physeal scar and the horizontal limits were hand-drawn at 
intervals with interpolation to select only trabecular bone. For TMD, the vertical limits 
were defined as being from 130 to 230 slices (3418 to 4914 µm) above the distal 
tibial physeal scar and the horizontal limits were hand-drawn at intervals with 
interpolation to select only cortical bone. These vertical limits were derived by 
examining the datasets and determining the distribution of cortical and cancellous 
bone in the distal tibiae of the experimental models. Figure 6-3 summarises these 
volumes of interest schematically.  
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6.3.5 Statistical Analysis 
All statistical analysis was performed using R (version 3.2.4).261 Normalised HO 
volume, TMD, and BMD of the control and active groups were compared using a 
Welch t-test. 
 
Figure 6-3: Schematic representation of volumes of 
interest for bone mineral density (bottom right) and 
tissue mineral density (top right) quantification. 
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6.4 Results 
6.4.1 Achilles Tenotomy Model Development 
One animal developed a minor subcutaneous haematoma. This did not lead to 
wound dehiscence and did not become infected. It is likely that this haematoma was 
the result of imperfect haemostasis at the time of surgery. Subsequent to this 
complication, meticulous operative haemostasis was achieved in all animals using 
swabs, cotton buds, and pressure. This haematoma resolved spontaneously over 2 
weeks. There were no other adverse events during the model development phase.  
All animals were able to bear weight on the operated limbs within 24 hours of 
operation. Weight gain, social interaction, and behaviour were normal for the duration 
of the post-operative period. There were no observable negative consequences due 
to the tenotomy or subsequent development of HO. 
No heterotopic ossification was detected in the contralateral (non operative) limbs of 
any of the rats (reconstructions not shown). 
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Table 6-1: Model development results. Weight and microCT measurement of volume of 
HO for each animal model. Absolute and normalised figures are given. 
Animal  
ID 
 
Weight At 
Death (g) 
Elapsed Time After 
Achilles Tenotomy 
Volume Of 
HO (mm3) 
HO volume 
normalised to 
bodyweight  
(mm3 / g) 
1.1.1 Not Recorded 5 Weeks 0.0 N/A 
1.1.2 Not Recorded 5 Weeks 2.41 N/A 
1.1.3 Not Recorded 5 Weeks 0.20 N/A 
Mean 
(SD) - - 
0.87 
(1.34) - 
1.1.4 566 10 Weeks 13.3 0.024 
1.1.5 485 10 Weeks 8.62 0.018 
1.1.6 545 10 Weeks 14.6 0.027 
1.2.4 474 10 Weeks 13.9 0.029 
1.2.5 494 10 Weeks 22.2 0.045 
1.2.6 494 10 Weeks 14.4 0.029 
Mean 
(SD) 
510 
(36.9) - 
14.5 
(4.37) 
0.029 
(0.009) 
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Animal 1.1.1  (5 weeks) Animal 1.1.2  (5 weeks) Animal 1.1.3 (5 weeks) 
   
Animal 1.1.4 (10 Weeks) Animal 1.1.5 (10 Weeks) Animal 1.1.6 (10 Weeks) 
   
Animal 1.2.4 (10 Weeks) Animal 1.2.5 (10 Weeks) Animal 1.2.6 (10 Weeks) 
   
Figure 6-4: 3-D microCT reconstructions of the mineralised tissue (HO and bone) in 
the right hind limb of rats that have undergone Achilles tenotomy. Scale bar = 5 mm. 
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6.4.2 Testing Hexametaphosphate in vivo 
Achilles tenotomy surgery was performed without any adverse events (zero 
incidence of haematoma, wound breakdown, and wound infection). During the 
second round of injections, one animal developed a haematoma at the site of the 
injection. This was possibly due to the tip of the needle causing damage to a vein or 
artery in the track of the injection. This had resolved spontaneously by the time of the 
next injection 2 weeks later. Animals injected with the blank carrier gel control were 
reluctant to bear weight on the injected limb for up to one hour post injection. Animals 
injected with the active therapeutic agent were observed to be in more discomfort 
than the control animals and were unwilling to bear weight for 2 – 4 hours post-
injection. After this time the animals were observed to behave normally. At no point 
did the discomfort of the animals exceed the terms of the animal licence. 
One of the animals in the second batch of the therapeutic group died as a result of 
the injection at week 6 after Achilles tenotomy. Death occurred within five seconds of 
administration of the injection of 1% alginate / 0.2 M HMP. After review of the case 
with the named veterinary surgeon, it was concluded that death had occurred due to 
inadvertent intravascular injection of the contents of the syringe with embolisation of 
the contents and immediate cardiorespiratory compromise and death. As a result of 
this event, the injection technique was modified to include aspiration before injection 
to check whether the tip of the needle was inside a blood vessel. Flashback of blood 
into the syringe would indicate this situation and the injection aborted and 
reattempted. No cases of flashback were observed in any subsequent injections. 
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The absolute and body weight-normalised volumes of HO in each animal model are 
shown in Table 6-2. 3-D reconstructions of the hind limbs with HO and close up 
views of the HO volumes are shown in Figure 6-7 and Figure 6-8. 
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Table 6-2: Testing hexametaphosphate in vivo results. Weight and microCT 
measurement of volume of HO for each animal model. Absolute and normalised 
figures are given. Tissue mineral density (TMD) and bone mineral density (BMD) 
values are included. 
Animal 
ID Code 
 
 
Weight 
At 
Death (g) 
 
Group / 
Batch 
 
Volume 
Of 
HO 
(mm3) 
 
HO volume 
normalised to 
bodyweight 
(mm3 / kg) 
 
TMD 
(g/cm3) 
 
BMD 
(g/cm3) 
2.1.1 555 Control / 1 26.9 48.5 0.35 1.18 
2.1.2 478 Control / 1 25.0 52.4 0.29 1.18 
2.1.3 436 Control / 1 21.1 48.5 0.31 1.19 
2.2.4 569 Control / 2 21.2 37.3 0.33 1.17 
2.2.5 495 Control / 2 7.50 15.2 0.35 1.13 
2.2.6 569 Control / 2 17.6 30.9 0.28 1.13 
Mean 
(SD) 
517 
(56) - 
19.9 
(6.90) 
38.8 
(14.1) 
0.32 
(0.031) 
1.16 
(0.027) 
2.1.7 505 HMP / 1 15.2 30.0 0.39 1.23 
2.1.8 514 HMP / 1 16.7 32.5 0.29 1.23 
2.1.9 476 HMP / 1 14.6 30.7 0.30 1.20 
2.2.1  Died HMP / 2 N/A N/A N/A N/A 
2.2.2 536 HMP / 2 15.3 28.6 0.29 1.15 
2.2.3 491 HMP / 2 15.7 32.0 0.16 1.08 
Mean 
(SD) 
498 
(20) - 
15.5 
(0.77) 
30.7 
(1.54) 
0.29 
(0.081) 
1.17 
(0.058) 
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Volume of HO after 10 Weeks by Experimental  
Group Normalised to Bodyweight 
 
Figure 6-5: Combined dot-plot and box-and-whisker plot for volume of HO in the right 
hind limb of rats that have undergone right sided Achilles tenotomy and subsequent 
fortnightly injections of 200 µ l of either control (1% alginate) or active (1% alginate / 
0.2 M HMP) into the site of formation of HO. n = 5 in the active group. n = 6 in the 
control group. All available data are shown. Box plot bounds = interquartile range. Box 
plot horizontal line = median. Whiskers = range. Welch t-test p = 0.22 
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Bone Mineral Density in Orthotopic  
Distal Tibial Cancellous Bone 
 
Tissue Mineral Density in Orthotopic 
Distal Tibial Cortical Bone
 
Figure 6-6: Combined dot-plot and box-and-whisker plot for  tissue 
mineral density (TMD) and bone mineral density (BMD) in the right hind 
limb of rats that have undergone right sided Achilles tenotomy and 
subsequent fortnightly injections of 200 µ l of either control (1% alginate) 
or active (1% alginate / 0.2 M HMP) into the site of formation of HO. n = 5 
in the active group. n = 6 in the control group. All available data are 
shown. Box plot bounds = interquartile range. Box plot horizontal line = 
median. Whiskers = range. Black dots = outliers >1.5 interquartile range. 
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Animal 2.1.1  (Control) Animal 2.1.2  (Control) Animal 2.1.3  (Control) 
   
Animal 2.2.4  (Control) Animal 2.2.5  (Control) Animal 2.2.6  (Control) 
   
Animal 2.1.7  (HMP) Animal 2.1.8  (HMP) Animal 2.1.9  (HMP) 
   
Animal 2.2.1  (HMP) Animal 2.2.2  (HMP) Animal 2.2.3  (HMP) 
N/A 
  
Figure 6-7: 3-D microCT reconstructions of the mineralised tissue (HO and bone) in the right 
hind limb of rats that have undergone Achilles tenotomy and subsequent fortnightly injections 
of 200 µ l of either control (1% alginate) or active (1% alginate / 0.2 M HMP) into the site of 
formation of HO. Scale bar = 5 mm. 
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Animal 2.1.1  (Control) Animal 2.1.2  (Control) Animal 2.1.3  (Control) 
   
Animal 2.2.4  (Control) Animal 2.2.5  (Control) Animal 2.2.6  (Control) 
   
Animal 2.1.7  (HMP) Animal 2.1.8  (HMP) Animal 2.1.9  (HMP) 
   
Animal 2.2.1  (HMP) Animal 2.2.2  (HMP) Animal 2.2.3  (HMP) 
N/A 
  
Figure 6-8: 3-D microCT reconstructions of HO in the right hind limb of rats that have 
undergone Achilles tenotomy and subsequent fortnightly injections 200 µ l of either control 
(1% alginate) or active (1% alginate / 0.2 M HMP) into the site of formation of HO. Ticks on 
bounding cuboids = 1 mm. 
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6.5 Discussion 
6.5.1 Achilles Tenotomy Model Development 
The conclusion from these data is that unilateral Achilles tenotomy followed by 10 
weeks of maturation in the adult rat is a simple and highly reliable model of HO. The 
reason that only three animals were taken to the 5-week time point is that the 
likelihood of developing HO at this point was shown to be low (only 2 out of three 
animals had any HO and the amount that did form was variable and small). This was 
to be expected from the published literature81 but still provided valuable confirmation 
that the model was behaving as expected and that our results are therefore 
generalizable and comparable to previous work. No further useful information could 
be gained by increasing the number of animals killed at this time point. 
HO in the right limbs of these models formed at the site of division of the Achilles 
tendon. This is interesting because there is very little muscle at this anatomical site. 
The HO in this model is therefore likely to have formed in the connective and scar 
tissue that would result from the Achilles tenotomy. Unfortunately, it was not possible 
to perform histology on these models to establish the exact tissue in which the HO 
formed. However, the purpose of this model is not to study the mechanism of HO 
formation but is to provide a simple and reliable platform on which to test the efficacy 
of a novel HO therapy. Having established that the model is reliable, this aim has 
been satisfied. 
6.5.2 Testing Hexametaphosphate in vivo 
The most significant result of this work is that a Welch t-test failed to demonstrate a 
significant difference in the volume of weight-normalised HO between the active and 
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control groups.  However, this does not automatically lead to rejection of the 
hypothesis that HMP can prevent or treat HO. This is because these experiments 
were the first time that HMP had been injected into an animal model of HO and the 
aim was as much about observing the way in which the treatment was tolerated as 
about expecting to see a statistically significant result at the first attempt. Apart from 
the unfortunate animal model death as a result of intravenous embolisation of the 
treatment, it was not shown to cause any lasting harm or any adverse effects on 
orthotopic bone. Also, the parameters used, including frequency of injection, dose of 
HMP, and choice of carrier vehicle were chosen with limited information and no in 
vivo data as guidance. This work will prove highly valuable in providing the first 
benchmark against which alterations in these parameters may be measured. For 
example, increasing the concentration of HMP per dose or administering the 
injections more frequently may demonstrate a larger effect. Additionally, once further 
experiments have been performed to optimise the dose, frequency, and vehicle, a 
larger number of animals per group will be required to power the statistical analyses 
appropriately; something that is not appropriate at this early stage of model 
development and first attempt at treatment. 
A further point to make is that there was significant inter-batch variation and this may 
have contributed to the final result lacking statistical significance. Figure 6-5 has 
been colour-coded to indicate which batch the animals were in; red for batch 1 and 
blue for batch 2. In the active group, all animal models generated a very similar 
normalised volume of HO and there is no discernable difference between the 
batches. In the control group, however, there is a clear difference between the HO 
volume generated in the animals in batch 1 and 2. The difference between the 
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volumes of HO generated in the two batches of control animals is striking, with a 
mean volume of HO in batch 1 of 49.8 mm3/kg (SD 2.2) and batch 2 of 27.8 mm3/kg 
(SD 11.4). In addition to the mean value of HO in control batch 2 being lower than 
expected, the distribution of values was much wider than in any other batch from 
either experimental arm. Indeed, there appears to be an outlier in this batch with only 
15.2 mm3/kg of HO. This is nearly half of the value of the next lowest data point. 
Careful analysis of the experimental notes does not provide any clue as to why this 
model should have produced such a small volume of HO (e.g. inadvertent NSAID 
administration). In fact, it is not clear why control batch 2 produced such a variable 
and small volume of HO in comparison to batch 1. The animals were all of the same 
strain, underwent the same operation, received the same control injections at the 
same frequency, were fed the same diet, and were housed in the same conditions. It 
is possible that this effect is simply a reflection that variation is an unavoidable 
characteristic of in vivo experimentation. One possible way to avoid this situation in 
future would be to avoid the batch system by performing the experiment on 6 control 
and 6 treatment arm animals concurrently. This is now feasible because the work 
described in this chapter has shown that the tenotomy and injections are well 
tolerated (as long as care is taken to avoid intravascular injection). 
Another important conclusion from this work is that there is no measurable adverse 
effect on orthotopic cortical or cancellous bone adjacent to the injection site. The 
most obvious potential problem with injecting a bone-mineral dissolving agent into a 
limb is that it would attack physiological and pathological bone equally. The data 
demonstrates that this is not the case, however, and it is worth considering what the 
explanation for this is. First, it was shown in Chapter 4 that HMP was able to dissolve 
 204 
both human HO and normal (albeit murine) bone and so the observed specificity for 
pathological bone is not due to a lack of ability to dissolve it. Second, it was also 
shown in Chapter 4 that HMP is more potent at dissolving HA in low pH conditions, 
such as those that predispose to HO. Therefore, it is possible that this effect is acting 
in a highly localised manner to potentiate the dissolution of HO while preventing 
dissolution of orthotopic bone. Generating evidence to test this hypothesis would be 
extremely challenging but might include investigation of local tissue pH at the site of 
HO formation or perhaps alteration of the pH of the administered treatment. 
However, the simplest explanation is the most likely; that forming HO mineral has a 
much higher surface to volume ratio than mature orthotopic bone and would be much 
more vulnerable to dissolution. Mature orthotopic bone is also covered in a thick 
periosteal membrane, which would further protect it from dissolution by HMP.  
It is significant to note that for hexametaphosphate to be taken further towards 
translation in the form of human trials, pre-clinical proof of efficacy in an animal 
model is not currently required by pharmaceutical regulators in the United States or 
Europe.262 As such, the failure of this experiment to show a statistically significant 
effect on the volume of HO is not necessarily a barrier to progress. The current lack 
of safety data for parentally administered HMP is a more important issue. However, 
without some evidence of efficacy, it is unlikely that any funding to perform the safety 
testing would be secured. In summary, both safety and efficacy will need to be 
demonstrated more compellingly before human trials can begin. 
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6.6 In Vivo Model Conclusions 
The Achilles tenotomy method provides a simple model for generating ectopic bone. 
This makes it ideal as means for testing a hydroxyapatite dissolving and inhibiting 
treatment for HO. The animal models tolerated the tenotomy operation well and did 
not show any adverse post-operative effects. Fortnightly injection with 200 µl of either 
(control) 1% alginate or active (1% alginate / 0.2 M HMP) was found to cause short-
term discomfort but no long-term harm. Care must be taken not to deliver the 
injections into the vascular system. There was no evidence of an adverse effect on 
orthotopic bone. Finally, while these data did not show a significant difference in the 
volume of HO in the control and active arms of the protocol, this was not the primary 
aim of this first attempt at using HMP as a treatment. The primary aims were to set 
up the model in our institution and to test whether it was possible to inject HMP as a 
treatment. Both of these aims have been achieved by this work and the conditions 
have been set for future work to optimise the dose, timing, and carrier vehicle for this 
treatment in order to show evidence of efficacy in preventing and treating HO. 
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7 CONCLUSIONS AND FURTHER WORK 
7.1 Conclusions 
Heterotopic ossification is a disabling condition that can occur as a consequence of 
many types of injury. It has come to prominence recently due to the increased 
prevalence in severely blast-injured survivors of the military interventions in Iraq and 
Afghanistan. HO presents a major barrier to the functional recovery of these patients 
and there is currently no adequate means of preventing its formation once injury has 
occurred. This work has attempted to increase our understanding of this condition 
and develop a new means of preventing and treating it. One of the key problems with 
studying HO is that there is a great deal of uncertainty in the literature surrounding 
the cellular and signalling mechanisms involved. There is no consensus that HO due 
to different aetiologies either forms through the same mechanisms or is even the 
same disease. 
In order to understand HO more fully, human samples were acquired and subjected 
to advanced physicochemical analysis. This is the first time that HO tissue has been 
examined using synchrotron nano tomography, mapped synchrotron X-ray 
diffraction, mapped X-ray fluorescence, or mapped Raman spectroscopy. The results 
of these investigations have shown that HO displays disordered physical structure 
above the micron to millimetre length scale, but highly ordered physical and chemical 
structure below this length scale. Additionally, tantalising evidence of an undescribed 
“calcium-first” mineralisation mechanism has been revealed by X-ray fluorescence 
imaging. It was not possible to make firm conclusions about the morphological 
parameters of HO because of the incredible degree of heterogeneity in the structure 
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of the samples. This variable morphology was seen both within individual samples 
over a very short length scale and between different samples. The only valid 
conclusion that can be made, therefore, is that the tools we currently use to describe 
normal bone morphology are inappropriate for HO. 
The novel treatment discovery and development work found that 
hexametaphosphate, a cyclical polyphosphate, is a highly promising candidate for 
development. It was shown to be able to dissolve synthetic and biological 
hydroxyapatite (the mineral component of bone) under physiological conditions in 
vitro. Encouragingly, this effect was shown to be controllable through the effect of pH 
and the action of the enzyme alkaline phosphatase, which is found ubiquitously in the 
body. Also, there is some evidence that hexametaphosphate is able to inhibit the 
synthesis of hydroxyapatite, which suggests a possible role as a combined 
prophylaxis and treatment for HO. Developing a delivery vehicle that can allow the 
targeted application of hexametaphosphate to the site of formation of HO was found 
to be extremely challenging. The same chemical properties that are thought to make 
hexametaphosphate effective at dissolving hydroxyapatite also make it challenging to 
incorporate into injectable hydrogels, which are still likely to prove to be the best 
method of delivery in the future. 
In order to test the feasibility of using hexametaphosphate for preventing and treating 
HO, an animal model was set up. The rat Achilles tenotomy model was shown to be 
simple, reliable, and well tolerated by the animal models. Having set up the model, 
hexametaphosphate injections were compared to controls. This is the first recorded 
use of hexametaphosphate to inhibit and treat HO in an animal model. This 
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experiment did not show a statistically significant result but it did show that it is 
possible to conduct this kind of work and provides a starting point from which further 
work can be compared. 
In summary, this project has increased our understanding of the chemical and 
physical structure of human post-traumatic HO, has discovered that 
hexametaphosphate is a promising candidate for further development as both a 
treatment and prophylaxis against HO, and shown that it is possible to test this in an 
animal model of HO. 
7.2 Further Work 
While a few subsamples of human HO investigated in this work have been, 
necessarily, destroyed by the process of analysis, the majority are intact. This means 
that there is no barrier to further analysis. In general, it would be of great interest to 
explore the mineralisation mechanism in more detail. In the first instance, this could 
be achieved simply through the use of mapped X-ray fluorescence of more sections 
of the tissue. Further insights may be gained by looking at what other chemical 
species are associated with the calcium-rich islands discovered in the course of this 
work. This may require nuclear magnetic resonance spectroscopy and specialised 
analysis. 
Development of new methods of quantifying and classifying the micro and macro 
scale morphology of HO would also be of great interest. If it could be shown that HO 
from different aetiologies formed in quantifiably different patterns, this would lend 
weight to the hypothesis that not all HO is the same disease and could allow 
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researchers to start describing different types of HO. The morphology is also of great 
importance to those who seek to investigate the effect of the mechanical environment 
of the stumps of amputees, which may allow a greater understanding of the effect on 
HO of topical negative pressure, for example. 
One intriguing finding that may benefit from further investigation is the presence of 
what appear to be calcospherites in the samples of human HO. If the composition of 
these structures could be analysed, then their function and role in HO formation may 
be better understood. 
In terms of treating and preventing HO using hexametaphosphate, the most pressing 
challenge is the lack of an optimal delivery system. Viscous uncrosslinked alginate 
was used for the in vivo work out of necessity but a shear-thinning gel may prove to 
be a better vehicle. Gellan and agarose proved promising but neither was 
satisfactory for use in the animal model. Further formulation engineering work needs 
to be carried out looking at a wider array of injectable hydrogels or even more novel 
approaches such as 3-D printed implantable reservoirs filled with 
hexametaphosphate. Understanding how to sterilise such a system would be of 
prime importance and is not an insignificant challenge. 
There are extant plans for further animal model experiments. The timing of injections 
and dose of hexametaphosphate per dose are easily modifiable and will be explored. 
These experiments have been planned so that any potential batch-effects are 
minimised. Once the dose and scheduling parameters are optimised, a definitive 
experiment will be carried out with sufficient numbers of animals in each arm of the 
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study to test the hypothesis that hexametaphosphate can inhibit and treat HO in vivo. 
If this is shown to be the case, then work towards human trials can begin. An integral 
part of this phase of work will be establishing what the regulatory requirements are 
for such a therapy and addressing these. Additionally, formal toxicity testing will need 
to be undertaken. Finally, safety and efficacy will need to be demonstrated before 
this concept can be utilised in the human setting. 
It is important to note that the funding, personnel, and resolve to continue with this 
work are already in place and I am confident that further progress will be made in the 
near future. The last few words of this thesis are reserved for the person who has 
taken the baton from me and will lead the next phase of this research as part of his 
PhD project: Mr Tom Robinson, good luck. 
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8 APPENDIX 1 
 
A version of Chapter 2 has been published in the journal Advanced Healthcare 
Materials: 
Eisenstein NM, Cox SC, Williams RL, Stapley SA, Grover LM. Bedside, Benchtop, 
and Bioengineering: Physicochemical Imaging Techniques in Biomineralization. 
Advanced Healthcare Materials 2016;5(5):507-28. doi: 10.1002/adhm.201500617 
A copy of this publication is included below. 
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9 APPENDIX 2 
 
A version of Chapter 4 has been published in the Journal of Materials Chemistry B: 
Eisenstein N, Williams R, Cox S, Stapley S, Grover L. Enzymatically regulated 
demineralisation of pathological bone using sodium hexametaphosphate. Journal of 
Materials Chemistry B 2016;4(21):3815-22. doi: 10.1039/c6tb00461j 
A copy of this publication is included below. 
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